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Abstract 
Lumpy skin disease (LSD) is a notifiable viral infection due both to its morbidity in cattle and 
its severe economic burden. The disease was confined to Sub-Saharan Africa but has in recent 
years spread to the Middle East and Europe.  Vaccination is the only way of preventing LSD. 
Live attenuated lumpy skin disease virus (LSDV) has been used as a vaccine against LSD. The 
most successful LSD vaccine is the Neethling vaccine strain (nLSDV) from South Africa. 
There are however, reports of nLSDV being too attenuated or too virulent in different breeds 
of cattle.  
A South African produced vaccine strain of LSDV, Herbivac, was said to be more 
immunogenic than nLSDV (personal communication, Deltamune). Whole genomic sequence 
comparison of Herbivac with nLSDV revealed a single potentially significant change in open 
reading frame (ORF) 131. This ORF encodes a superoxide dismutase (SOD) homologue. The 
mutation identified in Herbivac is a 2bp deletion which causes a frameshift mutation that 
restores the SOD homologue to resemble the full-length SOD homolog encoded by the virulent 
field strain. This SOD homologue gene is truncated in nLSDV.  
Protein structural alignment of SOD homologues from LSDV and other characterised SOD 
homologues was done. Both the truncated and full-length SOD homologues lacked the catalytic 
arginine at position 142 which is involved in SOD activity. Some similarities with known SOD 
homologues which act as SOD decoys, such as the Leporipoxviruses myxoma and Shope 
Fibroma virus, were observed. Like Leporipoxvirus’ SOD homologues, the full-length 
Herbivac SOD homologue contained regions of homology with the copper chaperone for SOD 
(CCS). The putative SOD protein from Herbivac, and not nLSDV, contained 6 out of 8 metal 
binding residues. Unlike the SOD decoy from myxoma virus, the full-length SOD homolog 
from Herbivac did not include a cysteine molecule at position 56 that stabilizes the SOD-CCS 
heterodimer. The alignment suggests that all SOD homologs from LSDV are inactive as 
enzymes. 
Transcriptome analysis of messenger RNA from spleens of mice infected with nLSDV or 
Herbivac for 24hrs was carried out to determine the effect of Herbivac or nLSDV infection on 
host gene expression. Compared to the PBS control, nLSDV and Herbivac induced the 
differential expression of 98 genes in common, largely related to response to viral infection. 
nLSDV differed in the unique expression of 6 genes and Herbivac differed in the unique 
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expression of 36 genes, including granzyme A and Poly (ADP-ribose) polymerase (Parp 9). 
Herbivac upregulated genes associated with pathogen pattern recognition, interferon response, 
immune response and cell death. More Gene ontology (GO) processes were enriched after 
Herbivac infection than nLSDV infection. Amongst these processes were immune response 
processes, the interferon and cell death related responses.  
To characterise the SOD homolog with respect to SOD activity, cell death and whether it plays 
a role in growth of viruses expressing it, recombinant viruses were constructed. The first set of 
recombinants included a SOD knock-out virus where the SOD gene from nLSDV was replaced 
with reporter gene GFP. A SOD knock-in virus was constructed with the SOD homologue gene 
altered to improve the stability of the gene. A reporter gene mCherry was also inserted.  
Histological examination of CAMs infected with nLSDVdSOD-M showed vacuolation and 
oedema to a greater degree than nLSDV, Herbivac and nLSDVSODis-M. Herbivac showed 
greater immune cell infiltration. SOD knock-in, nLSDVSODis-M showed increased epithelial 
hyperplasia and fibroplasia. 
Another set of recombinants without marker genes was made, nLSDVdSOD-UCT (SOD 
knock-out), and nLSDVSODis-UCT (SOD knock-in). Deleting the SOD homolog reduced 
virus yield by approximately ten-fold in MDBK cells. Histologically, the presence of the SOD 
homolog in nLSDVSODis-UCT caused greater inflammatory changes in the mesoderm after 5 
days of infection compared to nLSDVdSOD-UCT. 
In vitro functional studies were done in MDBK cells which are permissible to LSDV infection. 
No difference in SOD activity could be detected amongst the different viruses. Differences 
could, however, be detected in induction and inhibition of apoptosis. There was increased 
induction of apoptosis following infection by all viruses containing full-length SOD compared 
to infection with truncated or SOD knock-out virus. Viruses expressing a full-length SOD 
showed greater inhibition of camptothecin induced apoptosis than nLSDV or the SOD knock-
out. Similarly, full-length SOD induced cell death by necrosis to a greater extent than the SOD 
knock-out or nLSDV; and all viruses inhibited camptothecin induced necrosis.   
These results suggest that the presence of a SOD homolog in a vaccine could be advantageous 
with respect to growth of the vaccine to higher titres and to improved immunogenicity of the 
vaccine. Further work is required to test this hypothesis in a bovine animal model.  
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Chapter 1 Literature Review 
1.1 Lumpy skin disease 
1.1.1 Aetiology 
Lumpy skin disease (LSD) is a notifiable disease caused by the poxvirus lumpy skin disease 
virus (LSDV). The virus belongs to the family Poxviridae, which is divided into two 
subfamilies – Chordopoxviridae (vertebrate infecting) and Entomopoxviridae (invertebrate 
infecting) (Figure 1.1). The Chordopoxvirus subfamily is subdivided into ten genera namely 
Parapoxvirus, Yatapoxvirus, Capripoxvirus, Suipoxvirus, Orthopoxvirus, Molluscipoxvirus, 
Avipoxvirus, Leporipoxvirus, Cervidpoxvirus and Crocodylidpoxvirus. LSDV belongs to the 
genus Capripoxvirus  (Mercer et al., 2007a), International Committee on Taxonomy of Viruses 
(ICTV, 2018).  
 
Figure 1.1. Phylogenetic tree of poxviruses based on an amino acid sequence alignment of 20 genes. A node represents a 
genus and the species is shown in brackets. The capripoxvirus subfamily contains 3 species, namely lumpy skin disease virus, 
sheeppox virus and goatpox virus. Modified from Hendrickson et al. (2010). 
LSD mainly affects cattle (Bos indicus, Bos Taurus) and Asian water buffalo (Balus bubalais) 
and carries a significant economic burden due to the clinical presentation of the disease 
(reviewed in section 1.1.4) (OIE, 2017, Abera et al., 2015, Hunter and Wallace, 2001).  There 
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has been an instance where LSDV has been isolated from sheep where it causes mild disease 
(Tuppurainen et al., 2014). 
1.1.2  Historical background  
LSD was first identified clinically in Northern Rhodesia, modern day Zambia in 1929 
(reviewed by Hunter and Wallace (2001)). In the first part of the last century LSD was localised 
to Southern Africa but was later found in Kenya, Sudan and Ethiopia (Weiss, 1968, Davies, 
1982, Abera et al., 2015, Davies, 1981). It has now spread to most of the African continent 
except for a few countries that include Libya, Tunisia, Algeria and Morocco. In 2007 LSD 
spread to the Middle East (Sihvonen and Depner, 2016, OIE, 2017, Tuppurainen and Oura, 
2012, Beard, 2016). There has been a spread of the disease to Europe in the past few years 
including Russia (2015), Greece (2015) and Bulgaria (2016) (Beard, 2016). Table 1.1 gives the 
time-line for the spread of LSD. 
Table 1.1. Year(s) of first and subsequent lumpy skin disease incidences.   
Country Year incidence reported Reference 
Zambia 1929 Reviewed in (Hunter and Wallace, 
2001) 
Botswana, Zimbabwe, 
Republic of South Africa 
1943-1945 (Von Backstrom, 1945), reviewed by 
Hunter and Wallace (2001) 
Kenya 1957  (Davies, 1981, Davies, 1982, Burdin 
and Prydie, 1959) 
Sudan 1970, 1979 (Davies, 1981) 
Nigeria 1974 (Nawathe et al., 1982) 
Mauritania, Mali, Ghana, 
Liberia 
1977 (OIE, 2017) 
Tanzania, Kenya, Zimbabwe 1981-1986 (Davies, 1982), (Brenner et al., 2009) 
Somalia 1983 (Davies, 1991) 
Ethiopia  1984 (Mebratu et al., 1984) 
Israel 1989, 2006/2007 (Yeruham et al., 1995), (Brenner et al., 
2009) 
Egypt 1988/1989, 2006 (House et al., 1990) 
Egypt 2006 (El-Kholy et al., 2008) 
Ethiopia 1983, 2000/2001, 
2003/2004, 2006/2007, 
2010/2011 
(Farah, 2017, Ayelet et al., 2014) and 
reviewed by Abera et al. (2015)) 
Oman 2009 (Kumar, 2011) 
Israel 2006, 2012 (Tuppurainen and Oura, 2012) 
Lebanon, Jordan  2012/2013 Reviewed by Alkhamis and 
VanderWaal (2016) 
Turkey, Iraq, Iran, Cyprus 2013-2015 Reviewed by Tuppurainen et al. (2017) 
Bulgaria, Greece 2015/2016, Serbia OIE 20151005.3692103,(Sihvonen 
and Depner, 2016, Toplak et al., 2017) 
Russia 2015 OIE 20151016.3720589, Reviewed by 
Tuppurainen et al. (2017) 
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Figure 1.2. Geographical distribution of LSDV. LSDV used to be endemic to Africa and particularly Sub-Saharan Africa. More recently LSDV has spread to the Middle East and into Europe. 
The different colours represent the times of introduction into different countries. Grey - unknown; red - 1920-1930; pink - 1941-1950; brown-1951-1960; maroon - 1970-1980; dark blue - 1981-
1990; purple - 2009; green - 2011-2018. This figure is based on information from Hunter and Wallace (2001), Weiss (1968), Davies (1982), Abera et al. (2015), Davies (1981), Sihvonen and 
Depner (2016), OIE (2017), Tuppurainen and Oura (2012), Beard (2016).  
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1.1.3 Economic Impact 
Cattle are reared for different reasons including commercial and private/cultural  purposes 
(Ntombimbini and Klein, 2015). Since LSDV can spread rapidly with serious economic impact, 
LSD is classified as a notifiable disease by the World Organisation for Animal Health (OIE). 
A notifiable disease is defined as a disease that is required by law to be reported to government 
authorities. The primary economic losses are due to weight loss, a sharp decline in milk 
production, loss of traction (morbidity), poor growth, in some cases abortion, damage to hides 
and temporal to permanent infertility (reviewed by Abera et al. (2015), Tuppurainen and Oura 
(2012) and Gari et al. (2011). There are also other losses resulting from LSDV infection of 
cattle, namely, meat losses when infected animals are incinerated and costs of treating 
secondary infections (Abera et al., 2015).  
1.1.4 Clinical Signs of LSD 
Infected cattle present a biphasic, febrile response with skin nodules appearing before and 
during the second episode of the disease (Coetzer, 2004). In cattle, infection with LSDV causes 
a fever of up to 40-41⁰ C (Carn and Kitching, 1995a). The other clinical symptoms include 
depression, salivation, ocular and nasal discharges (Coetzer, 2004). After 4 to 10 days, lesions 
appear and these are characterised by erythematous raised foci (Mercer et al., 2007a). These 
lesions appear all over the body, head, neck, udder, scrotum and vulva and range in size from 
0.5 to 10 cm in diameter (Coetzer, 2004, Rovid, 2012, Prozesky and Barnard, 1982). Lesions 
are circumscribed, firm, rounded and raised. They may exude serum. The lesions are 
characterised by regions of necrosis which permeates the epidermis and dermis and underlying 
muscle tissue. Regions of necrosis separate the lesion from the skin creating nodules (Rovid, 
2012). These nodules can be removed when clasped between fingers (Figure 1.3) and they 
leave ulcerative lesions.  
Grouping of skin nodules causes the formation of larger plaques which lead to skin sloughing 
in the lower abdomen and limbs (Weiss, 1968, Von Backstrom, 1945). Secondary nodules can 
also form along with lymphadenopathy (inflammation of the lymph nodes), conjunctivitis 
(inflammation of the eyes) and rhinitis (inflamed nasal cavity) (Carn and Kitching, 1995a). 
Bulls can suffer from temporal or permanent infertility whilst infection of cows in their udders 
and teats can result in bacterial infections causing mastitis (Mercer et al., 2007a, Tuppurainen 
and Oura, 2012). There is significant reduction of milk production in infected animals (OIE, 
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2017). Lesions are not only localised to the skin but may appear in the stomach, uterus, vagina, 
udder and testes. Necrotic areas can be found in the respiratory tract and pneumonia can 
develop if pieces of necrotic tissue are inhaled (Coetzer, 2004). 
The severity of infection is generally dependant on the animal’s age, breed (host genotype) and 
the state of its  immune system upon contracting the disease (OIE, 2017). In one experiment 
where cattle were infected intravenously with a virulent LSDV strain, Dexter breed of cattle 
showed severe clinical disease, whereas the Friesian breed showed mild disease and the Dexter 
cross breed had unapparent clinical signs (Tuppurainen et al., 2005). In a retrospective study 
based on a questionnaire from farmers in Ethiopia, the cattle breeds Holstein Friesian (HF) and 
Jersey were found to be more vulnerable to LSDV infection than their locally bred Zebu cattle. 
In the same study LSDV related mortality was lower in the Zebu cows relative to the HF cows 
(Gari et al., 2011).  
 
Figure 1.3. Symptoms of lumpy skin disease. Cow with lesion on hide (A), sit fast lesions (B), lesions on vulva (C), necrotic 
lesions on the muzzle (D). A and B taken from Abutarbush et al. (2015) and C and D taken from Coetzer (2004). 
1.1.5 Histopathology  
Histological examination of lesions from LSDV infected animals shows differences depending 
on the stage of infection. During the course of infection, histological examination of lesions 
and skin sections from animals infected by LSDV show ballooning degeneration in the 
epidermal layers, the presence of intracytoplasmic inclusion bodies, vasculitis and proliferation 
of fibroblasts (Mercer et al., 2007a, Alexander et al., 1957, Neamat-Allah, 2015). Acute 
infection of cattle is associated with vasculitis and lymphangitis, which causes thrombosis and 
infarction with the subsequent effect of necrosis combined with immune infiltration (Prozesky 
and Barnard, 1982). Hence, the late stages of infection are characterised by fibroplasia where 
the dead cells (from necrosis) in the initial stages of infection were replaced by the 
inflammatory cells and fibroblasts. The last stage of disease also shows hyperkeratosis in the 
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epidermis. Necrotic cells appear oedematous with vesicles forming inside them. Appearance 
of inclusion bodies is also characteristic of late stage infection (Prozesky and Barnard, 1982). 
1.1.6 Diagnosis  
Characterisation of the clinical presentation of LSD, differential diagnosis and laboratory based 
tests are used routinely to diagnose LSD (Abera et al., 2015). There are many laboratory tests 
that are used to identify LSDV infection and the key tests that are recommended by OIE are 
summarised in Table 1.2. Some serological tools for the detection of LSD infected cattle have 
been developed. The only limitation is that these tests cannot differentiate between infected 
and vaccinated animals. 
Table 1.2. Diagnostic methods used to detect capripoxviruses for different purposes. Modifications to some of the tests 


































++ + +++ + N/A 
Antigen 
detection ++ ++ ++ ++ ++ N/A 
PCR ++ +++ ++ +++ ++ N/A 
Detection of immune response 
VN ++ ++ ++ ++ ++ ++ 
IFAT + + + + + ++ 
*A combination of agent identification methods applied on the same clinical sample is recommended.  
+++ (recommended method); ++ (suitable method); + (used in some situations, but cost, reliability, or 
other factors severely limits its application); N/A (not applicable); PCR (polymerase chain reaction); 
VN (virus neutralisation); IFAT (indirect fluorescent antibody test). 
An indirect fluorescence antibody test (IFAT) is routinely used to diagnose LSD (Tuppurainen 
et al., 2005, OIE, 2017). This test identifies LSDV antibodies in cattle serum (Gari et al., 2008). 
Western blot analysis using antibodies to structural proteins in the virus can also be used to 
detect LSDV (OIE, 2017). Innovative diagnostics (ID.vet) has developed the first 
commercially available ELISA for the detection of LSDV (ID Screen® Capripox Double 
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Antigen Multi-species available at https://www.id-vet.com/produit/id-screen-capripox-double-
antigen-multi-species/).  
One of the standard tools for the identification of capripoxviruses involved growth of the virus 
in a permissive cell line such as primary lamb or bovine cells and observing cytopathic effects 
(CPE) (Mercer et al., 2007b). However, this does not distinguish between sheeppoxvirus, 
goatpoxvirus or lumpy skin disease virus. With developments in molecular assay techniques, 
several polymerase chain reaction (PCR) based methods have been described (Armson et al., 
2017, El-Kholy et al., 2008). PCR is the most sensitive in the detection of poxviruses (Mercer 
et al., 2007a). One of the first PCR based assays to diagnose LSDV made use of primers that 
were designed to amplify the gene encoding the immunodominant P32 protein (Heine et al., 
1999). Other PCR tests have been based on amplification of the viral attachment protein gene 
(Ireland and Binepal, 1998, Albayrak et al., 2018). Bowden et al. (2008) described a highly 
sensitive real time qPCR to detect capripoxviruses based on amplification of a region of ORF 
74. A limitation of this test was that it could not distinguish between LSDV and the other two 
capripoxviruses (Bowden et al., 2008). PCR has therefore been coupled with Sanger 
sequencing of the PCR product, to confirm the presence of LSDV (El-Kholy et al., 2008).  
The newer PCR based methods for detection of LSDV have focused mainly on the rapid 
detection of LSDV, amenability of the test in outbreak areas and distinction between LSDV 
vaccine strains from wild type virulent LSDV. Menasherow et al. (2014) developed a PCR test 
based on three differences between the Neethling vaccine strain and the circulating wild type 
virus in Israel. Virulent LSDV was shown to have 27 nucleotides more compared to the vaccine. 
Secondly, there was a difference in the primer annealing temperature using LSDV specific 
primers between the two strains and lastly, a unique restriction site (MboI site) next the ORF 
126 (EEV gene) in the vaccine strain was identified. A high-resolution melting assay (HRM) 
was developed which recognises the 27 base-pair deletions in the vaccine strain (Neethling 
prototype), which also uses a thermal gradient to detect a product at 65 °C for the vaccine and 
not WT. Primers were used with 3’ ends unique to the vaccine strain. They also used MboI 
restriction enzyme digestion to distinguish and confirm the LSDV strains (Menasherow et al., 
2014).    
Another sensitive PCR based test was recently developed in the Balkans. Similar to the Israeli 
group, in this PCR, primers specific to the circulating strains and a vaccine strain (Lumpyvax) 
were used (Vidanović et al., 2016). More recently, Agianniotaki et al. (2017) described a new 
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diagnostic duplex PCR technique that can differentiate infected animals from vaccinated 
animals. The presence of a 12 base-pair deletion in the G-protein-coupled chemokine receptor 
(CPGR) in the vaccine strain is used to differentiate vaccine from WT virulent LSDV 
(Agianniotaki et al., 2017).  
There are efforts being made, using serological and PCR assays, to differentiate vaccinated 
animals from virulent LSDV infected animals (DIVA) in non-endemic areas (Tuppurainen and 
Oura, 2012, Tuppurainen and Galon, 2016). The inability to distinguish the antibody response 
following infection with wild type capripoxvirus from vaccination has made it difficult to 
conduct serosurveillance of LSDV in capripoxvirus endemic areas. For this reason PCR based 
techniques have become more important (Tuppurainen et al., 2017). 
1.1.7 Transmission 
Carn and Kitching (1995) demonstrated that LSDV transmission between infected animals and 
uninfected animals housed together was inefficient but that intravenous inoculation of animals 
using a field isolate was extremely efficient in establishing disease. They therefore postulated 
that infection was established by arthropods (Carn and Kitching, 1995b). Mechanical LSDV 
transmission by Aedes aegypti female mosquitoes from infected cattle to susceptible cattle  has 
been demonstrated (Chihota et al., 2001). Tuppurainen et al. (2013) showed that LSDV could 
be vertically transmitted by Rhinecephalus decolarutus ticks and confirmed the role of Ixodid 
ticks in both transstadial (A. hebraeum) and transovarial (Rhipicephalus (Boophilus) 
decoloratus) transmission of lumpy skin disease virus (Tuppurainen et al., 2013, Tuppurainen 
et al., 2011, Lubinga et al., 2013, Lubinga et al., 2014).  
Transmission of LSDV via semen has also been demonstrated (Annandale et al., 2014). The 
intrauterine spread of LSDV has been reported in premature calves from infected cows (Rouby 
and Aboulsoud, 2016). Transmission to suckling calves via infected milk and in cattle sharing 
drinking troughs has also been implicated as a possible route of transmission (Coetzer, 2004).  
1.2 Vaccination against LSDV  
1.2.1  Vaccines against LSD 
All the LSDV vaccines available commercially are live attenuated vaccines (Abutarbush et al., 
2016, Tuppurainen and Oura, 2012, Tuppurainen et al., 2017). The three members of the genus 
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capripoxvirus, namely, sheeppox, goatpox and LSDV are antigenically the same with a similar 
precipitating antigen (Kitching et al., 1986). Thus, attenuated LSDV, sheeppox virus and 
goatpoxvirus have been used as vaccines for LSD (Hunter and Wallace, 2001). The SPPV and 
GPV based vaccines are often used at a much higher dosage in cattle compared to the LSDV 
based vaccines (Tuppurainen et al., 2017). The disadvantage of using sheeppox or goatpox 
virus-based vaccines is that they are confined for use in areas where sheeppox and goatpox are 
endemic. This is because, the vaccine can be a source of infection for vulnerable sheep or goats 
(Coetzer, 2004). Recently, the Kenyan sheep and goatpox virus vaccine was actually shown to 
be LSDV (Tuppurainen et al., 2014).  This LSDV strain has not been highly attenuated and 
may be a source of clinical disease in vaccinated cattle (Tuppurainen et al., 2014). The other 
disadvantage of using sheeppox virus as a vaccine against LSD is the lack of adequate 
protection upon LSDV challenge. In a recent study which used a sheeppox virus (RM65) as a 
vaccine against LSDV in cattle in Israel, RM65 was shown to be less efficacious in protecting 
animals when compared to the Neethling vaccine strain from South Africa (Ben-Gera et al., 
2015).  
Whilst vaccination remains the best way of controlling infection and transmission of LSDV, 
different factors may affect its efficacy. Firstly, local reactions associated with the vaccine may 
hinder the uptake of the vaccines by farmers. This is because LSD symptoms  have been noticed 
in vaccinated cattle (Ben-Gera et al., 2015). Secondly, the efficacy of the vaccine is 
complicated by the need to have a cold chain (EFSA, 2015). Thirdly, because some animals 
remain asymptomatic when infected, transmission of wild type virulent LSDV during 
vaccination can occur. The use of the same needles during mass vaccination in resource 
constrained communities can spread wild type LSDV. Fourthly, the presence of maternal 
antibodies in calves born to either immunised or LSDV-infected cows may lower the protection 
conferred by vaccination.  Lastly, incorrect dosages from incorrect formulations may also 
render the vaccine ineffective (EFSA, 2015). Because LSD has been confined to Africa until 
recently, there have not been many commercial producers of the vaccine. For this reason there 
may be shortages of vaccine during acute endemics where a lot of doses are required in short 
notice periods (EFSA, 2015). 
The most widely used vaccine against LSDV is the South African Neethling strain produced 
by Onderstepoort Biological Products - OBP Neethling (reviewed by Hunter and Wallace 
(2001). This attenuated form of LSDV vaccine was made by passaging LSDV (Neethling strain) 
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fifty times in lamb cells and passaging twenty times in fertilised hens’ eggs (reviewed by 
Davies (1991)). The Neethling vaccine strain of LSDV has been shown to confer neutralising 
antibodies to other virulent strains of LSDV (reviewed by Hunter and Wallace (2001)). This 
vaccine is recommended by the manufacturer to be given at 6 months of age and then annually 
(OBP, South Africa). Vaccination is recommended to be done in the spring (MSD, South 
Africa). Other vaccines for LSD that are used in South Africa include Herbivac (Deltamune) 
and Lumpyvax (MSD Animal Health).  Both these vaccines have sequences almost identical 
to LSDV (Neethling strain) (Mathijs et al., 2016). 
The Kenyan sheeppox, goatpox (KSGP) vaccine is the standard vaccine used in Kenya for 
cattle (Carn, 1993). However,  as previously noted, molecular characterisation of the Kenyan 
sheeppox and goatpox virus vaccine (KSGP) O-240 revealed that this vaccine was not 
sheeppox as previously described, but a strain of LSDV (Tuppurainen et al., 2014). More 
recently, a goatpox virus strain (Gorgan strain) was shown to effectively protect calves against 
LSDV challenge (Gari et al., 2015). Other vaccines for LSDV exist, namely the Yugoslavian 
RM-65 sheeppox virus strain and the Romanian sheeppox virus (Coetzer, 2004). The sheeppox 
and goatpox virus-based vaccines cannot be used in South Africa because sheeppox is not 
endemic to South Africa.  
1.2.2 Vaccine efficacy 
Since vaccination remains the best way to control LSD, there is a great need for efficacious 
vaccines. As shown in Table 1.3 there are some serious concerns over the different types of 
LSDV vaccines used and their efficacy. Vaccine failure and the reinfection of vaccinated 
animals complicate LSD control and eradication (Gari Jimolu, 2011). Interpretation is 
complicated by the different sources and dosages of the vaccines used.  The live attenuated 
LSDV vaccine provides good protection in cattle and is generally superior to the sheeppox 
virus-based vaccines.  In a field study done in Israel the LSDV Neethling vaccine was 
significantly more effective at preventing LSD compared to the attenuated sheeppox vaccine 
(RM 65) (Ben-Gera et a., 2015).    
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Table 1.3. List of vaccines used against LSD, efficacy data and adverse reactions reported to date. 
Vaccine Manufacturer Country/Region used Notes  Reference 
Neethling vaccine 




 Widely used -Africa 
and the Middle East 
Made by passaging LSDV (Neethling strain) fifty times in 
lamb cells and passaging twenty times in fertilised hens’ eggs  
i) Provides good protection against LSD. 
ii) Immunity speculated not to be lifelong therefore annual 
vaccinations recommended.  
iii) More adverse reactions in European breeds compared to 
African breeds  
iv) More effective than sheeppox virus vaccine RM65. 
Weiss, 1968 
Van Rooyen et al, 1969 
Reviewed by Hunter and 
Wallace, (2001) 
(Katsoulos et al., 2018) 
(Ben-Gera et al., 2015) 
Yugoslavian 
RM65 SPPV   Middle East 
Incomplete protection in Israeli trial and some clinical signs 
of LSD in vaccinated cattle in a trial in Jordan 
Davies, 1991; Brenner et al., 
2009; Somasundaram, 2011; 
Abutarbush, 2014, Ayelet, 2013 






Northern Africa, Middle 
East, Turkey, Iraq, Iran 
KSGP O-240 associated with incomplete protection in Egypt. 
Failed to protect in Ethiopian cattle. KSGP O-180 failed to 
protect. This vaccine is actually LSDV. 
LSDV Neethling 
National Veterinary 
Institute (NVI) Ethiopia Failed to protect in an Ethiopian trial.  




Centre (JOVAC) Middle East 
More effective than the Ethiopian Neethling and KSGPO-
180. 
Bakirköy SPPV   Turkey  Currently used in Turkey. 
 
Tuppurainen et al., 2017 
LSDV Neethling 
strain  
MCI Sante Animale, 
Morocco   South African Neethling vaccine  Tuppurainen et al., 2017  
Romanian SPPV 
strain 
MCI Sante Animale, 
Morocco   To be tested in a trial Tuppurainen et al., 2017  
Herbivac 
Deltamune, South 
Africa  South Africa Derived from LSDV Neethling OPB  
Personal communication and 
also Sequenced by Mathjis, 
2015 
Lumpyvax  MSD, South Africa  South Africa  No available data Sequenced by Mathjis, 2015 
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The Kenyan sheep and goatpox virus failed to protect animals in Egypt in the 2006 LSD 
outbreak; and, the Yugoslavian RM 65 sheeppox virus failed to offer complete protection in 
Israel in the 2006/2007 LSD outbreak (reviewed by Tuppurainen and Oura (2012)  
In Ethiopia a comparison was done with three different vaccines to determine if they could 
protect from virulent LSDV.  The Ethiopian Neethling vaccine strain and KSGPO-180 strain 
were both produced in an Ethiopian factory and the Gorgan goatpox virus vaccine was 
produced in Jordan.   Vaccine failure was observed in 70 per cent animals vaccinated with the 
Ethiopian Neethling vaccine and 50 per cent after vaccinating with KSGPO-180 when 
experimentally challenged with a virulent LSDV strain (Gari et al., 2015). The virulent field 
strain came from naturally infected cattle and was passaged three times to bulk up virus for 
challenge. The Gorgan goatpox virus vaccine was shown to elicit better delayed 
hypersensitivity scores and antibodies as well as much better protection upon challenge with 
virulent LSDV. It was shown that vaccine failure was intimately linked to the inability of the 
Ethiopian Neethling  and KSGPV O-180 to elicit a strong immune response in sentinel animals 
(Gari et al., 2015).   This may have been due to manufacturing issues. 
1.2.3 Adverse reactions after vaccination 
Different studies with different vaccines against LSD have reported a range of adverse 
reactions.  The adverse reactions with LSDV (Neethling) vaccine were relatively minimal in a 
study done on Holstein-Friesian cattle in Greece. Pronounced swelling was seen at the injection 
site in 26/215 adult cows, but not in calves. This indicated that the vaccine was safer in calves 
than in adult animals. The swelling found in adult cows, which resolved within 10 days, was 
acceptable given the serious morbidity observed in virulent infection. Milk production was 
reduced for 12 days post-vaccination (Katsoulos et al., 2018).   
1.3 Poxviruses as vaccine vectors 
Poxviruses have been used for vaccination with the first record being the use of Cowpox virus 
to confer immunity against Variola virus (reviewed by (Riedel, 2005)). The eradication of 
smallpox, due to the elimination of the causal agent of the disease, Variola virus, was an 
important milestone in the history of medicine (Fenner, 1977, Fenner, 1980, Fenner, 1982).  
This goal was achieved after a global vaccination campaign using Vaccinia virus (VV), a virus 
that is antigenically similar to Variola virus (Fenner, 1982, Smith, 2013). Since then, 
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poxviruses continue to be researched for use as vaccine vectors (Sanchez-Sampedro et al., 
2015). Viral attenuation of poxviruses is also possible (Paoletti, 1996). These attenuated strains 
are known not to replicate and hence be safer for use as human vaccines (Schnell, 2001). 
Highly attenuated vaccines which are currently being used as vaccine vectors have been 
produced from vaccinia virus. New York Vaccinia (NYVAC), a highly attenuated strain of the 
Copenhagen strain of vaccinia virus was made by the deletion of 18 open reading frames 
(ORFs). These deleted ORFs included 2 genes involved in nucleotide metabolism, a viral 
haemagglutinin, serine protease inhibitors, genes responsible for formation of  type A inclusion 
bodies, a functional complement 4b binding protein and viral host range genes (Tartaglia et al., 
1992b). This vaccine vector is highly desirable as it does not disseminate in 
immunocompromised hosts (Pastoret and Vanderplasschen, 2003). 
Modified vaccinia Ankara (MVA) was produced by passaging vaccinia virus for more than 
530 times in an unnatural host. Chick embryo fibroblast cells were used to passage the virus 
(Mayr et al., 1975). Attenuation caused the deletions of 6 genes (approximately 30 000bp). One 
of the deleted genes included a host range gene which causes the virus not to complete its 
replication cycle in cells permissive to vaccinia virus (Meyer et al., 1991). Sutter and Moss 
(1992) managed to show that whilst MVA does not multiply in human cells, early and late viral 
protein synthesis and DNA replication takes place. This feature makes MVA ideal for 
heterologous protein expression. MVA was shown to produce similar levels of heterologous 
protein when compared with vaccinia virus (Carroll et al., 1997) (Sutter et al., 1994). The use 
of MVA as a vaccine vector has been reviewed by Altenburg et al. (2014). Some studies have 
shown MVA to upregulate more immunomodulatory genes than NYVAC (Guerra et al., 2007). 
MVA presents a great safety profile and was used successfully to immunise over 120 000 
individuals against smallpox without any serious side effects (Mayr et al., 1978).  
The canarypox-based vaccine vector, ALVAC has been used widely. This is a host cell derived 
vaccine which is naturally restricted to grow in avian species.  No infectious progeny has been 
demonstrated in non-avian species (Tartaglia et al., 1992a). Canarypox virus has been shown 
to be immunogenic in animals and human recombinant vaccines (Kyriakis et al., 2009, Fries et 
al., 1996). When MVA, NYVAC and ALVAC were compared as vaccine vectors against 
simian immunodeficiency virus (SIV), ALVAC induced a higher immune response followed 
by MVA and then NYVAC (Teigler et al., 2014). To date, the most successful HIV vaccine 
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with 31% efficacy, employed the use of a canarypox based vaccine in a prime boost regime 
with HIV gp120 protein (Rerks-Ngarm et al., 2009). 
1.3.2 Use of lumpy skin disease virus as a vaccine and recombinant vaccine vector  
LSDV is attractive as a vaccine vector due to its ability to express foreign antigens (Fick and 
Viljoen, 1999). As a poxvirus, it has a large genome of 150kbp, which, like that of vaccinia 
virus, can accommodate large insertions and therefore be used in the construction of 
recombinant vaccines (Moss, 1996, Smith and Moss, 1983, Panicali and Paoletti, 1982). LSDV 
induces both cellular and humoral immune responses (Boshra et al., 2013) and has been used 
as a vaccine vector for cattle, sheep and non-permissive hosts. Recombinant LSDV vaccines 
have been made against rabies and tested in animals (Aspden et al., 2002). High levels of 
antibody were obtained in vaccinated cattle. A recombinant LSDV against rinderpest was 
developed and it was found to be protective against rinderpest and lumpy skin in a challenge 
experiment in cattle (Romero et al., 1993). Using the thymidine kinase insertion site, Wallace 
et al. (2005) expressed Rift Valley Fever antigens in LSDV. In a mouse challenge model with 
Rift Valley Fever virus, protection against Rift Valley Fever disease was demonstrated 
(Wallace and Viljoen, 2005). A vaccine against Bovine Ephemeral Fever viral (BEFV) disease 
was developed using LSDV as a vaccine vector. However, in a small cattle challenge 
experiment, the vaccine was shown not to be protective against BEFV challenge although 
antibodies and cellular immunity was detected (Wallace and Viljoen, 2005). LSDV was also 
used as a vector for a vaccine against heartwater disease in sheep. It was used in a prime boost 
regime with a DNA vaccine and 90% of the sheep survived needle administered heartwater 
challenge (Pretorius et al., 2008).  
LSDV is an attractive vaccine vector in that the vaccine strain could not be passed between 
vaccinated and non-vaccinated animals (Carn and Kitching, 1995b).  
The other attractive feature of LSDV is its host-restriction to ruminants and inability to 
complete the replication cycle in non-ruminants including humans  (Fick and Viljoen, 1999). 
LSDV expressing rabies virus glycoprotein protected mice from rabies virus challenge 
demonstrating that the vaccine was effective in a non-permissive host (Aspden, 2004).   LSDV 
has been shown to be safe in two strains of immunocompromised mice, namely RAG mice and 
CD4 T cell knockout mice (Shen et al., 2011). LSDV expressing HIV genes were immunogenic 
in mice and non-human primates (Shen et al. 2011, Burgers et al. 2014).       
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LSDV has suitable sites on its genome which allows for insertion of foreign genes (Boshra et 
al., 2013). The region encoding the thymidine kinase enzyme has been successfully used as an 
insertion site (Wallace and Viljoen, 2005). Other sites for insertion have now been identified 
which include a ribonucleotide reductase gene and one intergenic region between ORFs 091 
and 092 (Aspden et al., 2002, Cohen et al., 1997). More recently, our group has successfully 
used other intergenic regions as insertion sites for generating recombinants (unpublished). All 
these features make LSDV suitable for use as a recombinant vaccine vector.  
1.4 Virus structure and genomic organisation 
1.4.1 Virus structure 
Poxviruses have been studied extensively with most of the work having been done on vaccinia 
virus (Cox et al., 1995, Moss, 2013). Using electron microscopy, poxviruses appear as brick 
shaped virions with dimensions of approximately 360 x 270 x 250 nm (Cyrklaff et al., 2005). 
Figure 1.4 shows an electron micrograph of LSDV. LSDV, like Orthopoxviruses is brick 
shaped (Babiuk, 2018) with a dumbbell shaped viral core. Poxviruses contain a dumbbell 
shaped viral core and two lateral bodies (reviewed by Laliberte and Moss (2010) and Condit 
(2007)). The core consists of a large double stranded molecule of DNA and approximately 80 
proteins. Twenty of the proteins are linked with transcription and mRNA modification (Moss, 
2012). The core is flanked by two lateral bodies which fit into the concavities of the core 
(Cyrklaff et al., 2005) and (reviewed by Laliberte and Moss (2010)). The lateral bodies are 
attached to the surface of the core and contain proteins with immunomodulatory function, e.g. 
vaccinia virus gene H1 (VH1), which enables the virus to evade host antiviral defences 
(Schmidt et al., 2013). 
 
Figure 1.4. Electron micrograph of LSDV. (X100 000 magnification). Taken from ARC, South Africa 
(http://www.arc.agric.za/arc-ovi/Pages/Vectors-and-Delivery-systems.aspx). 
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There are two distinct forms of the virus particles of poxviruses. One is the intracellular mature 
virus (MV) which contains a single membrane and the other the extracellular enveloped virus 
(EV) which contains two membranes (Hollinshead et al., 1999, Cyrklaff et al., 2005, Moss, 
2012). Section 1.4.2. describes the viral life cycle and indicates how the virus acquires the 
different membranes. After much controversy over the source of the innermost membrane, 
recent imaging techniques have revealed it to be the host endoplasmic reticulum (Weisberg et 
al., 2017). 
1.4.2 Life cycle of poxviruses  
Poxviruses replicate in the cytoplasm of their host cell (Dales, 1962, Dales, 1963) . A lot of 
knowledge on entry, replication and morphogenesis of poxviruses is based on studies done on 
vaccinia virus (Quemin et al., 2018). Figure 1.8 summarises key stages in the poxvirus life 
cycle. Poxviral entry is defined as the step where the viral core gets into the cytoplasm (Moss, 
2016). This can be achieved in one of two ways, fusion or endocytosis (Kilcher and Mercer, 
2015, Quemin et al., 2018).  
Understanding entry of the extracellular enveloped virus (EV) was previously complicated by 
the fact that it contains an extra membrane. Studies have shown that the outer membrane is 
dissolved prior to fusion of the MV with the plasma membrane or endosomal membrane. Law 
et al. (2006) discovered that when EV encounters the host cell membrane, cellular polyanionic 
molecules complex with viral proteins A34 and B5 to damage part of the outer viral membrane. 
The outer envelope is thus not incorporated into the host cell but partially dissolves to release 
the single enveloped virus  (Law et al., 2006, Roberts et al., 2009).  
The inner membrane fuses with the plasma membrane of a host cell introducing the viral core 
into the cell (Carter et al., 2005). Entry of the mature virions (MVs) was shown to be facilitated 
by 5 viral proteins namely, D8, A27 (Hsiao et al., 1999, Kochan et al., 2008, Vazquez and 
Esteban, 1999), H3, A26 and L1 (Moss, 2016, Foo et al., 2009). Entry of the viral core has 
been shown to be signalling dependant and is associated with actin/ezrin containing finger like 
protrusions (Locker et al., 2000). 
Upon entry, viral early proteins are produced to initiate synthesis of viral progeny (Liem and 
Liu, 2016). Transcription of intermediate genes happens simultaneously with DNA replication. 
The viral cores move towards the periphery of the nucleus where DNA replication ensues 
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(Condit, 2007). DNA replication occurs in the cytoplasm in specialised units called viral 
factories (Dales, 1962) and (reviewed by Moss (2013)). This segregation and 
compartmentalisation favours viral replication and possibly helps evade pathogen pattern 
recognition receptors (Liem and Liu, 2016). The viral factories contain transcription factors, 
viral mRNA, RNA-binding protein, translation related complexes, the eukaryotic translation 
initiation factors  (eIF4E and eIF4G), and ribosomal proteins (Katsafanas and Moss, 2007). 
These, together with cellular proteins, are involved in translating early mRNA into proteins 
(Liem and Liu, 2016).  
 
Figure 1.5. The life cycle of a poxvirus. The extracellular enveloped virus (EV) binds the plasma membrane of a target cell. 
The outer envelope is not incorporated into the cell membrane. The viral core is introduced into the cytoplasm where uncoating 
of the viral core happens. Early mRNA is transcribed and assists in DNA replication. Early proteins that include viral growth 
factors and cytokine inhibitors are produced. These favour viral growth. Other proteins that inhibit the cell antiviral machinery 
are also made. DNA replication occurs and through subsequent events a single enveloped intracellular mature virus is 
assembled.  The IMV is trafficked to the Golgi apparatus where envelope wrapping occurs to yield intracellular enveloped 
virus (IEV). The IEV is released from the cell as extracellular enveloped virus (EV) which can go on to infect other cells. 
Adapted from McFadden (2005). 
Poxvirus DNA replication occurs in the cytoplasm and starts as early as 2 hours post infection 
(Moss, 2013). DNA replication starts with a nick of pox DNA on one of the terminal hairpins. 
The hairpin on the terminus is unravelled allowing for DNA polymerase to bind. DNA 
replication produces concatemeric DNA molecules which are resolved by nucleases and 
packaged. About 10 000 copies of the genome are released from one cell although only half 
are packaged (Mercer et al., 2007a). Interestingly, it has been discovered that circular DNA 
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(like transfer vectors) also replicate in viral factories; this is advantageous in the construction 
of recombinant poxviruses (DeLange et al., 1986).   
DNA is packaged into a particle surrounded by a single membrane, derived from the 
endoplasmic reticulum, which matures to MV. Studies done on vaccinia virus have shown that 
A17, A14 and a scaffolding molecule D13 participate in membrane biogenesis with expression 
repression of these molecules being linked to accumulation of the viral cores in the cytoplasm 
of infected cells. H7 and L2 have also been involved in membrane biogenesis (Meng et al., 
2013, Maruri-Avidal et al., 2011). L2 has been shown to co-localise with the endoplasmic 
reticulum and confer stability to some poxviral proteins (Maruri-Avidal et al., 2011). Some of 
the MV is retained in the cell cytoplasm and some goes into the Golgi to make intracellular 
enveloped virus (IEV) with 3 membranes. When IEV fuses with the cell membrane, EV is 
released (Moss, 2006). Deep sequencing of VV and host cell transcriptomes (RNA-seq) has 
been used to map viral transcription start and stop sites precisely.  It has also been insightful in 
understanding the different classes of mRNA and host response to virus (Yang et al., 2010, 
Yang et al., 2011).  
1.4.3  Genome organisation of LSDV  
The LSDV genome is 151kbp in length and includes 2.4kbp inverted repeats in the terminal 
regions. The genomic organisation of poxviruses is linear with the 5’ and 3’ ends joined 
together by means of a phosphodiester bond. Capripoxviruses are AT rich with LSDV having 
an AT content of 73% (Tulman et al., 2001b). The genome organisation of poxviruses does not 
include introns and mRNA is not spliced (Condit, 2007). LSDV encodes 156 putative proteins.  
Conserved coding regions in LSDV are centrally located in the genome flanked by the terminal 
repeats (Tulman et al., 2001b). Figure 1.6 shows the arrangement of genes in LSDV. 
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Figure 1.6. A linear representation of the virulent LSDV genome (based on the Kenyan Nl2490 virulent field strain) 
with genes transcribed to the right being above and those to the left, below the long black line representing the genome. 
Genes are colour coded according to function and the internal terminal repeats (ITR) are shown below the open reading frame 
map as black blocks. Taken from Tulman et al. (2001b). Permission to reuse image was granted. 
Poxviruses express genes temporally in four phases (Assarsson et al., 2008), namely, 
immediate early, early, early-late and late. The early gene products are termed so because they 
are expressed early in infection, before DNA replication and the late gene products are 
expressed late in infection after DNA replication (Broyles, 2003). There are distinct promoters 
for early and late gene expression; it is not clear what regulatory factors distinguish immediate 
early from early gene expression. The early genes encode proteins which are important as 
virulence factors which alter the host cell response, whereas the late genes encode structural 
proteins and proteins important for morphogenesis. They also encode core proteins required 
for transcription and other functions required immediately upon infection. (Assarsson et al., 
2008). 
1.4.3.1  LSDV sequence comparisons 
As observed in other poxviruses LSDV encodes 26 proteins involved in translation, 
transcription and post-transcription. Seven homologues present in LSDV are important for 
DNA replication. LSDV also contains enzymes involved in nucleotide biosynthesis like 
homologues of thymidine kinase and ribonucleotide reductase. Thirty genes encode proteins 
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important in viral structure which include putative homologues of A36R, B5R and VV A4L 
which have been identified as genes encoding structural proteins of vaccinia virus.  
Studies on LSDV genomes have shown that the genomes of virulent LSDV are highly 
conserved. LSDV isolated from the Balkans recently was sequenced. Results showed that the 
genome was 99.95% similar to the virulent Neethling strain that was isolated in South Africa 
in 1999 (Toplak et al., 2017).   
Kara et al. (2003) compared the sequences of 2 virulent LSDVs and one attenuated LSDV 
(Table 1.4). Comparing the two virulent strains, the Kenyan (Kenyan 2490) and the South 
African (LD) isolates, mutations were found in the variable terminal regions of the genome 
(Kara et al., 2003).  
Significant differences were found between the Warmbaths virulent LSDV and the attenuated 
vaccine strain (nLSDV). 114 genes out of 156 had nucleotide changes that resulted in 438 
different amino acid changes. Of interest were the frameshift mutations which led to the 
truncation of 4 genes (Table 1.4). Amongst 9 frameshift mutations observed (see Table 1.4) 
were ORF 134 (a homologue of the B22R gene in Vaccinia virus) and ORF 131 (superoxide 
dismutase homologue (Kara et al., 2003). The relevance of these mutations becoming apparent 
in the DNA comparison of Herbivac and Neethling vaccine, described later.   
Most of the changes are found in ORFs belonging to Kelch like repeat motif family. These 
proteins have been shown to be involved in virulence and their disruption in nLSDV may be 
the source of attenuation. SPPV019 was shown to be linked to virulence and SPPV019 knock-
out viruses were shown to be attenuated (Balinsky et al., 2007).   Proteins containing the mutT 
motif (nudix hydrolases) are important in host range and studies have shown that knocking out 
this domain results in defects in replication in mutant vaccinia virus (Liu et al., 2015).  
More recently, three South African produced vaccines, namely, nLSDV (OBP), Herbivac 
(Deltamune) and Lumpyvax (MSD) were sequenced (Mathijs et al., 2016). The published 
sequence of the Neethling vaccine strain from Onderstepoort was used as a reference sequence 
(Kara et al., 2003). The genomes of the three vaccines were found to be almost identical with 
99.9% homology. All three vaccines were shown to have comparable genome sizes. The 
termini of these genomes were however, not sequenced. (Mathijs et al., 2016). 
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Table 1.4. List of ORFs found to be different between a virulent LSDV (Warmbaths strain) and 































17909-18817 (303) Kelch-like domain 
ORF134 122187-
128264(2026) 
121991-124156(722) Kelch-like domain 
ORF013 8932-9918 (329) 8784-9809 (342) interleukin-1 receptor-like 
protein 
ORF035 28592-29797(402) 28541-29671(377) hypothetical protein 
ORF131 119272-





ORF086 79895-80533(213) 79767-80396(210) mutT motif 
ORF087 80536-81297 
(253) 
80409-81008(200) mutT motif  
All three vaccine sequences resembled one another but differed from the published sequence 
in that they contained two amino acid changes namely T/M in ORF 56, V/A in ORF 116 and a 
further two nucleotide changes in a non-coding region of the genome. In addition to these 
changes Herbivac differed from nLSDV in that it contained a two-base pair deletion which 
caused a frame shift mutation and subsequent restoration of the ORF LW134 from LW134a 
and LW134b (Mathijs et al., 2016, Mathijs et al., 2017). ORF134 was previously reported to 
encode a putative protein similar to B22R, an ORF present in Orthopoxviruses (Kettle et al., 
1995). Deletion of vaccinia virus B22R causes attenuation, thereby increasing its safety profile 
(Legrand et al., 2004). A homologue of B22R (C15) in Ectromelia virus was shown to 
contribute to pathology in an animal model (Reynolds et al., 2017). The restoration of ORF134 
may have improved the immunogenicity of Herbivac but may also have increased its virulence. 
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Based on confidential unpublished data, Herbivac LSDV was regarded as being more 
immunogenic than nLSDV, from which it was derived (personal communication). The 
Herbivac genome was sequenced by Dr Nicola Douglass (unpublished) and compared to the 
SA Neethling vaccine sequence (LSDV LW) (Kara et al., 2003). The genomic sequences were 
almost identical with only 2 single nucleotide changes (SNPs) and 1 deletion of 2bp. The SNPs 
were found in LSDV genes LW056 (hypothetical protein) and LW116 (RNA Polymerase 
subunit). Both these SNPs resulted in conservative amino acid changes, unlikely to affect the 
function of the putative proteins. 
The deletion of 2bp was found in the homologue of the superoxide dismutase (SOD) open 
reading frame (ORF). This difference in Herbivac was confirmed by PCR and sequencing 
across the SOD homologue region. Since the mutation in the SOD locus was the only functional 
difference noted, the improved immunogenicity of Herbivac compared to LSDV LW is 
therefore most likely due to the mutation in the SOD locus. As stated above, the nLSDV 
vaccine SOD is truncated relative to virulent LSDV (LSDV Neethling 2490) due to a frameshift 
mutation. The nLSDV putative SOD protein is only 108 aa in length as opposed to 161 aa for 
the virulent nLSDV (Figure 1.8). The further deletion of two nucleotides from nLSDV in 
Herbivac results in the restoration of the SOD ORF in Herbivac (160aa) such that it resembles 
the SOD homologue from the more virulent Neethling strain 2490 (Tulman et al., 2001a) 
(Figures 1.7 & 1.8). The mutation of 2bp is found in a run of TA dinucleotides which could 
render this region unstable.   
It would appear as if the full-length SOD homologue benefits the virus in an animal host, as it 
was lost upon passage during the attenuation of nLSDV yet re-emerged upon passage in a 
bovine host. The sequencing data showed 60% of the raw reads to contain the deletion and 40% 
to resemble nLSDV (unpublished). Putting the results from our laboratory together with the 
published sequence of Herbivac (Mathijs et al., 2016, Mathijs et al., 2017) it is likely that  two 
different seed lots of Herbivac  were produced, which differed in the two loci (ORF 131 and 
ORF 134).   
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Figure 1.7. Nucleotide alignment of ORF 131 of LSDV Nl 2490, nLSDV, and Herbivac. CLC (Qiagen, USA) alignment 
programme available on CLC main workbench was used to align the SOD homologue ORFs from the virulent Nl 2490, the 
Neethling vaccine (nLSDV) and the LSDV vaccine Herbivac. Dots represent matching residues. Gaps are shown by dashes.  
 
Figure 1.8. Alignment of putative amino acid sequences of SOD homologue genes from the virulent Neethling 2490 
strain, Herbivac and LSDV LW (Neethling vaccine- nLSDV) strain (parent of Herbivac). Alignment was done using 
CLC workbench (Qiagen, USA).  
1.5 Virus host interaction: Innate immunity against viral infections 
In order to detect foreign pathogens that include viruses, cells employ pathogen associated 
molecular patterns (PAMPs) (Kawai and Akira, 2008) and damage associated molecular 
patterns (DAMPs) (Ma and Damania, 2016). The effect of the action of these pattern 
27 | P a g e  
 
recognition receptors (PRRs) includes production of type 1 interferons and many different 
cytokines and chemokines which can alter cell development (growth and death) as well as 
recruitment of the adaptive arm of the immune system (Ma and Damania, 2016, Delaloye et 
al., 2009).  
Antiviral sensing mechanisms include Toll-like receptors, nucleotide binding and 
oligomerisation domain like receptors (NLRs), retinoic acid inducible gene-1 like receptors 
(RLRs), cGMP-AMP (cGAMP) synthase (cGAS) and absent in melanoma 2 (AIM2) receptors 
(ALR) (Akira et al., 2006, Orzalli and Kagan, 2017, Ma and Damania, 2016). Sensing of the 
virus using TLRs occurs at the cell surface and the cytoplasmic-endosomal compartment. The 
aforementioned antiviral sensing receptors then employ adaptors through which their activity 
is exerted as shown in Figure 1.9. 
TLRs contain a homotypic protein-protein interaction with adaptor molecules, or procaspase 
thereby causing its proteolytic activation. Caspase-recruitment domain (CARD) and Pyhin 
domain (PYD) are some of the effectors. NLRs can bind viral RNA directly (Hong et al., 2012). 
NLRs combine with other proteins like procaspase-1 and an adaptor protein apoptosis-
associated speck-like protein containing a CARD (ASC) to form the inflammasome. The 
inflammasome multiprotein complex leads to cytokine production, in particular, IL1β and IL18 
which leads to activation of NF-κB. The inflammasome is activated after infection with DNA 
viruses like Vaccinia virus (Delaloye et al., 2009), (reviewed by Jacobs and Damania (2012)) 
and is implicated in inflammatory, caspase dependant programmed cell death (pyroptosis). 
During a viral infection, nucleotide oligomerisation domain (NOD 2) complexes with  
mitochondrial antiviral signalling protein (MAVS) to induce type 1 interferons via the 
activation of the interferon regulatory factors IRF3 and IRF7 (Figure 1.9) (Kanneganti, 2010). 
The activity of Nod-like receptors (NLRs) has been reviewed by (Jacobs and Damania, 2012). 
These NLRs, like TLRs, mediate their function through their interaction with NLR effector 
domains via protein-protein interactions. However, direct binding between viral PAMPs and 
ssRNA has been suggested (Jacobs and Damania, 2012). 
Other molecules can also form the inflammasome without NLRs and these include absent in 
melanoma 2 (AIM2) and retinoic acid inducible gene-I (RIG 1). Vaccinia virus was shown to 
trigger the AIM2 inflammasome with concomitant release of IL-1β, cleavage of caspase-1 and 
IL-1β maturation (Rathinam et al., 2010). AIM2, part of the PYHIN family plays a vital role 
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in sensing cytosolic dsDNA (Thompson et al., 2011). AIM2 binds dsDNA in the cytoplasm 
and forms the AIM2 inflammasome with concomitant activation of caspase 1 in pro-IL-Iβ 
containing cells, with subsequent maturation of pro-IL-Iβ to IL-Iβ (Schroder et al., 2009).  
Poxviruses have evolved many mechanisms of immune evasion (Bidgood and Mercer, 2015). 
LSDV is no exception and has homologues of cellular and viral gamma interferon (IFN-γ) 
receptor (R), IL-18 binding protein, IL-1R, IFN-α/β binding protein and interleukin-10 (IL-10). 
LSDV also encodes membrane bound immunomodulatory proteins that act like chemokine 
receptors, binding intracellular or extracellular factors. These include LSDV010.  
Other viral proteins like LSDV014 and LSDV034 are potent in inhibiting the antiviral effects 
of interferon (IFN). Serine proteinase inhibitors (serpins) exert an immunomodulatory role. In 
cowpox virus, Serpin CrmA was shown to block caspase activation leading to a reduction in 
IL-1β secretion (Ray et al., 1992). LSDV also encodes a gene class similar to the A52R gene 
family which encode proteins which act as Toll like receptor antagonists. These include 
LSDV001, LSDV009, LSDV136, LSDV150, and LSDV156. LSDV encodes proteins with 
ankyrin repeat motifs. These genes have been implicated in host range functions (Tulman et 
al., 2001a). 
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Figure 1.9. Innate immune system recognition of different antigens including poxviruses. Pathogen recognition receptors (PRRs) that are employed by the host against poxviruses include 
members of the Toll like receptor family, retinoic acid inducible gene-1 (RIG-1)-like receptors (RLRs), nucleotide oligomerisation domain (NOD)-like receptors (NLRs) and inflammasomes. 
Indicated by cartoon representations of poxviruses are known sites of interaction of poxvirus proteins with the host pathogen sensing mechanisms. Toll like receptors are important in sensing 
viral/viral related products (TLR 3,4,7,8 &9), bacteria via lipopeptides (TLR 1&2), fungi and drugs. TLRs trigger production of type 1 interferons, inflammatory cytokines (TNF α, IL 6, IL 1 β 
and IL 12) and chemokines, which subsequently activate the NFkB pathway and Type 1 interferon response. They use their leucine rich domains to sense pathogens and make use of intracellular 
adaptor molecules like myeloid differentiation protein 88 (MyD88), Toll/Interleukin-1 receptors domain (TRIP), TIR domain-containing adapter protein (TIRAP) and TIR domain-containing 
adapter inducing IFNβ (Trif)) and Trif-related adapter molecule (TRAM). Specific TLRs are numbered in the diagram together with their adaptors molecules. The RIG-like receptor family uses 
3 different receptors namely, melanoma differentiation-associated gene 5 (MDA5), laboratory of genetics and physiology 2 (LGP2) and RIG 1 which have adaptor molecules MAVS and IPS-1. 
Nod like receptors and the AIM2 like receptor family sense viral nucleotides and activate the inflammasome. The effect of the action of these PRRs leads to the production of Type 1 interferons 
(IFN) and IL1β/18 (Ma and Damania, 2016). This response ultimately constitutes an antiviral response. Taken from Offerman (2014), which was adapted from (Kawai and Akira, 2006) and 
(Kanneganti, 2010). 
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1.5.1 The interferon stimulated genes (ISG) 
Interferons play a role as antiviral cytokines (Baldanta et al., 2017). They exert their function 
through induction of interferon stimulated genes (ISGs) (Schoggins, 2014). This is mediated 
by the recruitment and activation of Janus Kinases (JAKs), activation of signal transducers and 
activators of transcription (STATs) whose activity once translocated into the nucleus is to drive 
the translation of interferon stimulated genes (ISGs) (Mercer et al., 2007a). Table 1.5 below 
shows ISGs expressed following virus infection and the function of these ISGs. 
Table 1.5. Interferon Stimulated Genes that are activated by Type 1 interferons. Modified from (Bowie and 




ISG15 Modification of viral proteins by 
ubiquitylation  
(Zhang and Zhang, 2011, 
Baldanta et al., 2017) 
APOBEC3, ADAR  RNA editing (Sharma et al., 2015, Smith et 
al., 1997) 
Mx PROTEIN Transcription and trafficking of other 
ISGs  
(Verhelst et al., 2013) 
PKR Inhibition of translation (Krishnamoorthy et al., 2001) 
RNaseL, 2’5’ OAS RNA degradation (Chawla-Sarkar et al., 2003) 
TRIM proteins Host response regulation and inhibition 
of viral transcription 
(van Tol et al., 2017) 
MicroRNAs Gene regulation  (Sedger, 2013) 
MDA-5, RIG-1, DAI Pathogen recognition (Bowie and Unterholzner, 2008) 
TRAIL, Fas, caspase 
4, RIDs, PKR, DAP 
kinase 
Apoptosis (Chawla-Sarkar et al., 2003) 
1.5.2 Apoptosis as an antiviral mechanism 
Apoptosis is a programmed cell death with innate immune function that is specifically activated 
to remove unwanted cells which can either be defective or virus infected (reviewed by Seet et 
al. (2003), (Veyer et al., 2017) (Everett and McFadden, 1999). Cytotoxic T-lymphocytes (CTLs) 
and natural killer cells (NK) mediate this process via the perforin/granzyme pathway. There 
are two pathways of apoptosis namely the intrinsic and extrinsic pathways (reviewed by Nagata 
(2018) (Figure 1.10). The extrinsic apoptotic pathway uses an external stimulus to induce 
apoptosis.  CTLs employ death receptors on the surfaces of infected cells to induce apoptotic 
cell death via the extrinsic pathway.  The intrinsic pathway of apoptosis does not involve 
receptors like the extrinsic pathway. Stimuli for death via the intrinsic pathway include use of 
positive or negative intracellular signals. Absence of growth factors, cytokines or hormones 
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which naturally inhibit cell death is one way negative signalling promotes apoptosis. Thus, loss 
of any signals that favour cell survival leads to cell death. Positive signalling of cell death 
include radiation, hypoxia, reactive oxygen species (free radicals), hyperthermia and, 
importantly, virus infections (reviewed by Elmore (2007)). Once these stimuli are detected, 
mitochondrial membrane permeabilization (MMP) occurs and pro-apoptotic factors are 
released from the intermembrane space (IMS). One of the factors released is cytochrome C. 
Cytochrome C activates the apoptosis protease-activating factor 1 (APAF-1) and ATP/dATP 
to generate the apoptosome. The apoptosome in turn activates caspase 9 which activates other 
caspases leading to apoptosis (Figure 1.10). 
 
Figure 1.10. Pathways of apoptosis. The extrinsic apoptotic pathway uses death ligands that include FAS, TRAIL and TNF-
α via their respective death receptors. The death receptor includes a transmembrane domain which is linked to the different 
death effectors like Fas-associated protein with death domain (FADD). The intrinsic apoptotic pathway does not use membrane 
bound death receptors but has sensing mechanisms to various intracellular stimuli that include DNA damage. B cell lymphoma 
proteins, Bcl-2 and Bclxl are antiapoptotic whereas members of the BH3 family are pro-apoptotic. The B cell lymphoma 2 
homology 3 (BH3) proteins interact with Bax and Bak to effect apoptosis. Bak and Bax affect mitochondrial outer membrane 
potential (MOMP) leading to the release of cytochrome c. Cytochrome c multimerises with pro-caspase 9 and apoptotic 
protease-activating factor 1 (Apaf-1) to form the apoptosome which activates procaspase 9 to caspase 9. Both the intrinsic and 
extrinsic pathway eventually lead to the activation of caspase 3 which acts on a variety of substrates to cause apoptosis (Taken 
from Nagata (2018)). Permission to reuse image was granted. 
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1.5.3  The different mechanisms of cell death  
The known forms of cell death are depicted in Figure 1.11. The unique feature of apoptotic cell 
death is nuclear fragmentation well before cell lysis (Duke and Cohen, 1986). When cells die 
via apoptosis, apoptotic bodies are formed which are engulfed by phagocytic cells 
(Arandjelovic and Ravichandran, 2015). Efferocytosis refers to the removal of apoptotic cells 
by macrophages, though recent literature has shown that this can be extended to other forms of 
cell death (Karaji and Sattentau, 2017). No inflammatory response is induced following 
apoptosis. Necrosis is a form of cell death which involves swelling of cells, nuclear and 
cytoplasmic disintegration and cell rupture (reviewed by (Gamrekelashvili et al., 2015)). In this 
form of cell death, damage associated molecular patterns (DAMPs) bound to nucleosomes are 
released (Yoon et al., 2014) and an inflammatory response is elicited. Both forms of cell death 
result in the cleavage of DNA, however apoptosis results in the cleavage of DNA into 
nucleosomal units in the cell (Nagata, 2000). Due to the activation of multiple lysosomes in 
necrotic cell death, initially cleavage was thought to be disorderly (reviewed by De Duve and 
Wattiaux (1966)); but later early necrosis was shown to be ordered with cleaved DNA 
containing predominantly 5’ overhangs (Didenko et al., 2003). Apoptosis results in the release 
of poly- or oligonucleosomes in contrast with necrosis, which results in degraded DNA and 
histones (Yoon et al., 2014). Unlike apoptosis, necrosis activates the inflammasome via the 
activation of IL-1β and IL-18 (Griffith and Ferguson, 2011). Inhibition of necrosis has been 
implicated in poxvirus dissemination (reviewed by Chan et al. (2015)).   
Pyroptosis is an inflammatory form of cell death characterised by caspase-1 activation and IL-
1β secretion. Necroptosis has been identified as a form of programmed cell death that augments 
or is a salvage mechanism for apoptosis, especially when drivers for apoptosis are blocked 
(reviewed by (Walsh, 2014)). Necroptosis is chiefly driven by receptor interacting protein 
kinase (RIPK3) and does not use caspases (Dunai et al., 2011). Necroptosis, a form of necrosis, 
involves the leakage of cellular contents into the extracellular milieu (reviewed by 
Gamrekelashvili et al. (2015)) and, like pyroptosis, elicits an inflammatory response (reviewed 
by Rock and Kono (2008)) and (Tait et al., 2014).  




Figure 1.11. Different forms of cell death elicit either an anti- or pro- inflammatory response. Apoptosis is characterised 
by DNA fragmentation which is mediated by caspase activated DNases. These introduce DNA breaks. Macrophages release 
transforming growth factor-β (TGFβ) and interleukin 10 (IL10) which inhibit inflammation. Necroptosis and pyroptosis are 
two different forms of necrosis which promote inflammation. This inflammatory response is mediated by the release of damage 
associated molecular patterns (DAMPs). The DAMPs activate the inflammasomes which in-turn activate the caspases. The 
DAMPs cause cells to release cytokines which are chemoattractant for immune cells (Taken from Nagata and Tanaka (2017). 
Permission to reuse image was granted. 
1.5.4  Inhibition of apoptosis 
Evasion of apoptosis can be advantageous to the virus as the virus can persist to complete its 
replication and produce progeny (reviewed by Zhou et al. (2017). Whilst some viral infections 
will inhibit apoptosis, others use it to aid viral dissemination (Zhou et al., 2017). In the case of 
a vaccine vector, evasion of apoptosis can help ensure that foreign antigens are expressed for 
a longer length of time. In the case of a vaccine, evasion of caspase mediated cell death can be 
beneficial since the infected cell will then engage in programmed necrosis (necroptosis) and an 
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inflammatory response will be induced. Figure 1.12 shows some of the sites and molecules 
targeted by viral proteins in the evasion of apoptosis. 
 
Figure 1.12. Outline of both the extrinsic and intrinsic apoptotic pathways showing sites at which viral proteins inhibit 
these pathways. (1) Binding of tumour necrosis factor (TNF) to the TNF-receptor (TNFR-1) triggers association of its 
cytoplasmic regions death domain (DD) with TNFR associated death domain protein (TRADD) which leads to nuclear κB 
activation. Binding of FasL to FasR also causes recruitment of the procaspase 8 via its Fas associated death domain (FADD). 
(2) TNF can also induce apoptosis when receptor interacting protein RIP interacts with FADD and procaspase-8. (3) 
Oligomerisation of the procaspase-8 results in cleavage resulting in activation of caspase-3 in (4) or (5) cleavage of BH3 
interacting domain death agonist (Bid) to its cleavage products truncated Bid (tBid). (6) tBid can either activate Bcl-2 
homologous antagonist killer (Bak)/Bcl-2 associated protein (Bax) in the mitochondria or Bak/Bax can make the mitochondria 
porous in response to calcium ions (Ca2+) from the endoplasmic reticulum or Golgi apparatus. (7) Permeabilization of the 
mitochondria is the result of Bak/Bax and this makes the mitochondria extrude cytochrome C and other caspases from the 
inner mitochondrial membrane to the cytoplasm. (8) Formation of the apoptosome from cytochrome c binding Apaf1 and 
subsequent activation of initiator caspase 9 (9) whose role is to activate effector caspases (Caspase 3). Smac from the inner 
membrane of the cytoplasm binds inhibitor of apoptosis proteins (IAPs) which further activates caspase 3 which in (10) cleaves 
target proteins resulting in the induction of apoptosis. The poxviral proteins from Myxoma virus (MYX) – M11, MYXV, 
M131, Vaccinia virus (VV) F1, Molluscum contagiousum MC163 and Shope Fibroma virus (SFV) S131R antagonise the 
apoptotic immune response. CrmA is a powerful inhibitor of apoptosis which inhibits the activated caspases. The same serpin 
was also shown to protect cells from FAS and TNF mediated cell death. CrmA is also integral at preventing perforin dependant 
apoptosis by inhibiting the effect of the serine protease granzyme B (reviewed by Seet et al. (2003)). Modified from Nichols 
et al. (2017). Permission to reuse image was granted. 
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1.5.5 Cell death and immunogenicity 
Evasion or induction of cell death can affect immunogenicity. There has been contradicting 
views on whether apoptosis is immunogenic or not (Griffith and Ferguson, 2011). Being a non-
inflammatory form of cell death, which clears a host of virally-infected cells, apoptosis is not 
an obvious mechanism to exploit to induce/improve immunogenicity of a live vaccine. 
However, a recombinant live rabies vaccine expressing  cytochrome C, a pro-apoptotic protein, 
was shown to induce protective immunity by induction of apoptosis (Dietzschold et al., 2006). 
Damage associated molecular patterns (DAMPs), induced by necrosis, cause an inflammatory 
response, which would enhance immunogenicity (reviewed by Griffith and Ferguson (2011).  
There is no report to date implicating the involvement of LSDV SOD homologues with 
improved immunogenicity.  
1.5.6 Modulation of host factors as a mechanism for immune evasion and host range 
The host first interacts with a virus at the cell surface. The second point of interaction is when 
a virus undergoes replication inside the cytoplasm of the infected cell. Early gene products 
often carry an immune evasion role and are also known as virulence factors. These molecules 
help subvert the host antiviral system and therefore determine virus tropism. As mentioned 
above, cell viral sensing mechanisms include the use of PRRs to inhibit viral replication. 
Therefore, in order to replicate inside a cell, poxviruses must inactivate certain anti-viral 
mechanisms such as dsRNA sensing mechanisms designed to supress viral replication, which 
include 2′,5′-oligoadenylate synthetase (OAS/RNase) and double stranded RNA dependent 
protein kinase R (PKR) (Sadler and Williams, 2008). Vaccinia virus produces an enzyme E3 
which antagonises the activity of OAS and PKR (McFadden, 2005, Chang et al., 1992). 
Vaccinia virus E3 is an early viral protein with a double stranded RNA (dsRNA) binding 
domain that suppresses the interferon  response by  preventing  activation  of  the  dsRNA- 
activated protein kinase R (PKR) (Chang et al., 1992, Watson et al., 1991). The same enzyme 
is encoded by the ORF034 in lumpy skin disease virus and has been reported to inhibit the 
activity of PKR (Tulman et al., 2001b).  LSDV encodes a repertoire of genes that determine its 
host range including homologues of VV C7L, N1L virulence, Myxoma (MYX) 004, an anti-
apoptotic gene product M011L and a rabbit fibroma virus p28 host range factor (Tulman et al., 
2001a). Studies show that the Kelch-like proteins expressed by capripoxviruses differ slightly 
and probably account for the strict host restriction of these viruses (Balinsky et al., 2007). 
LSDV contains homologues of all the genes in sheeppox and goatpox viruses and, in addition, 
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has 9 more ORFs, one or more of which possibly confer the ability of LSDV to grow in bovine 
cells. One of the unique genes expressed by LSDV is LSDV132 which was postulated to play 
a role in virulence and host range (Tulman et al., 2002). 
Vaccinia virus D9 and D10 are decapping enzymes which remove the 5’ cap on mRNA (Liem 
and Liu, 2016). This leads to degradation of host mRNA, thereby preventing synthesis of host 
proteins important in antiviral defence. Also, the degradation of mRNA limits the amount of 
RNA and dsRNA before final assembly of genomic DNA into immature viruses. This helps 
evade antiviral mechanisms against dsRNA which gets produced by DNA viruses (Burgess 
and Mohr, 2015, Silverman, 2015).  
Twelve host range gene families that help a virus replicate in a host have been identified and 
are shown in table 1.6.  Much work has been done on vaccinia virus and this is thought to apply 
to other poxviruses (reviewed by Bahar et al. (2011)). Table 1.7 documents known LSDV 
proteins that could modulate the host cell function or antiviral immune response.  
1.6 Generation of the superoxide anion in response to viral infection 
Poxviral infection activates processes that have been implicated in the generation of reactive 
oxygen species (ROS) including the superoxide anion (Liem and Liu, 2016). The amount of 
superoxide anion is also increased by the action of macrophages and lymphocytes which have 
been shown to produce superoxide anion as a defence mechanism against pathogens (Johnston 
et al., 1978). Phagolysosomes, which are cytoplasmic bodies formed between the fusion of a 
phagosome and a lysosome, are involved in the catabolism of pathogens, particularly bacteria 
(Armstrong and Hart, 1971, Klionsky et al., 2014). They produce superoxide which is 
complexed with nitrogen species (NO2) to form highly reactive oxygen species, namely, 
peroxynitrite (ONOO−). Action of superoxide or hydrogen peroxide can remove iron from iron 
clusters (4Fe-4S) and it is this iron that can also cause damage when it combines with hydrogen 
peroxide to form a highly reactive hydroxyl anion which can damage DNA. The product of 
superoxide dismutation, hydrogen peroxide, can also oxidise cysteine residues present in 
proteins of the pathogen (reviewed by Slauch (2011)). 
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Table 1.6. List of Poxvirus host range gene families and how they mediate their function (Oliveira et al., 2017, Bratke et al., 2013, Werden et al., 2008, Iyer et al., 2002).  
Host range gene 
family 
Putative proteins encoded by other 
poxviruses 
Role Reference 
K3L SWPV - C8, VV-WR K3L Inhibits antiviral PKR (Davies et al., 1993, Carroll et al., 1993) 
E3L VV E3L Inhibitor of PKR (Davies et al., 1993, Beattie et al., 1996, 
Langland and Jacobs, 2002) 
C7L/M063R CPXV-GRI-90, VV-C7L, MYXV- 
M062R, M063R & M064R 
Inhibits interferon  (Meng et al., 2009, Meng et al., 2012) 
TNF receptor (R) 
II homologue T2 
(Crm) 
MYXV T2, Crm B, C, D, E, CPXV-




(Smith et al., 1990, Smith et al., 1991, 





CPXV-203, CMLV-188, TATV-195, 
CPXV-GRI (B8R) & MPXV (B10R) 
Anti-apoptotic  (Hnatiuk et al., 1999) 
Bcl-2/M11L VV N1L, A52 and B14 Anti-apoptotic by 
sequestering apoptotic 
factors Bak & Bax 
(Everett et al., 2000, Wasilenko et al., 2003) 
Pyrin domain 
M13L 
MYXV 13L, RFV 13L, SWPV 014, 
DPV 024, YLDV 18L and TPV 18L 
Inhibit caspase 1 
activation & subsequent 
cytokine production 
(Johnston et al., 2005, Bratke et al., 2013) 
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Host range gene 
family 






SPI-1, SPI-2 (CrmA) and SPI-3, 










VV B5R Involved in cell to cell 
spread 














CPXV-BR 017/025, 220, 011, 213, Mediate protein -protein 
interactions using their 
repeat domains 
(Mercer et al., 2005, Sonnberg et al., 2008, 
Werden et al., 2008) 
Orthopoxvirus 
K1L family 
VV K1L Supports viral replication 
through interactions with 
protein factors 
(Ramsey-Ewing and Moss, 1996, Shisler 
and Jin, 2004) 
CPXV-cowpox virus, VARV-Variola virus, VV-Vaccinia virus, MYXV-myxoma virus, ECTV- Ectromelia virus, SWPV-Swinepox virus, TATV-
Taterapoxvirus, CMLV-Camelpox virus, YLDV-Yaba-like disease virus, TPV-Tanapox virus, DPV-Deerpox virus and RFV- Rabbit fibroma virus. 
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Table 1.7. Viral genes in LSDV that could be involved in modulating the immune response, host function and apoptosis. 
Adapted from (Tulman et al., 2001b, Kara et al., 2003). 







Homologues of IL 10, IFN-ϒ receptor (IFN-
R), IL-1R, IFNα/β binding protein and IL-
18 binding protein respectively 





Homologues of G protein-coupled CC 
chemokine receptor (GPCR), CD47 and 
OX-2 like proteins respectively 
Affect intracellular signalling 
transduction and or bind 
extracellular factors to evade the 
immune system and contribute 
to host range 
LSDV014, 
LSDV034 
Homologues of VV PKR inhibitors Intracellular roles in immune 
modulation or evasion by 
conferring resistance to antiviral 
effects of IFN 
LSDV149  Similar to Vaccinia virus C12L and 
Myxoma M151R 
Poxvirus serine protease 
inhibitors which have anti-
inflammatory roles and block 






Similar to VV A52R Antagonist for host cell IL-1, 
Toll like receptor signalling, 
Toll-like receptor 4 and IL-18R 
induction of NF-kβ 
LSDV0067 Homologues of epidermal growth factor 
(EGF), VV C7L host range, N1L virulence 
protein and A14.5l virulence protein, MYX 
M004&M011L anti-apoptosis, rabbit 
fibroma virus (RFV) N1R virus host range 
factor 






 Genes that contain Akyrin repeats Host range functions, inhibition 
of viral induced apoptosis  




VV K4L phospholipase D-like protein, 
cellular Cu Zn superoxide dismutase and 
tyrosine protein kinase 
LSDV131 function to be 
investigated and LSDV143 





VV A55R, A52R Kelch like protein  Host range function and  




Similar to Leporipoxvirus M011L Apoptosis regulator, inhibition 
of apoptosis 
LSDV- virulent field strain 2490 (Tulman), LD – Warmbaths strain-Kara, and LK-Neethling 
Kenyan 2490 strain.  
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1.6.1  Function of the superoxide anion 
Reactive oxygen species activate mitogen activated kinases such as MEK or MAPK which 
control cellular proliferation (Behrend et al., 2003). The role of superoxide in apoptosis and 
inflammation has been complicated by the fact that the superoxide radical behaves differently 
depending on its concentration (Teoh et al., 2005). In a pro-oxidative state, the superoxide 
radical has been shown to be anti-apoptotic (Teoh et al., 2005). Mild increases in superoxide 
can inhibit cell death signalling with a shift towards H2O2 causing an apoptotic response 
(Pervaiz and Clement, 2002b) (Kumar et al., 2007). This probably explains the varying effects 
reported regarding its role in apoptosis and inflammation.  
The ratio of superoxide to hydrogen peroxide in tumour cells firmly regulates apoptotic death 
(Kumar et al., 2007). In one experiment, Clement and Stamenkovic showed that preincubation 
of Jurkat cells with a SOD inhibitor diethyldithiocarbamide (DDC) raised superoxide 
concentration and consequently inhibited Fas mediated cell death (Clement and Stamenkovic, 
1996). Fas (also known as CD95) is a cell surface cell death receptor which is involved in 
inducing apoptosis (Krammer, 2000). Other reports have shown that the intracellular redox 
state of a cell affects its fate. This redox state is regulated through the function of a Na+/H+ 
exchanger (NHE). It actively extrudes H+. Superoxide anion activates NHE1 promoter activity 
while H2O2 inhibits NHE1 promoter activity which promotes survival (Akram et al., 2006, 
Kumar et al., 2007).  
1.6.2 The role of the superoxide anion in apoptosis 
Recent studies have shown that small increments in the superoxide anion tend to promote 
survival whereas an increase in hydrogen peroxide (a product of superoxide dismutation) 
promotes cell death. Table 1.8 below summarises some evidence for the claim. 
 
 
41 | P a g e  
 
Table 1.8. A summary of reports supporting the notion that the superoxide anion is anti-apoptotic and hydrogen 
peroxide is pro-apoptotic. 
Superoxide anion (O2-) 
ANTIAPOPTOTIC 
Hydrogen peroxide (H2O2) 
APOPTOTIC 
At low levels superoxide can inhibit cell death 
[Pervaiz & Clément, 2002]  
H2O2 activates Caspases 3&6 [Kumar et al., 
2007] which induces apoptosis 
Superoxide activates NHE promoter activity 
[Akram, et al 2006] 
H2O2 inhibits NHE 1 promoter activity [Kumar 
et al, 2007], which induces apoptosis 
Mitochondrial superoxide cannot be 
translocated into the cytoplasm [Novo and 
Parola, 2008] 
H2O2 can pass through mitochondrial 
membranes causing cytotoxic damage [Novo 
and Parola, 2008] 
Superoxide activates mitogen activated 
kinases such as MEK or MAPK which control 
cellular proliferation [Behrend et al., 2003] 
Myelorexidase of phagocytic cells can use 
H2O2 to form highly reactive hypochlorite 
[Novo and Parola, 2008] which kills infected 
cells 
Superoxide is a natural inhibitor of Fas-
mediated cell death [Clement and 
Stamenkovic, 1996] 
H2O2 induces apoptosis in Hela cells via the 
mitochondrial pathway [Singh et al, 2007] 
 
1.6.3 Role of antioxidants  
Antioxidant mechanisms exist in a cell with the primary role of removing reactive oxygen 
species like the superoxide anion. One of the antioxidants is superoxide dismutase (SOD) 
which is involved in the dismutation of the superoxide anion (O2
- ) to hydrogen peroxide (H2O2) 
and oxygen (O2) as per the equation below:  
O2·
- + O2·
- + 2H+ → O2 + H2O2 (McCord and Fridovich, 1969) 
Different types of SOD exist. There are SODs that contain copper and zinc (Cu, Zn SOD), 
manganese (MnSOD) and iron (FeSOD) (Scandalios, 1993). These enzymes perform the same 
function which is to catabolise the superoxide anion to oxygen and hydrogen peroxide. They 
differ in localisation. Cu Zn SOD is found in the cytosol, the mitochondrial intermembrane 
space and in peroxisomes. Mn SOD is found only in the mitochondria (Fukai and Ushio-Fukai, 
2011). 
SOD 
42 | P a g e  
 
1.6.3.1  Structure and activity of Cu Zn SOD 
The activity of SOD is intimately related to the structure of the enzyme. Copper zinc SOD is a 
homodimer with each subunit containing a β barrel which is made up of 8 β strands in an 
antiparallel fashion to make a Greek Key motif. This motif is indispensable for electrostatic 
guidance, dimerization and dismutation of the anion using the transition metal copper 
(reviewed by Perry et al. (2010). The hydrophobic motifs form the internal core and direct the 
β barrels into the active sites. Cu is held in the active sites by 3 histidines in the reduced state 
whereas Zn is bound by three histidines and one aspartic acid. The size of the pocket of the 
active sites poses steric hindrances to other molecules like phosphate which otherwise could 
occupy the active site. Presence of the hydrophobic core and the main chain β sheet give 
structure to the enzyme (reviewed by Perry et al. (2010). Figure 1.13 shows the structural form 
of cellular Cu Zn SOD. 
Cu Zn SOD is activated from its apo state when the copper ion is docked onto the enzyme 
(Culotta et al., 2006). Copper is supplied by the copper chaperone for SOD (CCS) (Rae et al., 
2001). In Cu, Zn SOD, the zinc is supplied by passive diffusion (Teoh et al., 2003). Before 
docking of copper to Cu Zn SOD and subsequent activation, a CCS-SOD 1 heterodimer is 
formed (Torres et al., 2001, Rae et al., 2001, Culotta et al., 2006, Lamb et al., 2001). Figure 
1.14 summarises the steps involved in activation of SOD from its apo state to a fully active 
SOD dimer. 
1.6.3.2  Activation of SOD  
During activation of SOD apo state, dimerization of SOD with the copper chaperone CCS is 
important for the transfer of Cu. The amino acids of SOD and CCS facilitates dimerization 
through protein to protein interactions (Casareno et al., 1998). Domains that facilitate 
dimerization in SOD and CCS have been identified (Schmidt et al., 2000). Amino acids of 
Domain II of CCS are homologous to some residues in Cu Zn SOD such that this domain was 
once called SOD 4 by some authors (Schmidt et al., 1999, Culotta et al., 1997). Copper is 
important for stabilising the heterodimer and copper transfer is achieved when Cysteine rich 
copper donor sites interact with histidine rich acceptor sites of SOD (Torres et al., 2001). 
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Figure 1.13. Functional domains in Cu, ZnSOD are shown and the preservation of structure between different SOD 1 
proteins. Homo sapiens SOD (Hs), B taurus (Bt), A. pompejana (ApSOD), X laevis (XISOD), S oleracea (SoSOD), P. 
atrosanguina (PaSOD), S mansoni (SmSOD), S cerevisiae (ScSOD). Elements that are important in structure and the formation 
of the secondary structure are annotated above the amino acid sequence alignment. C represents the Copper binding ligand, D 
cysteine, B, the bridging histidine, Z zinc binding domain. The second image shows the structure of HsSOD (1PUO). The 
structural elements are in colour and encoded with abbreviations (V-loop for variable loop. GK1 and GK2 for Greek loops 1 
and 2 and S-S, disulphide region). N denotes the amino terminal and C the carboxyl terminal. The metal binding ligands are 
represented as sticks with the bridging Histidine on position 61 in white. Taken from (Perry et al., 2010). Permission to reuse 
image was granted. 
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Figure 1.14. Putative mechanism for docking of copper onto SOD 1 by the chaperone, CCS. Step I and II- 
Copper is acquired by the chaperone and SOD 1 heterodimerises with CCS to form a CCS-SOD1 heterodimer. 
Step III- the heterodimeric complex is activated when exposed to molecular oxygen or the superoxide anion. 
Copper transfer occurs.  Step IV- the complex isomerises to an intramolecular disulphide. Taken from (Culotta et 
al., 2006).  
 
1.7 SOD homologues  
Many viruses encode SOD-like proteins. Baculoviruses, Orthopoxviruses including vaccinia 
virus and variola, Leporipoxiviruses (shope fibroma virus and myxoma virus), 
Entomopoxviruses like Amsacta moorei, chloroviruses and some viruses belonging to the 
Mimiviridae family encode SOD-like proteins (Cao et al., 2002, Teoh et al., 2003, Almazan et 
al., 2001, Becker et al., 2004, Kang et al., 2014, Lartigue et al., 2015). SOD homologues that 
have the same function as SOD enzymes have been reported for Megavirus chilensis and the 
Entomopoxvirus Amsacta moorei (Becker et al., 2004, Lartigue et al., 2015). Alignment of 
these SOD proteins show preservation of certain catalytic residues. However other SOD 
homologues which have not retained the ability to function as SOD enzymes but that have 
residues important in dimerization with the copper chaperone have been reported (Cao et al., 
2002, Teoh et al., 2005, Teoh et al., 2003). These SOD homologues inhibit the proper function 
of cellular Cu Zn SOD. An alignment of these SOD proteins reveals putative binding sites 
between the SOD homologues and the copper chaperone which may affect the proper 
metalation and activity of Cu Zn SOD (Figure 1.15).  
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Recombinant Leporipoxviruses myxoma virus (MYX) and SFV expressing SOD decoys 
M131R and S131R respectively were shown in in-situ gel assays to be catalytically inactive 
(Cao et al., 2002). The authors used a 6-hydroxydopamine test to investigate the activity of 
cellular Cu Zn SOD, after infecting cells with wild type MYX, SFV, SOD-knock-out and SOD 
knock-in viruses. They found that the cells infected with wild type virus and knock-in mutants 
had lower SOD activity compared to cells only suggesting a role of SOD in inhibiting activity 
of cellular SOD (Cao et al., 2002). Teoh et al, 2003 showed that the SOD expressed by SFV 
and MYX bind the copper chaperone for SOD (CCS). They also showed by 
immunoprecipitation, that when they used CCS specific polyclonal antibodies, they recovered 
SFV SOD (Teoh et al., 2003). Protein alignments showed SFV SOD contained a cysteine 
molecule at position 67, which could assist in the dimerization of CCS and SOD (Teoh et al., 
2003). The ability of Leporipoxviruses’ SOD to inhibit SOD activity was also shown through 
SOD activity assays which showed that infection of cells with viruses expressing SOD from 
SFV/MYX caused a 10-15% inhibition of cellular SOD activity (Teoh et al., 2005). On the 
other hand, SOD from vaccinia virus was shown to be inactive as a functional enzyme or decoy 
(Almazan et al., 2001). This was done by generating A45R knock-out and revertant A45R 
knock-in viruses which were investigated for SOD activity or inhibitory activity. In summary, 
Leporipoxviruses encode SOD homologues which are catalytically inert but bind the copper 
chaperone for SOD (Teoh et al., 2003). Shope fibroma virus (SFV) SOD acts in a way to 
perturb levels of the superoxide radical (Teoh et al., 2005). Thus, these SOD homologues act 
as decoy proteins binding the copper chaperone thereby depleting the amount of copper 
available for use by the Cu, Zn SOD (Teoh et al., 2003). This causes an intracellular increase 
in the superoxide anion. An increase in intracellular superoxide concentration through the 
inhibition of the SOD free radical scavenger has been shown to inhibit apoptosis in mammalian 
cells (Pervaiz and Clement, 2002a). 
More recently Molluscum contagiosum virus was shown to encode a protein (MC163) which 
contains a mitochondrial localisation domain, a transmembrane domain and a Cu Zn SOD 
domain (Coutu et al., 2017). MC163 Cu Zn SOD domain is 19% similar to full-length SOD 
from Herbivac. MC163 was shown to localise in the mitochondrion and reduce apoptosis. It is 
postulated that the SOD homologue binds proapoptotic proteins (Bak or Bax) thereby 
inhibiting them. Cellular and mutant Cu Zn SOD has also been shown to localise in the 
mitochondrion (Kawamata and Manfredi, 2008). The effect of this is to reduce mitochondrial 
membrane potential which is key to apoptosis (Coutu et al., 2017).  
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Table 1.9 shows a summary of tests that have been conducted on different SOD homologues 
and the results.  
Figure 1.15. Amino acid alignment of viral SOD-like proteins from ectromelia virus (EVM-144), cowpox virus (CPXV-187), 
camel pox (CMLV-165, variola (VAR_Bang_A45R, vaccinia strain MVA (VV_MVA-158R), rabbitpox (RPV-157), vaccinia 
strain Copenhagen (VV_Cop-A45R), and monkey pox (MPV-Zar-A46R) viruses. Capripoxviruses include sheeppox 
(ShPV_TU-126), lumpy skin disease virus (Nl 2490) (LSDV-131), and swinepox (SPV-129) viruses. Leporipoxviruses are 
myxoma (MYX-m131R) and Shope fibroma (SFV-s131R) viruses. Included in the alignment is a known active SOD enzyme 
from Amsacta moorei (AmEPV-255), bovine (SODC_BOVIN), residues from domain II of the copper chaperone for SOD 
(CCS_HUMAN) and human cellular Cu Zn SOD. Symbols below the consensus sequence are shown in the key. Taken from 
Cao et al. (2002). Permission to reuse image was granted. 
Table 1.9 summarises the studies done on SOD homologues to characterise them as active 
enzymes or SOD decoys which inhibit the activity of cellular SOD.  
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Table 1.9. Summary of all the tests done on poxvirus SOD homologues to determine whether they act as 
functional SOD enzymes or decoy proteins. 
SOD homologues tested  Summary of results Authors 
Myxoma virus and Shope fibroma 
virus (Leporipoxviruses). Wild 
type viruses, recombinant MYX 
and SFV expressing a decoy 
(M131R and S131R respectively)  
Myxoma and Shope Fibroma virus encode 
a decoy that does not function as an enzyme 
but as a functional decoy in cells 
(Cao et al., 
2002, Teoh 
et al., 2005, 
Teoh et al., 
2003) 
Vaccinia virus and recombinant 
vaccinia virus expressing a decoy 
(A45R)  
Vaccinia virus SOD homologue is not 
functional as an enzyme or as an inhibitor in 
cell culture. The homologue is packaged in 
the viral core. 
(Almazan et 
al., 2001) 
Amsacta Moorei virus (an 
Entomopoxvirus), protein 
expressed in bacterial system and 
purified 




Chlorovirus PBCV-1. WT virus 
was used and purified GST-tagged 
protein from bacterial plasmids 
were also used. 
Chloroviruses SOD (a245r) is packaged in 
the viral core and is a functional SOD 
enzyme. 
(Kang et al., 
2014) 
Megavirus Chilensis purified 
protein 
A functional SOD was purified which does 
not use a copper chaperone to insert copper 
and does not need copper for activity. 
(Lartigue et 
al., 2015) 
Molluscum contagiosum -  
transient expression of the MC163 
protein.  
The gene product was shown to localise to 
the mitochondrion and inhibit apoptotic cell 
death. 




1.8 Project motivation  
At the University of Cape Town (UCT) it was found that the SOD homologue gene in Herbivac 
differed from that of nLSDV. Herbivac contained a mixture of viruses, some with a full-length 
SOD homologue and others with the truncated SOD homologue resembling that of nLSDV. 
The first objective of the project was to determine if there was a difference between nLSDV 
and Herbivac in the innate response induced at 24 hours post infection in mouse spleens.   
On confirmation of the different response in mice the second objective of the project was to 
construct viruses with a deleted SOD gene and an improved, more stable SOD gene (SOD 
knock-out and SOD knock-in LSDVs). 
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The third objective of the project was to characterise the different recombinant viruses and 
compare them to Herbivac and nLSDV. Growth curves were done on chorioallantoic 
membranes (CAMs) of fertilised hens’ eggs and in cell culture (MDBK cells) to determine if 
the viruses differed from each other and nLSDV, which had a truncated SOD homologue gene.  
CAMs infected with the different vaccines and recombinants were analysed histologically to 
determine how they may differ with respect to pathogenicity and immunogenicity. 
In silico structural alignments of SOD were done to determine the presence of putative residues 
important in the activity or absence of activity of SOD homologues. The fourth and last 
objective was to investigate the role of the full-length SOD homologue in cell death. Using a 
known cell death inducer, the role of the full-length SOD homologue in inhibition of 
camptothecin induced cell death was investigated. Camptothecin is a known cancer drug that 
induces apoptosis in neoplastic cells. Camptothecin binds topoisomerase which is involved in 
maintaining the integrity of DNA during replication. Topoisomerases remove tension created 
in DNA by supercoiling. To allow for the replication fork and polymerases to act, 
topoisomerases create breaks in DNA which are resolved once DNA replication has occurred. 
Camptothecin inhibits type 1 topoisomerases (Xu and Her, 2015, Hsiang et al., 1989). When 
these topoisomerases are inhibited, tension in the DNA as well as stalling of DNA replication 
occurs causing DNA damage and thereby inducing apoptosis via the intrinsic pathway. Thus, 
observing behaviour of cells in the presence of camptothecin can be informative in 
understanding induction or inhibition of apoptotic cell death. Two types of cell death, namely 
apoptosis and necrosis were analysed. We hypothesised that the presence of the full-length 
SOD homologue would cause inhibition of apoptosis which would lead to viral persistence and 
increased immune response to the virus.  
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Chapter 2  Comparison of the innate host transcriptome induced 
in mice after infection with nLSDV and Herbivac 
 
2.1 Introduction 
The advent of systems biology and use of high throughput genomics and proteomics makes it 
possible to delineate vaccine induced immune responses that are predictive of the overall 
immune response (reviewed by Six et al. (2012)). Microarray technology uses knowledge of 
DNA hybridisation. Gene specific probes which are impregnated onto a glass or silicon chip 
by a robot are hybridised to cDNA molecules which have been reverse transcribed from mRNA 
and mixed with fluorescent probes or dyes (reviewed by Dhiman et al. (2001)). The value of 
microarrays is that they can simultaneously analyse the whole transcriptome on a single chip.  
Microarrays have been used to study host responses to vaccination (reviewed by Furman and 
Davis (2015) and Pepini et al. (2017)) as well as virus host interaction, reviewed by Law et al. 
(2013). In one study, MVA was used to infect HeLa cells and the host transcriptomic response 
was analysed. Whilst MVA does not complete its replication cycle in HeLa cells, 
morphogenesis is blocked at the stage where immature virus is formed, which is after MVA 
early gene expression. MVA infection resulted in differential expression of 410 host genes 
including 20 immune related genes and five cytokines.  The authors suggest that some of the 
upregulated genes, including NF-κB, could be responsible for antigen specific immune 
responses after vaccination with recombinant MVA (Guerra et al., 2004). 
The spleen contains the interface for the innate and adaptive immune system. T cell zones are 
present in the spleen and antigen presenting cells (APCs) present antigens to T cells. Dendritic 
cells drain in the spleen and so the spleen presents a unique organ to investigate host responses 
to vaccination. Studying the transcriptome of splenocytes following vaccination can be 
insightful in understanding the immunogenicity of a vaccine. In a recent study where subunit 
vaccines against Fasciola hepatica were made, the authors identified the best antigen 
formulation in their vaccine based on splenic gene expression (Rojas-Caraballo et al., 2017). 
In another study, a DNA vaccine against H5N1 with an extended NF kappa B site was shown, 
by microarray analysis of the genes expressed by splenocytes, to downregulate a gene, Lyst, 
which, they postulated would protect vaccinated animals from an inflammatory reaction that 
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could be deleterious (Redkiewicz et al., 2017). These studies show that the spleen is a suitable 
organ to use in the investigation of immunomodulatory responses of the host to a virus infection. 
In another study, an early innate immune molecular signature with a predictive score of 90% 
accuracy in predicting the humoral response to influenza was shown (Nakaya et al., 2011). 
Earlier, the same scientific group, analysed a repertoire of 30 000 genes and proteins to 
elucidate a unique molecular signature with a predictive value for the strength of the immune 
response to the successful  yellow fever vaccine (YF-17D) (Querec et al., 2009). In that study, 
microarray analysis was used to understand the transcriptome on peripheral blood mononuclear 
cell (PBMC) stimulated using the YF-17D vaccine (Querec et al., 2009). The results showed 
upregulation of 50 interferon and antiviral genes. An increase in the expression of the 
translation initiation factor Eif2ak4 was also shown to be predictive for a good cellular immune 
response to YF-17D (Querec et al., 2009).  
The role of the innate immune response in determining the magnitude and quality of adaptive 
immune response has resulted in a focus on understanding the innate response. Understanding 
the role of pathogen recognition receptors (PRRs) which are present on innate immune cells 
provides a unique insight into the overall immune response. These PRRs are inducible upon 
interacting with pathogen associated molecular patterns (PAMPs) (reviewed by Six et al. 
(2012)). Upon infection, viral nucleic acids often trigger PRRs (Sparrer and Gack, 2015).  
Intracellular DNA sensors have been described and include leucine-rich repeat flightless-
interacting protein 1 (Lrrfip1), Ifi16 (which is part of the PyHIN – pyrin and HIN200 family), 
RNA polymerase III, DExD/H box RNA helicases 9/36 (DDX9/36) and DNA dependant 
activator of IFN regulatory factors (DAI), which play a role in type 1 IFN production and 
cytokine production (Thompson et al., 2011). The molecule stimulator of interferon genes 
(STING) plays a role in TLR 9 independent production of type 1 interferons and other 
cytokines (Barber, 2014). Virus sensing by PRRs activates type 1 interferons which in turn 
upregulate major histocompatibility (MHC) Class 1 molecules. This makes virus infected cells 
targets for cytotoxic T lymphocytes (CTLs) and TNF-like death ligands (Upton and Chan, 
2014). Natural killer cells and cytotoxic cells make use of granzymes and perforin to kill cells. 
Granzyme B is the most documented and a classical example of an apoptosis inducer. 
Granzyme A, on the other hand, is involved in caspase independent cell death (Upton and Chan, 
2014).   
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An antiviral response by an infected cell includes cell death which could take the form of 
apoptosis or necrosis (Orzalli and Kagan, 2017).  It has also been shown that approximately 
300 genes are induced by the action of interferons with some of those genes being involved in 
apoptosis (reviewed by Kaminskyy and Zhivotovsky (2010)). MVA induces apoptosis in 
macrophages with a concomitant release of IFN β production (Royo et al., 2014).  
Traditionally, necrosis was thought of as an unorderly form of death, in contrast to apoptosis. 
However, there is a growing body of knowledge which supports the notion of necroptosis being 
a programmed form of cell death (reviewed by Nikoletopoulou et al. (2013), (Orzalli and 
Kagan, 2017)). This form of death is induced in addition to apoptosis or becomes pertinent in 
instances where apoptosis is inhibited by viral anti-apoptotic gene products (Chan et al., 2003). 
Unlike apoptosis, necroptosis is a highly inflammatory form of cell death (reviewed by Orzalli 
and Kagan (2017)).  
The aim of this part of the study was to compare changes in virus host interactions following 
infection of mice with either Herbivac or nLSDV. As nLSDV is being used as a vaccine for 
lumpy skin disease and as a vaccine vector, it will be important to establish whether the 2bp 
deletion in ORF131, which restores the gene encoding a SOD homolog, plays a role in 
modulation of the host immune response.  
MVA was used as a control in this experiment as it has been shown to induce a distinct gene 
expression profile following its use as a vaccine vector (Altenburg et al., 2014, Guerra et al., 
2004, Guerra et al., 2007, Guzman et al., 2012, Nájera et al., 2006, Teigler et al., 2014, 
Offerman et al., 2015). Our laboratory works with MVA and so it was available to use. 
In this study, RNA from spleens of mice infected with nLSDV or Herbivac was reverse 
transcribed and hybridised to Affymetrix© arrays containing DNA probes specific to all the 
genes present in a mouse. Mice that received PBS were used as a control to compute fold 
change of expression. Understanding host gene expression profiles following infection will be 
instrumental in understanding how LSDV works as a vaccine vector for both human and 
veterinary vaccine purposes. 




The Neethling vaccine strain used in this study is a commercial vaccine strain from 
Onderstepoort Biological Products (OBP), Onderstepoort, Pretoria. Herbivac LS (batch 008) 
was supplied to us by Deltamune, Pretoria. In this thesis, Herbivac LS will be called Herbivac. 
Both viruses were grown on chorioallantoic membranes (CAMs) of 7-day old embryonated 
specific pathogen free (SPF) White Leghorn chicken eggs (AviFarms, South Africa). Titration 
of the two lumpy skin disease viruses was done using the immunostaining method. Sera from 
cattle immunised with Herbivac was used detect LSDV. LSDV to be titrated was serially 
diluted from 10-1 to 10-8. Virus (100µl) was added to MDBK cells.  After 72 hours of incubation, 
virus was removed, and cells washed using PBS. A primary antibody raised against cattle and 
conjugated to a peroxidase was then added.  Hydrogen peroxide and di-anisidine dye were 
added. After washing off the substrate, LSDV positive foci stained brown and were counted to 
determine the titre in plaque forming units for the LSD virus. Streaking of virus cultures was 
done on Luria agar to check for bacterial contamination of the virus stocks.  
MVA was originally obtained from Prof Keith Dumbell, who obtained it from Prof. A. Mayr 
(Veterinary Faculty, University of Munich, Germany). It was grown and titrated on chick 
CAMs by Dr Offerman (Offerman, 2014).  
Ethics approval for the use of embryonated eggs was granted by the University of Cape Town 
(ethics number 013/016). 
2.2.2 RNA extraction  
2.2.2.1 Inoculation of mice 
Naïve BALB/c female mice were divided into four groups of three mice. The different groups 
received an intravenous inoculation of 100µl of 105 pfu/100µl of the following 
vaccines/controls 1) nLSDV, 2) Herbivac 3) Modified vaccinia Ankara (MVA) or 4) 100µl 
phosphate buffered saline (PBS). MVA was used as an experimental control and PBS a 
negative control. After 24 hours of infection, the mice were sacrificed by cervical dislocation 
in the absence of anaesthesia. Spleens were collected and stored in RNAlater (Qiagen, Venlo, 
Limburg, NL). All virus inoculations, animal handling and sacrificing of mice was done by Mr 
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Rodney Lucas at the UCT Research Animal Facility. Ethics approval for the mouse work was 
granted by The University of Cape Town ethics committee (ethics number 013/017) 
2.2.2.2 RNA extraction from mouse spleens 
Three spleens from 3 animals which received the same virus were pooled and homogenised 
using TissueRuptor blender (Qiagen) in TRIzol® reagent (Life Technologies, USA). From this 
pooled homogenate RNA was prepared in triplicate. DNase treatment was done using On-
column PureLink® according to the manufacturer’s guidelines. RNA was isolated using the 
RNA extraction kit (Qiagen) and eluted in ultra-pure water. RNA quality and concentration 
were determined using the Nanodrop ND1000 (Thermo Scientific, USA) and the Agilent 
Bioanalyser at CPGR (South Africa).  
2.2.3 Microarray hybridisation and data analysis  
For microarray hybridisations, 200ng of RNA was used to make cDNA. The samples were 
fragmented and labelled according to the Affymetrix WT PLUS protocol. Hybridisation of the 
targets was done on the Affymetrix Mouse Gene ST 2.0 arrays followed by incubation 
overnight. After washing and staining of the chip, the chip was scanned using the GeneChip® 
Scanner 3000 7G. 
2.2.3.1 Generation of gene lists 
Dr Armin Darfur and Dr Kristy Offerman from UCT provided the bioinformatic analysis 
pipeline and support for this study. The output from the microarray readings were *CEL files 
and these served as input for differential expression analysis. CEL files were normalised using 
Robust Multi-array averaging (RMA) (Irizarry et al., 2003) and similar probes on different 
arrays were used to do the averaging. RMA is available from Bioconductor as a component of 
the Affymetrix ‘affy’ package (Gautier et al., 2004). The result was log2 transformed data which 
was annotated using the Mouse Gene ST 2.0 and filtered in the first filtering step using the 
Genefilter package. This filtration step included an intensity filter which reported only genes 
that were >log2 in 20% of the samples (Gentleman et al., 2011). Another filtration step using a 
variance filter was done and this filter only enriched for genes whose interquartile ranges of 
the log transformed data was less than 0.5. Differential gene expression was measured using a 
linear regression model approach using the R package, Limma (Smyth, 2005).  A heatmap was 
made using heatmap.2 from the CRAN package gplots (Warnes et al., 2009) and depicted the 
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unsupervised hierarchical clustering based on the genes with p-value < 0.05 and log2 fold 
change (FC) above or below cut-off (±1). Note, genes with a p-value of <0.05 and absolute 
fold change of >1 and above was noted whereas genes with a p-value of >0.05 and absolute 
fold change of <1 were assigned 0. See Appendix 1 for the R script used.  
A tool for drawing Venn diagrams was used (Venny, available at 
http://bioinfogp.cnb.csic.es/tools/venny/). This enables visualisation of genes, biological 
processes and pathways that are common or unique to Herbivac or nLSDV infection (Oliveros 
and Venny, 2007).  
2.2.3.2 GO processes 
The MGI Gene Ontology Term Finder available at 
http://www.informatics.jax.org/gotools/MGI_Term_Finder.html was used to find GO terms 
associated with a set of differentially expressed genes. Gene ontology allows for the creation 
and maintenance of a structured, curated database of genes and related information based on 
evidence found in the literature. For this study, biological processes which represent an orderly 
amalgamation of molecular functions is reported (GO Ontology Consortium). To do this, the 
gene list from R containing all the differentially expressed genes was loaded onto the MGI 
Gene ontology tool. Biological processes were listed for each virus. 
2.2.3.3 Pathway analysis 
Ingenuity pathway analysis IPA® (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) was used to find 
pathways that were either activated or inhibited following infection with Herbivac or nLSDV. 
The gene list generated by the R program along with the log2 FC values was imported onto the 
IPA console. Top canonical pathways were determined. The Z score was used to determine 
whether a pathway is activated, inhibited or whether the information on the pathway is 
unknown. The number of genes present in the data set was expressed as a ratio of the total 
number of genes in that pathway.  
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2.3 Results 
2.3.1 Comparative differential host gene expression following infection with 
Herbivac or nLSDV 
Host gene expression in response to Herbivac and nLSDV was investigated using microarrays. 
RNA was isolated from spleens of BALB/c mice 24 hours after infection. The group of mice 
that received PBS only was used for baseline expression and expression of genes in the virus-
infected groups was investigated for up/down regulation against the expression data of mice 
that were inoculated with PBS. RNA from mice infected with MVA was used as an 
experimental positive control. Genes that were significantly up or down regulated (with an 
adjusted p-value of < 0.05) and a fold log2 fold change of greater than 0 were described as up 
regulated and smaller than 0, down regulated.  
Figure 2.1 shows a heatmap of the genes that were differentially expressed by MVA, Herbivac 
and nLSDV. Unsupervised hierarchical clustering of the differentially expressed genes 
demonstrated that the viruses induced distinct, overall transcriptomic responses in mouse 
spleens (Figure 2.1).  
 
Figure 2.1. A Heatmap showing differential expression induced in mouse spleens obtained from mice infected with 
MVA, nLSDV or Herbivac. Only genes (with p-value < 0.05) with log2 fold change of above or below the set cut off of >0 
or < 0 as compared to the PBS group are shown.  Unsupervised hierarchical clustering of the samples is shown by the 
dendrograms. Heatmap analysis was  performed in the R package, gplots (Warnes et al., 2009). 
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2.3.1.1 Herbivac and nLSDV induce a different host 
transcriptome  
The differentially expressed genes induced after nLSDV or Herbivac infection are listed in 
Table 2.1 with their levels of up or downregulation. The gene lists produced from data analysis 
showed that Herbivac and nLSDV induced largely similar host responses in mice (97 genes) 
and a few dissimilar responses – 36 unique to Herbivac and 6 unique to nLSDV. Infection with 
Herbivac caused differential gene expression of more genes than infection with nLSDV. The 
genes that were differentially expressed after MVA infection correlated with those reported by 
Offerman et al. (2015). 
Table 2.1. Differentially expressed genes in response to Herbivac, MVA and nLSDV infection. The differences in Log2 
fold changes (FC) between virus and control are shown. 
Full list of annotated up & down regulated genes  
Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Sp100 nuclear antigen Sp100 1.49 0.95 1.02 1.46 
Sp100 nuclear antigen Sp100 1.49 1.78 1.02 1.46 
Sp100 nuclear antigen Sp100 1.49 1.5 1.02 1.46 
Ms4a4c membrane-spanning 4-domains, subfamily 
A, member 4C 
1.58 1.74 1.11 1.42 
BC094916 cDNA sequence BC094916 1.52 1.97 1.1 1.38 
Ifit2 interferon-induced protein with 
tetratricopeptide repeats 2 
1.66 1.92 1.22 1.36 
Trim12c tripartite motif-containing 12C 1.44 1.24 1.07 1.35 
Ifih1 interferon induced with helicase C domain 
1 
1.73 2.06 1.28 1.35 
Plac8 placenta-specific 8 1.44 1.59 1.08 1.33 
Pyhin1 pyrin and HIN domain family, member 1 1.78 1.83 1.35 1.32 
Ifi44l interferon-induced protein 44 like 2.34 2.96 1.8 1.3 
Eif2ak2 eukaryotic translation initiation factor 2-
alpha kinase 2 
1.64 1.97 1.26 1.3 
Cmpk2 cytidine monophosphate (UMP-CMP) ki0se 
2, mitochondrial 
1.89 1.85 1.47 1.29 
Fcgr4 Fc receptor, IgG, low affinity IV 1.62 1.99 1.26 1.29 
Isg15 ISG15 ubiquitin-like modifier 1.99 2.09 1.56 1.28 
Herc6 hect domain and RLD 6 1.8 2.08 1.41 1.28 
Ifi202b interferon activated gene 202B 1.86 2.04 1.45 1.28 
Rtp4 receptor transporter protein 4 1.52 2.31 1.2 1.27 
Ifit1 interferon-induced protein with 
tetratricopeptide repeats 1 
2.67 2.91 2.12 1.26 
Ifi44 interferon-induced protein 44 2.21 2.94 1.75 1.26 
Phf11b PHD finger protein 11B 1.96 1.88 1.55 1.26 
Slfn8 schlafen 8 1.29 1.77 1.02 1.26 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Trim30a tripartite motif-containing 30A 1.72 2.31 1.39 1.24 
Phf11c PHD finger protein 11C 2.24 2.96 1.81 1.24 
Gm20559 predicted gene, 20559 1.28 1.78 1.03 1.24 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
60 
2.09 2.69 1.7 1.23 
Gm14446 predicted gene 14446 2.99 3.39 2.43 1.23 
Znfx1 zinc finger, NFX1-type containing 1 1.48 1.8 1.2 1.23 
Irf7 interferon regulatory factor 7 2.32 2.88 1.93 1.2 
Oas1b 2'-5' oligoadenylate synthetase 1B 1.54 1.92 1.28 1.2 
Klrk1 killer cell lectin-like receptor subfamily K, 
member 1 
1.46 1.44 1.23 1.19 
Pydc3 pyrin domain containing 3 1.7 2.36 1.43 1.19 
Setdb2 SET domain, bifurcated 2 1.6 2.21 1.36 1.18 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
58 
1.25 1.79 1.06 1.18 
Mx2 myxovirus (influenza virus) resistance 2 2.69 3.45 2.28 1.18 
Oas3 2'-5' oligoadenylate synthetase 3 1.96 2.55 1.68 1.17 
Bst2 bone marrow stromal cell antigen 2 2.25 2.73 1.92 1.17 
Pydc4 pyrin domain containing 4 2.24 2.98 1.91 1.17 
Tdrd7 tudor domain containing 7 1.19 1.36 1.03 1.16 
Ms4a4a membrane-spanning 4-domains, subfamily 
A, member 4A 
1.71 1.93 1.47 1.16 
Oas1g 2'-5' oligoadenylate synthetase 1G 2.55 3.31 2.21 1.15 
Parp12 poly (ADP-ribose) polymerase family, 
member 12 
1.73 2.51 1.52 1.14 
Mov10 Moloney leukemia virus 10 1.23 1.68 1.08 1.14 
Oasl1 2'-5' oligoadenylate synthetase-like 1 2.45 2.86 2.15 1.14 
Trim30c tripartite motif-containing 30C 2.78 3.42 2.43 1.14 
Trafd1 TRAF type zinc finger domain containing 1 1.35 1.66 1.18 1.14 
Apol9b apolipoprotein L 9b 2.97 2.85 2.64 1.13 
Helz2 helicase with zinc finger 2, transcriptional 
coactivator 
1.26 1.65 1.12 1.13 
Fcgr1 Fc receptor, IgG, high affinity I 1.82 1.79 1.61 1.13 
Ly6c2 lymphocyte antigen 6 complex, locus C2 2.08 2.17 1.86 1.12 
Slfn1 schlafen 1 1.31 1.98 1.17 1.12 
Ms4a6d membrane-spanning 4-domains, subfamily 
A, member 6D 
2.22 2.47 1.98 1.12 
Daxx Fas death domain-associated protein 1.66 2.05 1.48 1.12 
Gca Grancalcin 1.24 1.37 1.12 1.11 
Trim30d tripartite motif-containing 30D 2.24 2.23 2.01 1.11 
Mx1 myxovirus (influenza virus) resistance 1 3.3 3.89 2.96 1.11 
Tlr3 toll-like receptor 3 1.24 1.33 1.13 1.1 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 1.6 2.23 1.45 1.1 
Oasl2 2'-5' oligoadenylate synthetase-like 2 2.55 3.29 2.31 1.1 
Tor3a torsin family 3, member A 1.62 2.12 1.49 1.09 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Irgm1 immunity-related GTPase family M 
member 1 
1.22 2.13 1.12 1.09 
Cxcl11 chemokine (C-X-C motif) ligand 11 2.3 3.08 2.11 1.09 
Usp18 ubiquitin specific peptidase 18 2.48 3.14 2.27 1.09 
Zbp1 Z-DNA binding protein 1 1.52 3.16 1.39 1.09 
Gm12185 predicted gene 12185 1.68 2.49 1.56 1.08 
Ly6a lymphocyte antigen 6 complex, locus A 2.1 3.34 1.95 1.08 
Gm15056 predicted gene 15056 2.28 2.61 2.11 1.08 
Tnfsf10 tumor necrosis factor (ligand) superfamily, 
member 10 
1.63 1.86 1.53 1.07 
Xaf1 XIAP associated factor 1 1.44 2.11 1.34 1.07 
Tuba8 tubulin, alpha 8 2.05 2.14 1.94 1.06 
BC147527 cDNA sequence BC147527 1.65 1.9 1.56 1.06 
Xdh xanthine dehydrogenase 2.01 2.48 1.9 1.06 
Rnf213 ring finger protein 213 1.53 2.71 1.46 1.05 
Slfn4 schlafen 4 1.93 2.67 1.84 1.05 
Parp14 poly (ADP-ribose) polymerase family, 
member 14 
1.06 2.01 1.01 1.05 
Parp11 poly (ADP-ribose) polymerase family, 
member 11 
1.26 1.84 1.2 1.05 
Stat2 signal transducer and activator of 
transcription 2 
1.26 2.2 1.2 1.05 
Phf11d PHD finger protein 11D 2.3 2.44 2.19 1.05 
Cd69 CD69 antigen 1.45 1.8 1.41 1.03 
Slfn5 schlafen 5 1.78 2.77 1.73 1.03 
I830012O16Rik RIKEN cD0 I830012O16 gene 2.29 1.97 2.22 1.03 
Oas2 2'-5' oligoadenylate synthetase 2 2.29 3.46 2.25 1.02 
Gm12250 predicted gene 12250 1.14 2.94 1.12 1.02 
Pi4kb phosphatidylinositol 4-kinase, catalytic, 
beta polypeptide 
1.69 1.68 1.65 1.02 
Ccl3 chemokine (C-C motif) ligand 3 1.39 1.22 1.38 1.01 
Sp100 nuclear antigen Sp100 1.03 1.5 1.02 1.01 
Sp100 nuclear antigen Sp100 1.03 1.78 1.02 1.01 
Sp100 nuclear antigen Sp100 1.03 0.95 1.02 1.01 
Gm5431 predicted gene 5431 2.7 3.33 2.67 1.01 
Mlkl mixed lineage kinase domain-like 1.52 2.1 1.54 0.99 
Sgcb sarcoglycan, beta (dystrophin-associated 
glycoprotein) 
1.12 1.29 1.13 0.99 
Gm6904 predicted gene 6904 1.52 1.98 1.53 0.99 
AW011738 expressed sequence AW011738 1.21 1.66 1.23 0.98 
AI607873 expressed sequence AI607873 1.12 1.47 1.15 0.97 
Cd274 CD274 antigen 1.12 2.01 1.15 0.97 
Pde7b phosphodiesterase 7B 1.45 1.68 1.54 0.94 
Chic1 cysteine-rich hydrophobic domain 1 1.12 1.66 1.2 0.93 
Gzmb granzyme B 2.63 3.44 2.85 0.92 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Cxcl10 chemokine (C-X-C motif) ligand 10 1.5 3 1.68 0.89 
Gm4951 predicted gene 4951 1.04 2.55 1.26 0.83 
Gbp10 guanylate-binding protein 10 1.21 3.24 1.5 0.81 
Gbp11 guanylate binding protein 11 1.63 3.47 2.04 0.8 
Slfn3 schlafen 3 1.7 0 0 N/A 
Gzma granzyme A 1.64 0 0 N/A 
F830016B08Rik RIKEN cDNA F830016B08 gene 1.63 2.01 0 N/A 
Mndal myeloid nuclear differentiation antigen 
like 
1.53 1.34 0 N/A 
Tlr7 toll-like receptor 7 1.53 1.41 0 N/A 
Apol11b apolipoprotein L 11b 1.48 0 0 N/A 
AW112010 expressed sequence AW112010 1.38 0 0 N/A 
Zufsp zinc finger with UFM1-specific peptidase 
domain 
1.34 1.48 0 N/A 
Lgals9 lectin, galactose binding, soluble 9 1.31 1.55 0 N/A 
Rsad2 radical S-adenosyl methionine domain 
containing 2 
1.3 0.79 0 N/A 
Ifitm3 interferon induced transmembrane 
protein 3 
1.28 1.75 0 N/A 
Lgals3bp lectin, galactoside-binding, soluble, 3 
binding protein 
1.28 1.66 0 N/A 
Anxa4 annexin A4 1.21 1.33 0 N/A 
Gm6548 eukaryotic translation elongation factor 1 
alpha 1 pseudogene 
1.19 1.35 0 N/A 
Nmi N-myc (and STAT) interactor 1.15 1.4 0 N/A 
Tmem184b transmembrane protein 184b 1.14 1.17 0 N/A 
Iigp1 interferon inducible GTPase 1 1.13 2.64 0 N/A 
Epsti1 epithelial stromal interaction 1 (breast) 1.12 1.63 0 N/A 
Trim21 tripartite motif-containing 21 1.12 1.27 0 N/A 
Nampt nicotinamide phosphoribosyltransferase 1.11 1.59 0 N/A 
Nt5c3 5'-nucleotidase, cytosolic III 1.11 0 0 N/A 
Gm6637 predicted gene 6637 1.1 0 0 N/A 
Il15 interleukin 15 1.1 0.97 0 N/A 
Parp9 poly (ADP-ribose) polymerase family, 
member 9 
1.1 1.93 0 N/A 
Stxbp3a syntaxin binding protein 3A 1.09 0 0 N/A 
Atp10a ATPase, class V, type 10A 1.08 1.47 0 N/A 
Gm1966 predicted gene 1966 1.07 1.86 0 N/A 
H2-T24 histocompatibility 2, T region locus 24 1.06 1.19 0 N/A 
Tspo translocator protein 1.06 0 0 N/A 
Pkib protein kinase inhibitor beta, cAMP 
dependent, testis specific 
1.05 1.69 0 N/A 
Lgmn Legumain 1.03 0 0 N/A 
Ascc3 activating signal cointegrator 1 complex 
subunit 3 
1.01 1.01 0 N/A 
1600014C10Rik RIKEN cD0 1600014C10 gene 0 0.96 0 N/A 
A530099J19Rik RIKEN cD0 A530099J19 gene 0 -1.38 0 N/A 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Adar adenosine deaminase, RNA-specific 0 1.12 0 N/A 
Ank progressive ankylosis 0 -0.95 0 N/A 
Aqp1 aquaporin 1 0 -1 0 N/A 
Arid5a AT rich interactive domain 5A (MRF1-like) 0 0.78 0 N/A 
Atm ataxia telangiectasia mutated homolog 
(human) 
0 1.24 0 N/A 
Atp8b4 ATPase, class I, type 8B, member 4 0 1.41 0 N/A 
B4galt5 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 5 
0 1.38 0 N/A 
BC023969 cDNA sequence BC023969 0 0.85 0 N/A 
Btnl10 butyrophilin-like 10 0 -0.91 0 N/A 
C130026I21Rik RIKEN cD0 C130026I21 gene 0 0.8 0 N/A 
C2 complement component 2 (within H-2S) 0 1.23 0 N/A 
Ccnb2 cyclin B2 0 -1.06 0 N/A 
Cd209b CD209b antigen 0 -1.2 0 N/A 
Cd24a CD24a antigen 0 -1.01 0 N/A 
Cd55 CD55 antigen 0 -1.07 0 N/A 
Cdkl1 cyclin-dependent kinase-like 1 (CDC2-
related ki0se) 
0 -0.89 0 N/A 
Cebpb CCAAT/enhancer binding protein (C/EBP), 
beta 
0 0.92 0 N/A 
Cers6 ceramide synthase 6 0 0.96 0 N/A 
Cfb complement factor B 0 2.02 0 N/A 
Ctsc cathepsin C 0 1.29 0 N/A 
Ctse cathepsin E 0 -0.99 0 N/A 
Cxcl9 chemokine (C-X-C motif) ligand 9 0 2.7 0 N/A 
Depdc1a DEP domain containing 1a 0 -1.26 0 N/A 
Ear1 eosinophil-associated, ribonuclease A 
family, member 1 
0 -2.31 0 N/A 
Etnk1 ethanolamine kinase 1 0 1.06 0 N/A 
Fam26f family with sequence similarity 26, 
member F 
0 1.55 0 N/A 
Fbln5 fibulin 5 0 -1.05 0 N/A 
Gas6 growth arrest specific 6 0 -0.86 0 N/A 
Gbp2b guanylate binding protein 2b 0 2.42 0 N/A 
Gbp3 guanylate binding protein 3 0 1.69 0 N/A 
Gbp4 guanylate binding protein 4 0 2.36 0 N/A 
Gbp7 guanylate binding protein 7 0 1.98 0 N/A 
Gbp8 guanylate-binding protein 8 0 1.29 0 N/A 
Gdap10 ganglioside-induced differentiation-
associated-protein 10 
0 1.79 0 N/A 
Glipr2 GLI pathogenesis-related 2 0 1.13 0 N/A 
Gm19763 predicted gene, 19763 0 1.23 0 N/A 
Gm614 predicted gene 614 0 0.87 0 N/A 
Gm7609 predicted pseudogene 7609 0 1.35 0 N/A 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Hemgn Hemogen 0 -1 0 N/A 
Hmbs hydroxymethylbilane synthase 0 -0.88 0 N/A 
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 
0 -1.23 0 N/A 
Hpse Heparanase 0 1.25 0 N/A 
Hsh2d hematopoietic SH2 domain containing 0 1.26 0 N/A 
Hsp90ab1 heat shock protein 90 alpha (cytosolic), 
class B member 1 
0 0.97 0 N/A 
Hspa8 heat shock protein 8 0 1 0 N/A 
Hsph1 heat shock 105kDa/110kDa protein 1 0 1.23 0 N/A 
Ifi27 interferon, alpha-inducible protein 27 0 -0.97 0 N/A 
Igfbp3 insulin-like growth factor binding protein 3 0 -1.43 0 N/A 
Igtp interferon gamma induced GTPase 0 1.8 0 N/A 
Il33 interleukin 33 0 0.84 0 N/A 
Irf1 interferon regulatory factor 1 0 1.3 0 N/A 
Irgm2 immunity-related GTPase family M 
member 2 
0 1.39 0 N/A 
Itk IL2 inducible T cell kinase 0 0.74 0 N/A 
Keap1 kelch-like ECH-associated protein 1 0 0.89 0 N/A 
Kel Kell blood group 0 -1.16 0 N/A 
Klf1 Kruppel-like factor 1 (erythroid) 0 -0.8 0 N/A 
Lrat lecithin-retinol acyltransferase 
(phosphatidylcholine-retinol-O-
acyltransferase) 
0 -1.34 0 N/A 
Ly6e lymphocyte antigen 6 complex, locus E 0 1.09 0 N/A 
Marco macrophage receptor with collagenous 
structure 
0 -1.04 0 N/A 
Mgst3 microsomal glutathione S-transferase 3 0 -0.92 0 N/A 
Mid1 midline 1 0 1.08 0 N/A 
Mif macrophage migration inhibitory factor 0 1.14 0 N/A 
Mrc1 mannose receptor, C type 1 0 -1.17 0 N/A 
Ms4a6c membrane-spanning 4-domains, subfamily 
A, member 6C 
0 1.39 0 N/A 
Msh3 mutS homolog 3 (E. coli) 0 0.93 0 N/A 
N4bp1 NEDD4 binding protein 1 0 0.92 0 N/A 
0a25 N(alpha)-acetyltransferase 25, NatB 
auxiliary subunit 
0 1.16 0 N/A 
Nlrc5 NLR family, CARD domain containing 5 0 2.1 0 N/A 
Nxpe2 neurexophilin and PC-esterase domain 
family, member 2 
0 -1 0 N/A 
Ogfr opioid growth factor receptor 0 1.27 0 N/A 
Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
0 1.12 0 N/A 
Pigq phosphatidylinositol glycan anchor 
biosynthesis, class Q 
0 -0.9 0 N/A 
Pkhd1l1 polycystic kidney and hepatic disease 1-
like 1 
0 -1.01 0 N/A 
Ppa1 pyrophosphatase (inorganic) 1 0 1.9 0 N/A 
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Symbol Name Herbivac MVA nLSDV Herbivac-nLSDV 
ratio 
Ppm1k protein phosphatase 1K (PP2C domain 
containing) 
0 1.03 0 N/A 
Prg2 proteoglycan 2, bone marrow 0 -1.58 0 N/A 
Psmb10 proteasome (prosome, macropain) 
subunit, beta type 10 
0 1.34 0 N/A 
Psmb9 proteasome (prosome, macropain) 
subunit, beta type 9 (large multifunctio0l 
peptidase 2) 
0 1.1 0 N/A 
Rhd Rh blood group, D antigen 0 -0.91 0 N/A 
Sepw1 selenoprotein W, muscle 1 0 0.93 0 N/A 
Slc7a11 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 11 
0 0.93 0 N/A 
Smchd1 SMC hinge domain containing 1 0 1.27 0 N/A 
Socs1 suppressor of cytokine sig0ling 1 0 1.65 0 N/A 
Sp110 Sp110 nuclear body protein 0 1.21 0 N/A 
Stat1 signal transducer and activator of 
transcription 1 
0 1.76 0 N/A 
Tfrc transferrin receptor 0 -0.8 0 N/A 
Tlcd1 TLC domain containing 1 0 -0.78 0 N/A 
Tlr11 toll-like receptor 11 0 -1 0 N/A 
Tmem120b transmembrane protein 120B 0 -0.84 0 N/A 
Tnf tumor necrosis factor 0 1.15 0 N/A 
Trim25 tripartite motif-containing 25 0 1.08 0 N/A 
Ubr4 ubiquitin protein ligase E3 component n-
recognin 4 
0 1.18 0 N/A 
Vps54 vacuolar protein sorting 54 (yeast) 0 1.1 0 N/A 
Vwa5a von Willebrand factor A domain containing 
5A 
0 1.02 0 N/A 
Wars tryptophanyl-tRNA synthetase 0 1.37 0 N/A 
Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
0 -1.64 -1.21 0 
Gbp5 guanylate binding protein 5 0 2.59 1.04 0 
Gbp9 guanylate-binding protein 9 0 1.91 1.03 0 
Irg1 immunoresponsive gene 1 0 1.31 1.01 0 
Zcchc2 zinc finger, CCHC domain containing 2 0 1.53 1.05 0 
Lilrb4 leukocyte immunoglobulin-like receptor, 
subfamily B, member 4 
0 0 1.25 0 
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Figure 2.2. Venn diagram showing uniquely differentially regulated transcripts in response to infection with Herbivac, 
nLSDV and MVA. In each circle, the numbers of differentially expressed genes are indicated. The numbers inscribed inside 
the blue, yellow and green circles show the number of genes uniquely up/down regulated in response to Herbivac, nLSDV and 
MVA respectively. The intersections show the numbers of genes that were differentially expressed in response to two or three 
viruses. 
Where Herbivac and nLSDV caused differential expression of host genes in common the level 
of upregulation was, in general, higher after infection with Herbivac than with nLSDV, but the 
significance of this is not clear (Figures 2.1 and 2.2).  
Herbivac and nLSDV both upregulated genes associated with the immune response. Three 
clusters based on the function of the differentially expressed genes were constructed (figures 
2.3 and 2.4). Immune related genes were similarly regulated by both viruses (Herbivac and 
nLSDV) (figure 2.3). Herbivac downregulated two immune related genes (Olfr430 and Fcamr) 
whilst nLSDV infection was associated with downregulation of one gene only (Fcer2a) (Figure 
2.3).  
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Figure 2.3. Radial plot showing differences in the level of expression of immune system related genes. This radial plot 
shows genes whose log2 fold change was > 1 (upregulated) and <1 (downregulated). Genes that were not significantly up/down 
regulated were assigned 0. 
Genes associated with an interferon response, pathogen recognition receptors and cell death 
were identified. Again, Herbivac and nLSDV induced the upregulation of the same host genes, 
although Herbivac infection appeared to upregulate the equivalent genes to a greater degree 
than nLSDV (figure 2.4). The significance of this difference was not ascertained. Thirty-six 
genes were differentially expressed after Herbivac infection only (table 2.2). Interferon related 
genes - Ifitm3, Iigp, Il15, F830016B08Rik, Gm 1966, Gm 6548, Nmi, Gm6637 and 
A530099119Rik were only upregulated after Herbivac infection and not nLSDV (figure 2.4A).  
The trend of regulation was also consistent between Herbivac and nLSDV for pathogen pattern 
recognition. Only one gene -Trim 21 - was upregulated in response to Herbivac alone (Table 
2.2 and figure 2.4B)). Genes of the Pyrin and HIN domain (Pyhin), Pyrin Domain Containing 
(Pydc), Interferon 1 (Irf 1) and Oas (2'-5'-oligoadenylate synthetase 1) families appeared more 
highly upregulated following inoculation with Herbivac compared to nLSDV (Figure 2.4B). 
The statistical significance of these differences were not ascertained.  
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Figure 2.4  Radial plot showing differences in the level of expression of (A) interferon related genes and (B) genes 
involved in pathogen pattern recognition. This radial plot shows those genes with a log2 fold change > 1 (upregulated) and 
<1 (downregulated). Genes that were not significantly up/down regulated were assigned 0. 
The most striking difference between Herbivac and nLSDV was the upregulation of two genes 
associated with cell death, Parp 9 (log2 FC of 1.1) and Gzma (log2 FC of 1.93) by Herbivac 
only and not nLSDV (Figure 2.5).   
 
Figure 2.5  Radial plot showing differences in the level of expression of genes related to cell death. The genes shown in 
this radial plot were upregulated with a log2 fold change > 1 and downregulated with a log2 fold change of <1. Genes that were 
not significantly up/down regulated were assigned 0. 
The genes uniquely dysregulated by nLSDV or Herbivac infection are listed in table 2.2. 
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Table 2.2 List of genes uniquely differentially expressed in response to nLSDV and Herbivac infection. Blue coded genes 
were downregulated, and black coded genes upregulated.  
Genes uniquely differentially expressed by nLSDV  
Gene Symbol Gene name Description  
Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
positive regulation of humoral 
immune response mediated by 
circulating immunoglobulin 
Gbp5 guanylate binding protein 4 negative regulation of 
interferon-alpha production 
Gbp9 guanylate-binding protein 9 cellular response to interferon-
gamma 
Irg1 interferon, alpha-inducible protein 27 RNA polymerase II activating 
transcription factor binding 
Lilrb4 leukocyte immunoglobulin-like 
receptor, subfamily B, member 4A 
integral component of 
membrane 
Zcchc2 zinc finger, CCHC domain containing 
2 
phosphatidylinositol binding 
Genes uniquely differentially expressed by Herbivac 
Gene Symbol Gene name Description  
Olfr430 olfactory receptor 430 G-protein coupled receptor 
signalling pathway 
Fcamr Fc receptor, IgA, IgM, high affinity adaptive immune response 
Olfr693 olfactory receptor 693 G-protein coupled receptor 
signalling pathway 
A530099J19Rik RIKEN cDNA A530099J19 gene  
Anxa4 annexin A4 negative regulation of NF-
kappaB transcription factor 
activity 
Apol11b apolipoprotein L 11b  
Ascc3 activating signal cointegrator 1 
complex subunit 3 
cell proliferation 
 
Atp10a ATPase, class V, type 10A nucleotide binding 
AW112010 expressed sequence AW112010  
Epsti1 
epithelial stromal interaction 1 (breast) 
 
F830016B08Rik 
RIKEN cDNA F830016B08 gene 
cellular response to interferon-
beta 
Gm1966 predicted gene 1966  
Gm6548 predicted gene 6548  
Gm6637 predicted gene 6637  
Gzma granzyme A apoptotic process 
H2-T24 
histocompatibility 2, T region locus 24 
antigen processing and 
presentation of peptide antigen 
via MHC class I 
Ifitm3 interferon induced transmembrane 
protein 3 
type I interferon signalling 
pathway 
Iigp1 
interferon inducible GTPase 1 






Lgals3bp lectin, galactoside-binding, soluble, 3 
binding protein 
 
69 | P a g e  
 
Gene Symbol Gene name Description  
Lgals9 
lectin, galactose binding, soluble 9 






Mndal myeloid nuclear differentiation antigen 
like 




NAD biosynthetic process 
 
Nmi 
N-myc (and STAT) interactor 
cellular response to interferon-
gamma 
Nt5c3 5'-nucleotidase, cytosolic III transferase activity 
Parp9 poly (ADP-ribose) polymerase family, 
member 9 
double-strand break repair 
 
Pkib protein kinase inhibitor beta, cAMP 
dependent, testis specific 
cAMP-dependent protein kinase 
inhibitor activity 
Rsad2 radical S-adenosyl methionine domain 
containing 2 




negative regulation of cell 
proliferation 
Stxbp3a 
syntaxin binding protein 3 
cellular response to interferon-
gamma 
Gene Symbol Gene name Description  
Tlr7 
toll-like receptor 7 
toll-like receptor 7 signalling 
pathway 
Tmem184b transmembrane protein 184b transporter activity 
Trim21 
tripartite motif-containing 21 
negative regulation of NF-




negative regulation of tumor 
necrosis factor production 
 
2.3.2 Host processes and pathways activated by Herbivac and nLSDV. 
The clustering of genes based on molecular function was done manually using knowledge of 
the genes and their function (Figures 2.3 - 2.5). However, a curated database exists where gene 
ontology terms have been defined. The gene lists were analysed on a gene ontology server 
(MGI) and gene ontology (GO) processes associated with the gene lists were elucidated. Both 
Herbivac and nLSDV shared 58 GO processes (Figure 2.6) with 16 processes being unique to 
Herbivac and eight to nLSDV (Table 2.3). Processes that involve pattern recognition receptors 
were identified. These pathways were however common between Herbivac and nLSDV 
infection. Since most biological processes were similar, emphasis was put on dissimilar 
processes.  
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Figure 2.6 Venn diagram showing GO processes associated with Herbivac and nLSDV. In each circle, the number of 
differentially expressed processes are shown. The number inscribed inside the blue and yellow circles show the number of 
processes uniquely up/down regulated in response to Herbivac and nLSDV respectively. The intersection shows the number 
of processes that were upregulated in response to both viruses. Only processes showing a p value of < 0.05 are shown. 
Herbivac infection was associated with immune response regulation and processes relating to 
apoptosis (table 2.3). Of interest was the large number of processes related to cell death, 
immune response and interferon response that were activated following Herbivac infection 
compared to those activated following nLSDV infection. nLSDV surprisingly had GO 
processes that pointed towards a bacterial infection such as response to lipopolysaccharide and 
responses to stimuli of bacterial origin. This was an unexpected finding as the virus used to 
inoculate these animals was tested for bacterial contamination by streaking viral stocks on 
Luria Agar. No contamination was detected. 
Ingenuity pathway analysis (IPA) was used to analyse pathways that were activated or inhibited 
by the genes that were differentially regulated after infection with Herbivac or nLSDV. IPA 
was also used to identify biological processes; the same results that were obtained by the MGI 
GO annotation tool were identified (results not shown). Pathway analysis revealed that the two 
viruses affected the same pathways (Figure 2.7 and 2.8). Fourteen pathways were affected by 
both Herbivac and nLSDV (Figures 2.7 and 2.8). Pathway analysis revealed that the genes 
involved in the interferon response were similar after the two viral infections further supporting 
results presented in Figure 2.4. The number of differentially expressed genes affecting a 
pathway were expressed as a fraction of the total number of genes involved in that particular 
pathway and presented as a ratio (orange line in Figures 2.7 and 2.8). The ratio of genes 
involved in PRRs, death receptor signalling, and apoptosis signalling were similar for the two 
viral infections, again showing that the two viruses induced the differential expression of the 
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same genes and consequentially, the same pathways. No pathway was shown to be 
downregulated. 
Table 2.3 Summary of processes unique to nLSDV AND Herbivac. The gene lists were used to determine processes likely 
to be affected by nLSDV and Herbivac infection. Processes exclusive to nLSDV or Herbivac are listed. 
 
The activation scores indicated by the colour of the bars (orange – upregulation, blue for 
downregulation and grey for unknown activation status), were very similar following Herbivac 
and nLSDV infection. Herbivac and nLSDV infection had the same activation score for 
pathways involved in pathogen recognition receptors in recognition of viruses and bacteria, 
interferon signalling, death receptor signalling and retinoic acid mediated apoptosis signalling. 
Only UVA induced MAPK signalling was activated following Herbivac infection and 
unknown following nLSDV infection (Figures 2.7 and 2.8).  
The number of pathways unique to Herbivac were greater than those unique to nLSDV (Table 
2.4), again suggesting that Herbivac causes an elevated host response in mice compared to 
nLSDV. Pathways unique to Herbivac are those involved in metabolism and immunity whereas 
those unique to nLSDV infection were involved in the immune response only. No information 
on the activation level (denoted by an orange colour) was associated with these unique 
pathways. It is therefore impossible to infer whether there was upregulation or downregulation 
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of these pathways. This pattern of activation was noticed for most of the pathways that were 
identified by IPA (grey bars in Figures 2.7 and 2.8). 
 
Figure 2.7 Graphical presentation of top canonical pathways intercepting with genes affected by Herbivac infection. 
The Z score uses the fold change to compute whether a pathway is upregulated (activated) ORANGE or unknown GREY. No 
pathways were downregulated. The ratio (orange line) presents the number of genes identified from the experimental gene 
lists in relation to the total number of genes involved in that pathway. The inverted (–log scale) shows the level of significance 
with molecules having a low p value having the highest –log values. 
 




Figure 2.8 Graphical presentation of top canonical pathways intercepting with genes affected by nLSDV infection. The 
Z score uses the fold change to compute whether a pathway is upregulated (activated) ORANGE or unknown GREY. No 
pathways were downregulated. The ratio (orange line) presents the number of genes identified from the experimental gene 
lists in relation to the total number of genes involved in that pathway. The inverted (–log scale) shows the level of significance 
with molecules having a low p value having the highest –log values. 
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Table 2.4. Summary of pathways unique to nLSDV AND Herbivac. The gene lists were used to determine pathways likely 
to be affected in response to nLSDV and Herbivac infection.  
 
 
2.4 Discussion  
Whole gene expression profiling using microarrays provides a systematic approach to 
understanding virus host interactions. To date, no study has been done to compare the host 
transcriptome after infection with nLSDV and Herbivac. Host gene expression was analysed 
in mouse spleens 24 hours post infection. Compared to the PBS control, nLSDV and Herbivac 
induced  differential expression of 97 genes in common, largely related to response to viral 
infection, and which have been shown in other poxvirus studies (Offerman et al., 2015, Royo 
et al., 2014). nLSDV infection resulted in the differential expression of 6 unique genes and 
Herbivac infection resulted in the differential expression of 36 unique genes. MVA and 
Herbivac both induced differential expression of 23 genes whereas nLSDV and MVA both 
induced differential expression of 5 genes (Figure 2.2). In comparison, Herbivac and not 
nLSDV could thus perform slightly more similar to the greatly documented MVA. 
There were more upregulated genes following all viral infections than downregulated genes 
which is most likely due to the non-permissive nature of the infection. In a non-permissive host, 
some viral proteins may not be able to target host antiviral machinery as they do in a permissive 
host. The antiviral K3L genes from the three different capripoxviruses have been shown to 
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inhibit PKR (a host sensor of viral double stranded RNA) differently depending on the host. 
These differences may play a role in determining host range (Park and Peng, 2018). Guerra et 
al. (2003) showed that after VV infection, almost 90% of the host transcripts were 
downregulated compared to mock controls, maybe due to the permissive nature of infection 
(Guerra et al., 2003). Also, in this study Guerra et al. (2003) looked at 6 and 10 hours post 
infection in HeLa cells which is unlike this study that was done in vivo after 24 hours. Looking 
at earlier time points may therefore be informative but due to the non-permissive nature of 
infection this remains only speculative. In another study, in HeLa cells as well, MVA was 
shown to induce a distinct gene profile with induction of genes involved in cell structure 
(Guerra et al., 2004). Such genes were not detected in this study, possibly because of the nature 
of target cells in the spleen. Most of the genes that were differentially expressed after MVA 
infection were associated with an immune response.  This is not unique to this study as Guerra 
et al. (2004) showed that infection with MVA caused differential expression of 20 transcripts 
associated with cytokines, members of the tumour necrosis factor and Nuclear kappa B family 
(Guerra et al., 2004).  
Offerman et al. (2015) investigated the host gene expression profile of mice that were infected 
intravenously with Herbivac, Canarypoxvirus (CNPV), Fowlpox virus (FWPW), MVA and 
two novel Avipoxviruses. Herbivac was shown to induce upregulation of 463 genes and induce 
downregulation of 85 genes. In that experiment MVA induced  the increased expression of 299 
genes and downregulation of 177 genes (Offerman et al., 2015). This also supports findings in 
the present study which demonstrated that LSDV induced mainly upregulation as opposed to 
downregulation of genes.  
Genes that were differentially expressed which were associated with an enrichment of specific 
processes and pathways are discussed below. Although Herbivac uniquely upregulated the 
expression of activating signal cointegrator 1 complex subunit 3 (Ascc3), which is important 
for cell proliferation (Dango et al., 2011), Herbivac also upregulated a negative regulator for 
cell proliferation schlafen 3 (Slfn 3) (reviewed by Mavrommatis et al. (2013)). Whether the 
upregulation of Ascc3 contributed to the cell proliferation observed (chapter 3, figure 3.29) is 
not known. There was no enrichment of processes relating to proliferation.  
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Toll-like receptor (TLR) 
TLRs are part of the antiviral sensing mechanism (as reviewed in section 1.5). TLRs are 
important in evoking immune effector responses with TLRs 3, 4, 7, 8 and 9 playing a role in 
the induction of type 1 interferons (Kawai and Akira, 2006). TLRs 3 and 7 were induced 
following Herbivac infection whereas only TLR3 was induced following nLSDV infection in 
mice. TLR3 activation is mediated by dsRNA which is abundantly present during the 
bidirectional RNA transcription of different DNA strands or as an intermediary product in 
DNA replication (Thompson et al., 2011, Weber et al., 2006, Kawai and Akira, 2006). DsRNA 
is a potent activator of the innate antiviral immune system (Weber et al., 2006). TLR7 is located 
inside the cell in the endosomal compartment where it senses ssRNA (Petes et al., 2017) and 
is critical to the induction of a potent innate immune response. TLR7 can cooperate with other 
antiviral mechanisms like RIG 1 (Szabo et al., 2014). TLR7 induction leads to the production 
of proinflammatory cytokines (Petes et al., 2017). TLRs 3,7,8 and 9 are found mostly inside 
the cell and it would be logical to find TLRs 3 and 7 upregulated following a poxviral infection 
(reviewed by (Buonaguro et al., 2011). 
Signalling via the TLR pathway is important in dendritic cell maturation which is indispensable 
for B lymphocyte activation. TLR signalling has been linked to both IgM and IgG secretion 
(Pasare and Medzhitov, 2005) as well as the consequent induction of inflammatory cytokines 
like TNF-β, IL-1β, IL-6 and IL-12 (reviewed by Buonaguro et al. (2011). The ability of 
Herbivac to induce the activation and upregulation of two Toll like receptor genes (Tlr 3 and 
7) leads one to speculate that the interferon response would be greater after Herbivac than 
nLSDV which only induced the upregulation of Tlr 3. This is supported by the finding that 
there were more interferon related processes induced after infection with Herbivac compared 
to nLSDV (Table 2.3). 
Interferon 
The induction of pathogen pattern recognition receptors like TLRs is important in the 
development of an interferon response (Kawai and Akira, 2008). Both vaccine strains, 
Herbivac and nLSDV, influenced the upregulation of several genes involved in pathogen 
pattern recognition and the interferon response (Figure 2.4). Both Herbivac and nLSDV 
induced the same profile of interferon related pathways (Figure 2.7 and 2.8). The number of 
differentially regulated genes involved in the IFN response was higher in mice infected with 
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Herbivac (37 genes) compared to those induced by nLSDV (28 genes) (Figures 2.4). A study 
comparing the transcriptome of macrophages infected by  a panel of different poxviruses 
showed that MVA induced a strong interferon response (Royo et al., 2014). This may be why 
MVA is widely used successfully as a vaccine vector (Pavot et al., 2017) and a vaccine (Volz 
and Sutter, 2017). Though both LSDVs induced a strong IFN response, and will potentially 
perform well as vaccines/vectors, because Herbivac induced expression of more IFN related 
genes it could possibly perform better as a vaccine/vector.  
IFN activation has been shown to increase the ability of macrophages to phagocytose (Royo et 
al., 2014). Both virus infections were associated with the upregulations of ISG15 which has 
been shown to be a potent interferon stimulated gene with potent antiviral activity (Yángüez et 
al., 2013). ISG15 can bind viral proteins directly and has been associated with in vitro 
activation of macrophages and reduction of vaccinia virus titre (Baldanta et al., 2017). Since 
both nLSDV and Herbivac upregulated this potent ISG they are likely to activate macrophages 
leading to an elevated antiviral response. It can thus be inferred that when used as a vector, 
LSDV can lead to the phagocytosis of the heterologous antigen being expressed by the viral 
vaccine, leading to subsequent major histocompatibility class presentation. 
Of note Herbivac and not nLSDV infection induced the expression of Trim 21. Though there 
have been conflicting reports regarding its role, its expression has been associated with a 
modest increase in IFN β production (Yángüez et al., 2013). Trim 21 was shown to lead to 
about 20% increase in IFN-β production in dendritic cells stimulated by different immunogens 
(Zhang et al., 2013).  The mechanism of action of Trim 21 is that it binds the antiviral DNA 
sensor DDX41 causing its ubiquitination and subsequent degradation. The effect is that DDX41 
will not be able to detect DNA (Yángüez et al., 2013). It appears the virus hijacks this 
regulatory mechanism to evade PRRs like DDX41. 
Querec et al. (2009) showed that the immunogenic and successful yellow fever vaccine (YF- 
17D) had a gene signature with a high predictive value of an effective immune response. Their 
study identified most of the antiviral, immune system and interferon genes that were 
differentially expressed in our vaccinated mice. These genes included Oas1-3, Tlr7, DDX58, 
Ifihi, Cxcl10, DHX58, Eif2ak2, and Mx1. The response was predictive of a CD8+ T cell 
response. It can therefore be inferred that both nLSDV and Herbivac would induce a strong T 
cell response. The MVA control has been associated with the induction of interferon induced 
proteins (IFIT1 and ISG15) which were also upregulated in the present study (Guerra et al., 
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2007) which increase confidence in the results of this study. The same study by Guerra et al. 
(2007) also showed that MVA infection was associated with the differential expression of 
OASL, RIG 1 and MDA5. 
Immune response 
The immune response is regulated largely by type 1 IFN genes (Trinchieri, 2010). Both nLSDV 
and Herbivac induced the upregulation of very similar genes associated with the innate immune 
response (Figure 2.3). A few transcripts were uniquely regulated by Herbivac which included 
interleukin 15 (Il15) and Tlr7 (Table 2.2). Il15 is a cytokine produced by monocytes and 
macrophages in response to viral infection and causes proliferation of natural killer cells (Mak 
and Saunders, 2006, Ekmekcioglu et al., 2008, Verbist et al., 2012). This interferon related 
cytokine was upregulated after Herbivac infection only (Table 2.2). A multivalent influenza 
protein expressed by vaccinia virus which also expresses Il15 was shown to induce T cells and 
consequently protect animals against lethal challenge (Valkenburg et al., 2014).  
A few transcripts were downregulated after infection with Herbivac and these included 
olfactory receptors (Olfr430 and Olfr693) and Fc IgA, IgM, high affinity receptor (Fcamr). Of 
the Fc receptors, IgE low affinity II and alpha polypeptide (Fcer2a) was downregulated after 
nLSDV infection. Downregulation of Fcamr has been previously reported (Offerman et al. 
(2015). MVA and Herbivac downregulated Fcamr and all 6 poxviruses (CNPV, FeP2, FWPV, 
PEPV, Herbivac and MVA) downregulated Fcer2a in their experiment. Fc receptors are 
important in the humoral immune response (Sun, 2014). Binding of an immunoglobulin to Fc 
receptors mediates antibody dependent cell mediated cytotoxicity which aids in killing virally 
infected cells (Reid et al., 2011). Downregulation of Fcer2a may be an immune evasion 
strategy employed by LSDV against the adaptive immune system. This may be desirable for a 
vector as it may reduce anti-vector immunity and antibody dependant enhancement of infection. 
Cell death 
A strong interferon and immune response leads to activation of different host antiviral 
mechanisms including cell death, which, is in turn inhibited by the infecting virus. Overall, 
Herbivac induced an increased interferon response and immune response. It is thus interesting 
to establish which antiviral response is either activated or inhibited by Herbivac or nLSDV to 
understand the role of the full-length SOD homologue on virus host interaction.  
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There was an increased induction of cell death related genes after Herbivac infection and 
consequently more cell death processes than those induced by nLSDV. The presence of 
necrotic nodules (sometimes known as sit-fasts which are zones of necrosis) on skin of infected 
animals supports the finding that LSDV infection induces cell death (Abutarbush et al., 2015). 
Upon histological examination of lesions on CAMs, van Rooyen et al. (1969) showed regions 
of necrosis on the superficial cell layer of the ectoderm. LSDV is known to encode genes that 
are thought to inhibit cell death in a productive infection (Kara et al., 2003). Viruses may, 
however, inhibit cell death in the early stages of replication to allow for maturation of the virus 
before dissemination (Danthi, 2016). The poxviruses MVA and NYVAC were reported to 
induce apoptotic cell death in HeLa cells, dendritic cells and macrophages (Guerra et al., 2006, 
Guerra et al., 2007, Royo et al., 2014).   
The cell death related genes upregulated after Herbivac infection included the granzymes A 
and B (Gzma and Gzmb), Poly (ADP-ribose) polymerase (Parp 9,11,12 and 14), TNF-Related 
Apoptosis Inducing Ligand (Tnfsf10) and Death-associated protein 6 (Daxx). In contrast, 
nLSDV did not show upregulation of Parp 9 and Gzm A (Figure 2.5). Upregulation of Parp has 
been shown to recruit nicotinamide adenine dinucleotide (NAD+) which eventually leads to 
necrosis (Ha and Snyder, 1999). NAD is produced when a cell undergoes oxidative stress (Di 
Lisa and Ziegler, 2001). Interestingly, pathway analysis demonstrated that the NAD 
biosynthetic pathway was somewhat affected after Herbivac infection alone (though the 
activation profile was unknown; see Figure 2.7). When cleaved by caspases, Parp is known to 
cause the release of the apoptosis inducing factor from the mitochondria leading to cell death 
(Hong et al., 2006). Granzyme A is present in CD8+ CTLs and NK cells and is the most 
abundant granzyme. It affects apoptotic cell death by cleaving Arginine or Lysine residues. 
Gzma elicits a caspase independent mode of apoptosis (reviewed by Lieberman (2010). 
The presence of a SOD homologue in leporipoxviruses was shown to inhibit cell death in a 
permissive host (Cao et al., 2002, Teoh et al., 2005, Teoh et al., 2003). Since Herbivac and 
nLSDV differed in only one locus, it could be inferred that LSDV SOD was playing a role in 
cell death. This appears to suggest that the antiviral immune response employed other means 
of cell death to clear Herbivac which were not engaged to eliminate nLSDV. The host may 
employ caspase independent programmed cell death in the presence of apoptosis inhibitors. 
Poxviruses are known to encode proteins from the Serpin protease family that include CrmA 
which inhibits caspase activity (reviewed by Nichols et al. (2017)). Thus, the host may engage 
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other caspase independent mechanisms like necrosis. However, since these two viruses were 
similar with the exception of the SOD homologue, the additional arm of cell death employed 
could be attributed to the presence of the full-length SOD homolog in Herbivac. Since LSDV 
does not replicate in mice, the full-length SOD homologue present in Herbivac could have 
conferred survival or inhibition of cell death which resulted in the host engaging in other forms 
of cell death and increasing transcripts associated with cell death.  
Results from the MVA experiment were congruent to literature which shows that MVA induces 
apoptosis in dendritic cells (Guzman et al., 2012). Upregulation of genes involved in cell death 
was also observed after MVA infection. MVA had 16 genes upregulated which are important 
in apoptosis. Parp 1 cleavage was shown by Guerra et al. (2007) after MVA infection. This 
provides further confidence in the dataset that was generated by this study. However, it is 
important to note that due to the algorithm used, assignment of no fold change (0) could have 
been as a result of variations in the replicate experiment hence a p value of >0.05. Also, since 
only genes with an absolute change of >1 were noted, some genes whose individual expression 
level was not as high but whose contribution to a pathway in concert with other genes, could 
be significant, may have been missed or under represented by assigning 0. For comparative 
purposes though, and hypothesis generation, noted differences will be used as a basis for future 
studies. 
In summary, our results showed that in a non-permissive host, Herbivac and nLSDV induced 
upregulation of many interferon and immune related genes but Herbivac infection resulted in 
expression of a unique profile of cell death related genes. Due to unique upregulation of 
transcripts involved in caspase independent cell death and necrosis related cell death (Gzma 
and Parp 9) which was associated with Herbivac, we postulate that the improved 
immunogenicity that is seen in cattle in Herbivac compared to nLSDV may be due to an 
immunogenic form of cell death linked to the presence of a full-length SOD decoy. In the 
following chapter, recombinant viruses in which the truncated SOD from nLSDV is knocked 
out or replaced with a SOD resembling SOD from Herbivac are characterised with respect to 
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Chapter 3  Characterisation of the impact of the LSDV SOD 
homolog on viral growth, SOD activity and cell death. 
3.1 Introduction  
Poxvirus replication occurs in the cytoplasm (section 1.4.2) where poxviruses encode their own 
transcription machinery which makes it possible for viral replication and transcription to occur 
in specialised viral factories (Liem and Liu, 2016). When a poxvirus uncoats and DNA 
replication occurs, this stage can be manipulated to generate recombinant poxviruses (Yao and 
Evans, 2003). The knowledge of homologous recombination between the genomes of two 
replicating poxviruses and the subsequent finding that DNA can recombine with pox viral DNA 
has accelerated the generation of recombinant poxviruses (Weir et al., 1982, Sanchez-
Sampedro et al., 2015).  
Panicali and Paoletti (1982) first described the generation of recombinant vaccinia virus. In 
that study, they inserted the thymidine kinase gene from herpes simplex virus. This was made 
possible by the co-transfection of the thymidine kinase gene (containing vaccinia virus flanking 
sequences) and vaccinia virus.  Other studies have successfully shown that huge inserts can be 
added to pox genomes owing to the large genomes of poxviruses. In one study, up to 25 kb of 
foreign DNA was successfully inserted into a vaccinia virus genome  Recombination in 
vaccinia virus occurs with near to perfect accuracy and the virus remains infectious after 
manipulation of DNA (if essential genes are not disrupted) (Carroll and Moss, 1997, Smith and 
Moss, 1983). LSDV, like other poxviruses, has a large genome which replicates in the 
cytoplasm of permissive cells and can be manipulated in the same way as vaccinia virus. 
The process of generating recombinant poxviruses makes use of a transfer vector containing 
the gene of interest fused with a poxvirus promoter and start codon, stop codon and a pox 
terminator sequence - TTTTTNT (Mackett et al., 1984, Yuen and Moss, 1987) and flanked by 
regions homologous to the insertion site in the poxvirus (Souza et al., 2005, Mackett et al., 
1982, Wyatt et al., 2017). These flanking regions aid in homologous recombination for 
insertion of the gene(s) into genomic DNA during viral replication. Vaccinia virus has been 
shown to use as little as 12bp of homologous sequence for recombination (Yao and Evans, 
2001).  
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To select for recombinant viruses over wild type viruses, marker and selection genes are usually 
inserted, either within the flanking regions of DNA or outside the flanks (Souza et al., 2005). 
DNA recombination occurs in the cytoplasm as the poxvirus DNA undergoes replication 
(Mercer et al., 2007). In this thesis, the E. coli xanthine (guanine) phosphoribosyltransferase 
(ecoGPT) was used as a metabolic selection marker (Boyle and Coupar, 1988). The ecoGPT 
gene encodes a phosporibosyltransferase that helps supply guanine from xanthine available in 
the media as a salvage pathway for guanine synthesis (Mulligan and Berg, 1981). Hence, in the 
presence of an antiviral agent, mycophenolic acid (MPA), which is an inhibitor of purine 
biosynthesis, expression of ecoGPT allows for the synthesis of purines from 
xanthine/hypoxanthine via the salvage pathway (Falkner and Moss, 1988). MPA is an antiviral 
agent that inhibits inosine monophosphate dehydrogenase, which catalyses the synthesis of 
xanthine monophosphate. The depletion of xanthine monophosphate leads to inhibition of cell 
growth due to lack of purine nucleotides (Falkner and Moss, 1988).  
Different expression markers are useful in the selection of recombinant viruses with or without 
metabolic selection (Rice et al., 2011, Morrow et al., 2012). Fluorescent proteins (FPs) have 
been used as reporters of gene expression (Paszkowski et al., 2016, Marzook et al., 2014, Al 
Ali et al., 2016). GFP was isolated in 1961 and it has been used a lot in recombinant DNA 
technology (Shimomura, 2005). The whole structure of the fluorescent protein is key to its 
generation and maintenance of fluorescence (Kremers et al., 2011). Selection of recombinant 
viruses can therefore be done by picking fluorescent foci of cells or by cell sorting. The reporter 
genes eGFP and mCherry were used in this thesis. GFP absorbs at 488 nm and emits at 507nm 
and GFP transfected cells fluoresce within 16-24 hours post infection (Zhang et al., 1996).  
mCherry absorbs 587 nm and emits at 610 nm and is a useful FP due to its brightness and photo 
stability (Shaner et al., 2005). Figure 3.1 shows a simplified diagram of how a poxvirus 
recombinant is made.  
To understand the role of different viral genes, mutants can be generated where the gene under 
investigation is deleted or reintroduced (in a revertant virus). In 1991, Blasco et al, 
characterised a profilin homologue by creating a knockout with GPT in place of profilin 
(Blasco et al., 1991). Similar strategies have been used to determine roles of genes and 
homologues (Almazan et al., 2001, Cao et al., 2002, Teoh et al., 2005, Teoh et al., 2003).  
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Figure 3.1. Schematic of the generation of a recombinant poxvirus via homologous recombination. Homologous 
recombination takes place between homologous poxviral sequences in a transfer vector and the poxviral genome. Cells are 
infected with a poxvirus and transfected with a transfer vector. The transfer/shuttle vector contains sequences of homology to 
poxvirus DNA at the site of insertion (left flank and right flank). After infection, DNA from the poxvirus replicates in the 
cytoplasm where homologous recombination occurs within the flanking seuqences. The transfer vector contains a cassette 
containing the target gene being inserted, a selection marker and an expression marker within the flanks. Expression of the 
target gene, as well as the marker and selection genes, is driven by a poxviral promoter.   
Poxviruses express a SOD homologue which is a late protein that is packaged in the viral core 
(Almazan et al., 2001, Cao et al., 2002, Teoh et al., 2003) and most likely exerts its effect from 
the early stages of infection. SOD homologues are known to perturb the levels of the superoxide 
anion through interference with the activity of SOD (Cao et al., 2002, Teoh et al., 2005, Teoh 
et al., 2003). Hydrogen peroxide, the product of SOD catalysis has been implicated in apoptotic 
cell death, whereas the superoxide anion, the substrate for SOD catalysis has been noted to be 
pro-survival (Pervaiz and Clement, 2002a, Kumar et al., 2007).  SOD homologues have been 
implicated in the pathogenesis of leporipoxviruses. The presence of a SOD homologue in a 
revertant Shope Fibroma Virus (SFV) was shown to be associated with increased diameter of 
lesions in vivo, when inoculated into rabbits. Microscopic investigation revealed that there was 
proliferation of fibroblasts, necrosis and leukocyte infiltration in animals infected with wild 
type SFV containing a SOD homologue (Teoh et al., 2005). In addition, the SOD knockout 
virus did not protect infected Jurkat cells from mitochondrial and Fas-associated cell death 
(Teoh et al., 2005). The SOD knock-out mutants resulted in increased growth capabilities in 
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cell culture yielding ten times more virus than the revertant virus (Cao et al., 2002, Teoh et al., 
2005).  
Herbivac encodes a full-length SOD homologue whereas nLSDV does not. Herbivac SOD is 
almost similar in size to the SOD found in the virulent field strain of LSDV (160 aa). SOD 
from the virulent strain has several substitution mutations when compared with nLSDV and 
Herbivac. There is a 1bp deletion in nLSDV and Herbivac which in nLSDV caused a frameshift 
mutation resulting in a truncation. SOD was put back in frame by the additional 2bp deletion 
in Herbivac. The 1bp deletion caused several amino acid differences (Figure 1.7). The further 
2bp deletion in Herbivac SOD is the reason why it is a full-length SOD. 
The objective of this chapter was to investigate if the presence of SOD had an impact on the 
phenotype of LSDV on infected cells or CAMs. This chapter describes the generation of 
recombinant viruses in which i) SOD was deleted and ii) SOD resembling that of Herbivac was 
reintroduced into the SOD locus. The SOD gene used here was modified in the region where 
the 2bp deletion had occurred. Careful analysis revealed that there were AT dinucleotide 
repeats and this region was suspected to be highly unstable. Modifications in the SOD ORF 
were made to make it more stable. The recombinant viruses were compared to one another as 
well as the parent nLSDV and Herbivac for growth in cell culture and on chorioallantoic 
membranes of fertilised hens’ eggs (CAMs). The viruses were also compared with respect to 
histological changes in infected chick CAMs. The activity of cellular SOD from cell lysate 
derived from cells that had been infected with recombinant viruses expressing full-length SOD 
or the truncated SOD was also investigated. 
A further objective was to characterise the apoptotic and necrotic activity of the different 
viruses expressing either the truncated or the full-length SOD homologue and to compare them 
to LSDV with SOD knocked out.  
3.2 Methods  
 3.2.1  Viruses  
The Neethling vaccine strain (nLSDV) and Herbivac were grown and titrated as described in 
section 2.2.1. 
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3.2.2 Alignment of different SOD homologues 
Different SOD or SOD-like protein sequences were aligned. These included full length active 
SOD from humans and cow obtained from GenBank. The protein sequence of a stabilised form 
of SOD (section 3.3.2.2) and Herbivac (UCT), which are not available on NCBI, were deduced 
by translating their respective nucleotide sequences using CLC Bio (Qiagen©). SOD-like 
ORFs from variola virus, vaccinia virus, sheeppox virus, myxoma virus, LSDV (Neethling 
vaccine strain, Nl 2490, Neethling vaccine LW 1959, Herbivac and nLSDVSODis) and 
Amsacta Moorei entomopoxvirus were included in the alignment. The sequence of human 
copper chaperone CCS was also included in the alignment. The chaperone is homologous to 
SOD and dimerises with SOD during its activation from the apo state. The structures for bovine 
and human SOD were obtained from the protein databank (1SOS and 1EQ9). SOD alignment 
was done using the TCoffee Expresso program available on the TCoffee server. Structural 
alignment was done on ESPript 3.0 Server. 
3.2.3 Construction of transfer vectors 
3.2.3.1 Construction of transfer vector pHM1 (for generating 
nLSDVdSOD-M) by overlapping PCR and cloning  
To delete SOD (ORF131) from nLSDV, a transfer vector was constructed (see Figures 3.3 and 
3.9). This transfer vector (pHM1) contained LSDV ORFs 130 and 132 as flanking sequences, 
with a positive marker for selection (ecoGPT) and the eGFP marker gene placed between the 
flanking sequences. Overlapping PCR was used to assemble three DNA fragments into one 
large fragment (see Figure 3.2). The primers used for these PCR reactions are listed in Table 
3.1. The three plasmids pZG1, pZG2 and pZG4 were constructed by Zek Gimbot. pZG1 and 
pZG2 contain LSDV ORFs 130 and 132 respectively inserted into pGEM®-T easy (Promega, 
USA). pZG4 contains a gene cassette of ecoGPT and eGFP constructed from the plasmid 
pRO2-DNA. The pSS promoter was placed upstream of eGFP whilst the p7.5 promoter was 
used for eGPT expression.  
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Table 3.1. Primers used to amplify flanking sequences of LSDV 130 and LSDV 132 from pZG1 and pZG2 respectively, and 
the selection and marker genes from pRO-2. The nucleotides are colour coded to correspond to figure 3.2. Primer 130 LEFT 
FLANK REV is complementary to primer pRO-2-GPT FOR and primer pRO-2-eGFP REV is complementary to primer 132 
RIGHT FLANK FOR. Primers were designed such that the three products produced could be joined by overlapping PCR using 
the outermost primers to amplify one single large fragment. 
Name Primer 
130 LEFT FLANK FOR 5’- GGTACCGGAGACAACATTGAACAAACCGATAATG -3’ 
130 LEFT FLANK REV 5’- GGAATTAGTGATCACTCGAGGCATGCATCGATCTATAGTTTGTTATTATCAGTTGCATG -
3’  
pRO-2-GPT FOR 5’- CATGCAACTGATAATAACAAACTATAGATCGATGCATGCCTCGAGTGATCACTAATTCC -
3’ 
pRO-2-eGFP REV 5’- GCAATTCCGATAATTCCATATGCAACGAATTCCATCCGATCCAATGTCGACGTATACAG -
3’ 
132 RIGHT FLANK FOR 5’- GTATACGTCGACATTGGATCGGATGGAATTCGTTGCATATGGAATTATCGGAATTGC -3’ 
132 RIGHT FLANK REV 5’- ACTAGTGATACATCACACAATGTAACAAGTTCAG -3’ 
 
Figure 3.2. Diagram showing the binding sites of primers described in Table 3.1.  Primer sequences are indicated 
by coloured arrows above and below the cassette pointing in the direction of amplification. Primer segments 
coloured red indicate sequences complementary to LSDV 130 (left flank) and LSDV 132 (right flank). Primer 
segments coloured blue indicate the nucleotides that were added to facilitate assembly of the PCR fragments and 
are complementary as shown in the diagram. Red text within the cassette indicates the location of restriction sites 
and highlighted blue text indicates the location of the EcoGPT promoter (p7.5kDa) and the GFP promoter (pSS).   
The schematic of primer binding sites and the resultant assembly product is shown in Figure 
3.2. PCR amplification using primer sets for the left and right flanking sequences of LSDV, as 
well as the GPT and eGFP genes, were used to amplify linear products to use in the subsequent 
assembly and PCR reaction. The reverse primers for the left flanking (LSDV 130 REV) 
sequence were designed with an additional oligonucleotide sequence complementary to the 
selection and marker gene cassette (blue in Figure 3.2 and Table 3.1). The pRO 2 DNA forward 
primers also contained a region complementary to the left flank (colour coded red in Figure 3.2 
and Table 3.1). The reverse primer (pRO 2 eGFP REV) included oligonucleotides 
complementary to a region in the right flank (colour coded red). The right flank forward (LSDV 
132 FOR) primers also contained an overlapping sequence which was complementary to a 
region in the marker gene cassette (colour coded blue).  
Three PCR reactions were carried out using the KAPA Hifi Polymerase master mix (Kappa 
Biosystems, SA) to amplify the Left flank, Right flank and pRO-2 DNA. The cycling 
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conditions included an initial denaturation step at 95 °C for 5 minutes, 25 cycles of: 
denaturation at 95 °C for 30 seconds, annealing for 30 seconds at 55°C for the left and right 
flank, and 60°C for the marker genes, and extension at 72°C for 30 seconds for the left and 
right flanks and 2 minutes for the marker genes. The final extension time was 7 minutes at 
72°C. After amplification, the PCR products were gel purified, quantified using the nanodrop 
and used in the subsequent assembly reaction.  
The left flank forward and the right flank reverse primers were used to assemble the three genes 
into one fusion product. Equimolar amounts of DNA were added into the same tube for the 
overlapping PCR. The primers used for the assembly reaction were LSDV 130 forward and 
LSDV 132 reverse. The conditions for the overlapping PCR included an initial denaturation 
step at 95 °C for 5 minutes, 25 cycles of: denaturation at 95 °C for 30 seconds, annealing for 
30 seconds at 55°C and extension time at 72°C for 3 minutes. A final extension time of 7 
minutes was done.  
The product from the overlapping assembly PCR was cloned into pJET (ThermoScientific, 
USA) (Appendix 1) according to standard methods and manufacturers’ recommendations 
(Thermo Fisher, USA). pJET is a blunt end (open) cloning vector. It is compatible with most 
laboratory strains of E coli. It contains eco471R gene which is a lethal gene that enables positive 
selection for recombinant plasmids only. pJET also contains an ampicillin resistance gene 
which enables cells which take up bacteria expressing it to survive in the presence of ampicillin.  
3.2.2.2 Construction of transfer vector pHM2v3 (for generating 
nLSDVSODis-M) 
To generate recombinant SOD knock-in (nLSDVSODis-M), a transfer vector, pHM2v3 
(Figure 3.11), containing the SOD gene flanked by GPT and LSDV 132 was designed. Part of 
the GPT gene was used as the left flanking sequence and LSDV 132 was used as the right 
flanking sequence. The SOD of Herbivac contains AT dinucleotide repeats in the region of the 
2bp deletion relative to nLSDV. This region was speculated to be unstable. In order to stabilise 
this region, the degeneracy of the genetic code was utilised. Nucleotides encoding the same 
amino acids were used to replace the AT rich area. The chain of ATs was replaced with 
ATCTACATAC to produce the improved SOD. The final vector included SODis, an 
expression marker mCherry downstream of the mH5 promoter and flanking sequences for 
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homologous recombination (Figure 3.11). GenScript (New Jersey, USA) synthesised the insert 
and cloned it into pUC 57 simple vector. 
3.2.4  Generation of recombinant LSDVs with and without SOD 
3.2.4.1 Isolation of nLSDVdSOD-M 
Figure 3.3 below shows how recombination can take place between the transfer vector 
pHM1 and nLSDV. Primary lamb testes cells were grown in a 12-well culture plate 
overnight until they were 70% confluent. Parent LSDV (Neethling vaccine strain – 
Onderstepoort SA), at a multiplicity of infection of 0.004 was used to infect cells for two 
hours. X-tremeGENE™ Hp transfection reagent (Roche, Switzerland) was warmed to room 
temperature and mixed with the plasmid (3ug) at a ratio of 1:1. After removing virus, the 
transfection complex was added. After 48 hours of incubation, DMEM with 10% FCS was 
added to the cells. Cells were viewed using a fluorescence microscope and images were 
taken (Figure 3.13). The cells were incubated for an additional 24 hours after which virus 
was extracted from the cells through 3 cycles of freeze-thaw.  
 
Figure 3.3. Schematic showing how homologous recombination can occur between the transfer vector pHM1 and viral 
DNA of nLSDV to generate nLSDVdSOD-M. The left (130) and right (132) flanks can recombine to delete the SOD 
homologue gene present in nLSDV and replace it with GPT and eGFP. 
After infection and transfection in primary LT cells, virus was passaged in MDBK cells in the 
presence of selection medium. Selection medium contained mycophenolic acid at a 
concentration of 2.5ug/ml MPA in complete media and was supplemented with 15µg 
hypoxanthine and 250µg xanthine (Sigma-Aldrich, USA). The virus was passaged 7 times in 
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the presence of MPA. At the eighth passage, a serial dilution to isolate a single fluorescing 
recombinant virus was done. The virus from the single focus was expanded in a 6-well plate. 
The recombinant virus was confirmed to be correct by PCR. MDBK cells were infected with 
cell lysate from the single focus propagated in a 6 well plate and incubated without MPA for 3 
days.  The media was removed from the 6 well plate and cells were washed with 1X PBS. 
Solution A (100 mM KCl, 10 mM Tris-HCl pH 8.3 and 2.5 mM MgCl2) was added first. 
Proteinase K (final concentration 120 µg/ml; Sigma-Aldrich, USA) was added to Solution B 
(10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2 and 1.5% Tween-20). Solution B was added and 
using a sterile cell scraper the cells were removed from the well. The lysate was incubated at 
600C for 1 hour followed by10 minutes incubation at 950C. 5ul of the lysate was used for PCR, 
as described in section 3.2.4.4.  
3.2.4.2 Isolation of nLSDVSODis-M 
The plasmid pHM2v3 (Figure 3.11) was used to transfect cells infected with nLSDVdSOD-M. 
The schematic below (Figure 3.4) shows how the recombinant nLSDVSODis-M was made. 
 
Figure 3.4. Diagram to show strategy of insertion of SODis and mCherry into nLSDVdSOD-M to generate nLSDVSODis-M. 
Part of the GPT gene and right flank (132) can recombine to insert SODis and mCherry replacing it with eGFP. 
A 70 – 90% confluent layer of lamb testes cells in a 12 well plate was infected with 
nLSDVdSOD-M at an MOI of 0.05. X-tremeGENE™ Hp transfection reagent (Roche, 
Switzerland) was warmed to room temperature and mixed with plasmid pHM2v3 (3 µg) at a 
ratio of 1:1. After 2 hours, virus was removed, and the transfection complex was added. After 
48 hours of incubation, DMEM with 10% FCS was added to the cells. Cells were viewed using 
a fluorescence microscope. After a further 48 hours, the cells containing recombinant virus 
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were lysed in 1mM Tris and used to infect MDBK cells. Red fluorescing foci were picked, and 
the virus grown in MDBK cells. A total of 3 rounds of picking was done. Since both the parent 
and recombinant viruses contained the GPT gene, MPA selection could not be used to select 
nLSDVSODis-M. PCR, as described in section 3.2.4.4, was used to confirm that the 
recombinant was correct (Figure 3.18).  
3.2.4.3  Isolation of recombinant SOD knock-in and SOD knock-
out viruses without marker genes 
To confirm that the differences identified from experiments using nLSDVSODis-M and 
nLSDVdSOD-M were not due to the presence of marker genes, recombinants without marker 
genes were constructed. The SOD knock-out virus without marker genes nLSDVdSOD-UCT 
and the SOD knock-in virus, nLSDVSODis-UCT were constructed.  
A plasmid without the marker genes and the SOD gene - pHM1dSOD was made by Ruzaiq 
Omar by excising GPT and eGFP from within the flanks by treating pHM1 with NsiI and EcoRI 
and blunting it using T4 polymerase (New England BioLabs, Massachusetts, USA). This 
plasmid was circularised using T4 ligase (New England BioLabs, Massachusetts, USA).  
A plasmid containing SODis between the flanking sequences (130 and 132) was made by 
excising the marker genes from pHM1 as described above. pHM1 was treated with NsiI and 
EcoRI to remove GPT and GFP. The linear vector backbone was blunted. SODis along with its 
promoter sequence was excised from pHM2v3 and blunted. A blunt end ligation was then used 
to generate pHM1-SOD_pos containing SODis between LSDV 130 and 132 flanking 
sequences. Competent E..Coli cells (Lucigen, USA) were transformed by pHM1dSOD or 
pHM1-SOD_pos. These transfer vectors were confirmed to be correct by Sanger DNA 
sequencing (CAF, Stellenbosch University, SA).  
To construct and isolate nLSDVdSOD-UCT (SOD knock-out without markers), primary lamb 
testes cells were seeded into a 6-well plate at a total of 5x105cells/well. Cells were infected 
with nLSDVdSOD-M (expressing eGFP) at an MOI of 0.05 within two hours of seeding. 24 
hours post seeding and infecting, cells were transfected with 3µl XtremeGeneHP + 6µg 
pHM1dSOD (Figure 3.20). Six days post transfection a lysate was prepared by two rounds of 
freeze-thawing (37°C/-80°C). Virus from this lysate was passaged in MDBK cells and single 
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non-fluorescing foci were picked. This was done five times before a serial dilution was made 
in a 96-well plate and a single non-fluorescing focus was isolated for large scale preparation of 
the virus. 
For the construction of nLSDVSODis-UCT (SOD knock-in without markers), a monolayer of 
primary lamb testes cells were infected with nLSDVdSOD-M (expressing eGFP) at an MOI of 
0.001 and transfected with 6ug of transfer vector pHM1-SOD_pos (Figure 3.20). Cells were 
lysed by three cycles of freezing and thawing 48 hours post infection and transfection. The 
lysate was passaged in MDBK cells and three rounds of picking of non-fluorescing foci were 
performed. A single non-fluorescing focus was isolated on a 96-well plate and expanded in 
MDBK cells. PCR analysis confirmed the recombinant to be nLSDVSODis-UCT. 
3.2.4.4 PCR  
All recombinant LSDV viruses were confirmed to be correct by PCR using appropriate primer 
pairs. Primer set A binds in the LSDV 130 and LSDV 132 regions which flank the SOD gene 
region. Primer set A comprised forward primer HM 130 FW (5’-
GGAGCACCATTTCCATATAC-3’) and reverse primer HM 132 REV (5’-
AGTAGCTTAAAAGGAGGGAAG-3’). Primer set B binds in the SOD ORF (131). Primer 
set B included forward primer HM131 FW (5’-CGAGTTCGGTGATGAAAC-3’) and reverse 
primer HM 131 REV (5’-AATTCCATACGCGACACC-3’).  
The PCR conditions for both primer sets were: an initial denaturation step at 95°C for 5 minutes, 
25 cycles of: denaturation at 95 °C for 30 seconds, annealing for 30 seconds at 55°C and 
extension time at 72°C for 1 minute. A final extension time of 7 minutes at 72°C was done. 
The PCR ready mix ImmoMix™ Red (Bioline, USA) was used.  
PCR was also performed which used primers that bind outside the left flank, LSDV 129 
forward (5’-GAGCCCTGTAATTCACTTTT-3’) and within the right flank LSDV 132 reverse 
(5’-ATCGATGGAAAAGATCCG-3’) (Figure 3.19).  The conditions for the PCR included an 
initial denaturation step at 95°C for 5 minutes, 25 cycles of: denaturation at 95°C for 30 seconds, 
annealing for 30 seconds at 59°C and extension time at 72°C for 3 minutes. A final extension 
time of 7 minutes at 72°C was done. For this PCR, Phusion® High-Fidelity DNA Polymerase 
(New England BioLabs, Massachusetts, USA) was used. 
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3.2.5 Preparation of LSDV stocks 
The Neethling vaccine (nLSDV) and recombinant LSDV viruses were bulked up in 500ml 
hyperflasks (Corning® HYPERFlask®). MDBK cells in a hyperflask were infected at an MOI 
of 0.01 and incubated for a fortnight.  After the cells had lifted, virus was harvested by 3 cycles 
of freeze-thawing. The lysate was subjected to centrifugation at 800 rpm for 10 minutes. The 
supernatant was collected and centrifuged through a 36 % sucrose cushion at 11000 rpm for 1 
hour at 4°C using a Sorvall RC5C Plus centrifuge and Sorvall S534 rotor. After centrifugation, 
the supernatant was decanted, and the pellet was suspended in 500ul PBS per tube. Aliquots of 
200ul were made and stored at -80 °C.  
3.2.6 Growth curves of the different LSDV viruses in cell culture 
The viruses nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT were compared for growth 
in tissue culture. MDBK cells were seeded at a concentration of 5x105 cells per well of a 12 
well plate. Cells were infected at an MOI of 0.015 in triplicate and lysates were prepared 2 
hours post infection and at subsequent 1-day intervals from days 1 to 5. At each time point a 
plate was frozen. All the plates were frozen and thawed three times in total to release virus. 
The Reed and Muench (1938) endpoints dilution method was used to determine the virus titre. 
Titrations in TCID50 units were converted to focus forming units per ml (ffu/ml). 
3.2.7 Growth curves of different LSDV viruses on chick chorioallantoic membranes. 
Viruses nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT were compared for growth on 
chick chorioallantoic membranes (CAMs). Seven-day-old specific pathogen free eggs (SPF) 
from Leghorn chickens Avifarms (Pty) Ltd (Lyttelton, South Africa) were used and inoculated 
as described by Offerman et al. (2013). CAMs were inoculated with PBS, nLSDV, 
nLSDVdSOD-UCT and nLSDVSODis-UCT. Viral titrations were done from 2 days to 5 days 
post infection. Membranes were dropped by making a hole at the air sac and dorsal area. Care 
was taken to make a hole in a well vascularised area. A pipette bulb was used to move the air 
sac to the dorsal area where viral inoculation was done. Two hours post dropping membranes, 
viruses were diluted to a concentration of 104 TCID50/ml. A tuberculin insulin syringe was used 
to inject 100 µl of virus (103 TCID50) to each egg. Once eggs were infected, they were incubated 
at 34°C. Eggs were harvested daily from Day 0 to Day 5 and membranes were pooled (3 per 
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virus per time point). A low speed spin was done (800 rpm for 1 minute) and the supernatant 
was titrated using the TCID50 method (Reed and Muench, 1938). Titrations were performed in 
triplicate.  
3.2.8 CAM Histology 
The method described by Offerman et al. (2013) was used to prepare CAMs for histology. The 
first experiment compared CAM sections from eggs inoculated with nLSDV, Herbivac, 
nLSDVdSOD-M and nLSDVSODis-M. Six days post infection, 3 membranes per virus were 
harvested. At this point, all membranes had a mean titre of 106 TCID50/ml. The membranes 
were fixed in 10% buffered formalin (formaldehyde (37–40 %), NaH2PO4.H20 (35.03 M), 
Na2HPO4 (anhydrous, 21.84 M)). The membranes were rolled into small cylinders which were 
embedded in paraffin. Thin sections were cut into 5µm thick sections on an approximately 5-6 
cm long x 1-2 cm wide block. Haematoxylin and Eosin staining (H&E) was done as described 
by Fischer and colleagues (Fischer et al., 2008). Images were taken using a light microscope.  
The same experiment was done using the recombinant viruses without marker genes. Seven-
day-old CAMs were infected with 103 TCID50/100µl nLSDV, nLSDVdSOD-UCT or 
nLSDVSODis-UCT. A single representative membrane (n=1) was harvested from each 
treatment on days 1, 3 and 5. The CAMs were fixed in 10% buffered formalin and embedded 
as described above. Five sections per membrane per day were stained using H&E, evaluated 
under the light microscope and blinded tissue scoring was done based on immune infiltration, 
hyperplasia, ballooning degeneration and presence/absence of inclusion bodies in the chorionic 
or allantoic epithelium. Scoring was done by a specialist veterinary pathologist Dr. Sophette 
Gers (PathCare VetLab, Cape Town South Africa). 
3.2.9 Preparation of homogenates for SOD activity determination 
To perform the SOD activity assay, cellular homogenates were made from uninfected and 
infected cells. MDBK cells were infected with nLSDV, Herbivac, nLSDVSODis-M and 
nLSDVdSOD-M at an MOI of 10 for 2, 6 and 24 hours. After the stipulated time, cells were 
washed with PBS and homogenised in 2X lysis buffer (Abcam - ab179835, Lot # GR292167-
16) containing 2mM EDTA. The homogenate was clarified by centrifugation at 1500 rpm for 
5 minutes.  The supernatant was used for SOD activity determination and protein quantification. 
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3.2.10 Reactive Oxygen Species (ROS) assay 
Most commercially available kits involve the use of hypoxanthine/xanthine and xanthine 
oxidase to generate superoxide anions. SOD present in cell lysates or homogenate then acts on 
the superoxide anion dismutating it to hydrogen peroxide. The SOD determination kit (19160) 
(Sigma, USA) based on a highly soluble tetrazolium salt WST-1 (2-(4-Iodophenyl)- 3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)- 2H tetrazolium monosodium was used in this experiment 
to determine SOD activity. This direct method of detecting SOD activity uses a tetrazolium 
salt which reacts with the superoxide anion released by the xanthine oxidase system. If there is 
a lot of functional SOD in the homogenate, there is a decline in the amount of the superoxide 
anions available to react with the dye hence the absorbance drops. When there is an inhibitor 
or a functional SOD decoy, the superoxide anion is continually produced and therefore the 
absorbance increases. The assay measures the activity of SOD present in cell lysate.  
The 19160 SOD determination kit (Sigma, USA) was used according to the manufacturer’s 
protocol. The assay measures directly the amount of superoxide produced by xanthine oxidase 
when it metabolises xanthine. The produced superoxide radical reacts with the water-soluble 
tetrazolium salt (WST-1) to form a soluble dye (WST-1 formazan) (see Figure 3.5). If there is 
a functional SOD enzyme, the produced superoxide is dismutated to hydrogen peroxide 
resulting in a decrease in absorbance. 
 
 
Figure 3.5. Mechanism of the SOD determination kit. Xanthine oxidase (XO) is used to generate superoxide anions from 
xanthine. The generated superoxide anions are dismutated to oxygen and hydrogen peroxide by cellular Cu Zn SOD. The rate 
of inhibition of this reaction by the reaction of WST and the superoxide anion is inversely related to the amount of superoxide 
anion present in the cell lysate. An increase in WST 1-formazan, a coloured product is inversely proportional to the amount of 
SOD present in the lysate. In the presence of an inhibitor like a SOD decoy there is an increase in WST-1 formazan (increase 
in absorbance). Figure taken from Sigma SOD determination kit 19160, USA. 
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In the presence of a SOD inhibitor, the levels of the superoxide anion increase resulting in an 
increase in absorbance. Clarified homogenate (20µl) was loaded into the assay. A kinetic assay 
at one-minute intervals was selected and absorbance was measured at 450nm. SOD activity 
was calculated in the linear phase of the reaction i.e. in the first 20 minutes. The absorbance 
reading at 5 minutes was subtracted from the absorbance reading at 15 minutes. SOD activity 
was calculated according to the equation below: 
Percentage SOD activity = (Change in Absorbance of Blank – Change in Absorbance of Sample
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝐵𝑙𝑎𝑛𝑘
 )*100 
SOD activity was given as a percentage of the blank. Different amounts of bovine SOD were 
used to monitor the assay. Units used included 5.6 mU, 56 mU, 5.6 U and 56 U.  
3.2.10.1 Protein Quantification 
Protein quantification was done using the Bio-Rad DC protein assay kit as per manufacturer’s 
manual (Solution A Cat # 500-0113 and Solution B Cat # 0114) (Bio-Rad, USA). Absorbance 
readings were obtained using a Versa Max spectrophotometric reader (Molecular Devices, 
USA) at 750 nm. The amount of protein was used to normalise the activity of SOD and activity 
of SOD was expressed as percentage activity/mg of total protein. 
3.2.11 Apoptosis assays 
3.2.11.1  Induction of apoptosis/necrosis by viruses 
MDBK cells were first seeded into a 96 well plate at a seeding density of 1 x 104 cells/well. 
After overnight incubation, cells were infected with the four viruses. The infected cells were 
then incubated for 24 hours. Apoptotic cell death was measured over a period of 2, 6 and 24 
hours post infection to investigate the death profile over time. For the 2 and 6-hour time points, 
an MOI of 10 was used. For the 24-hour time point, an MOI of 1 was used. A monolayer of 
cells was infected with nLSDV, Herbivac, nLSDVdSOD-M or nLSDVSODis-M. After 2, 6 
and 24 hours, cell death via the apoptotic pathway was investigated by removing all the medium 
in which the cells were grown and using the cell lysate to determine the amount of apoptosis 
induced.  
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To investigate necrosis, the media in which the infected cells were growing was collected and 
added directly to the microplate to measure the amount of oligonucleosomes released into the 
milieu by dying cells. Oligonucleosomes released both into the cytoplasm because of apoptotic 
cell death and into the media along with dying cells (necrosis) were measured using the Cell 
death detection ELISAPLUS assay (Ref No. 11774425001, Roche, Switzerland).  
Figure 3.6 shows the mechanism of the cell death ELISA kit in determining oligonucleosomes 
released into the milieu by dying cells. Readings were taken using a VersaMax™ ELISA 
Microplate Reader (Molecular Devices, USA). Measurements were done at 405nm and a 
reference wavelength of 490nm was used.  
 
Figure 3.6. Mechanism of the cell death ELISA kit. A sample containing nucleosomes from the apoptotic or necrotic fraction 
is added to the streptavidin microplate. An immunoreagent composed of anti-histone biotin which immobilises the 
nucleosomes to the streptavidin plate and anti-DNA antibody conjugated to horse radish peroxidase is then used in quantifying 
the number of bound nucleosomes. After incubation and washes, 2,2’-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) -
ABTS substrate is added for 20 minutes. A stop solution is then added to stop the reaction. Reading is done at 405 and 490 nm 
on a spectrophotometer. Figure taken from Roche Cell Death Detection ELISAPLUS, USA.  
Apoptosis and necrosis were also investigated in a non-permissive cell line – HeLa S3 cells 
(ATCC, USA). An M.O.I of 10 was used in the non-permissive cell line. Apoptosis and 
necrosis were investigated as described above at 24 hours post infection. 
3.2.11.2 Inhibition of apoptosis by viruses after camptothecin induction 
To measure the ability of a virus to inhibit apoptosis or necrosis, a known inducer of apoptosis 
and necrosis called camptothecin was used. A dilution series of camptothecin was performed 
initially to determine the ideal concentration to induce apoptosis. For MDBK cells, a 
concentration of 1µg/ml was selected as able to induce both apoptosis and necrosis. In HeLa 
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S3 cells, a concentration of 100µg/ml camptothecin was found to be the concentration to use 
in inducing apoptosis/necrosis. 
Cells were seeded and infected as described above, in duplicate. Camptothecin was added to 
one set of wells, so that there were wells that were infected but had no camptothecin added and 
wells which were infected and had camptothecin added. After 24 hours, the assay for 
determining apoptosis or necrosis as described above, was used. 
3.2.11.3 Calculation of the amount of mono/oligonucleosomes released 
after induction of apoptosis/necrosis and enrichment factor. 
To ascertain the exact number of oligonucleosomes being released into the cytoplasm 
(apoptosis) or media (necrosis) after camptothecin induced apoptosis/necrosis a mathematical 
formula was used. Enrichment refers to the amount of oligonucleosomes released into in the 
cytoplasm or medium following induction of apoptosis or necrosis respectively. The formula 
for calculating this is given below: 
Enrichment factor =  
𝑚𝑈 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑎𝑚𝑝𝑡𝑜𝑡ℎ𝑒𝑐𝑖𝑛 𝑎𝑑𝑑𝑒𝑑
𝑚𝑈 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑎𝑚𝑝𝑡𝑜𝑡ℎ𝑒𝑐𝑖𝑛 𝑎𝑑𝑑𝑒𝑑
 
mU – Absorbance  
Once the enrichment factor was computed, an investigation into the fold decrease or fold 
increase in the amount of apoptosis or necrosis was done. The formula for calculating fold 
reduction in apoptosis is given below. 
Fold decrease in apoptosis =
  𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 [𝑢𝑛𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠] 
𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
3.2.12 Statistics  
All statistics, unless specified, used one-way ANOVA followed by Tukey’s test for differences 
between groups. This was performed using GraphPad Prism version 5.0 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad.com). The significant p value 
was set at p < 0.05. 
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3.3 Results 
3.3.1 Comparison of the LSDV SOD homologue amino acid sequences  
The putative amino acid sequences of the SOD homologues from nLSDV and Herbivac were 
compared to other published SOD and SOD decoy genes from poxviruses and animals.  Figure 
3.7 shows an alignment of a selection of different SOD homologues. The homologue from 
nLSDV is a truncated protein (108 aa) lacking some key residues described below. SOD from 
Herbivac was shown to be 160 aa. The LSDV SOD from the virulent field strain Nl 2490 
contain 161 aa.  None of the LSDV putative SOD protein sequences (from the virulent and 
vaccine strains of LSDV) had the catalytic arginine at position 142 in Figure 3.7. An R-to-G 
amino acid substitution is present at this site in both the virulent strain and Herbivac. Eight 
metal binding residues, mostly histidine and aspartic acid, are important for catalytic activity 
and binding metals (Perry et al., 2010). The virulent strain of LSDV, nLSDV and Herbivac 
contained 6 of these residues. All the LSDV strains contained all the Zn binding sites. The 
much studied myxoma virus SOD homologue contained 7 out of the 8 metal binding residues 
and 2 copper binding residues. Vaccinia virus SOD on the other hand contained only 1 copper 
binding site and no Zn binding site.  
The cysteine at position 56, which is present in bovine SOD, human SOD, CCS, myxoma SOD 
homologue (position 55) and AMV SOD was absent from all the LSDV strains. LSDV Nl 2490 
and Herbivac contained all the 8 antiparallel strands and helical turns whereas nLSDV 
contained 6 out of the 8 strands present in functional SOD. Regions of homology between CCS 
and SOD homologues from LSDV were present. However, the SOD homologue from nLSDV 
contained only 1 out of the three residues that are important in SOD-CCS heterodimerisation. 
All the SOD homologues (with the exception of A45R from VV) and enzymes from different 
hosts contained all 3 residues important for dimerization, namely glycine at positions 50 and 
114, and isoleucine at position 152. Lastly, cysteine residues at positions 56 and 145, 
responsible for maintenance of structure by intramolecular bond formation, were absent from 
all LSDV SOD homologues, but present in those with known SOD activity (AMV, human and 
bovine SOD). 
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Figure 3.7. Structural alignment of SOD and SOD homologues. SOD-like proteins from LSDV (Neethling vaccine strain, virulent Nl 2490, Neethling vaccine LW 1959, Herbivac and nLSDVSODis), Myxoma 
virus, variola virus, sheeppox virus, vaccinia virus, Amsacta Moorei Entomopoxvirus and vaccinia virus were included in the alignment. Also included in this alignment are residues 71 to 235 of Human CCS and 
the human as well as bovine SOD. The structures for bovine and human SOD were obtained from the protein databank (1SOS and 1EQ9). SOD alignment was done using the TCoffee Expresso program available on 
the TCoffee server. Structural alignment was done on ESPript 3.0 Server. A key showing some of the residues of interest is shown in the alignment.  
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3.3.2  Construction of transfer vectors to insert an improved SOD gene into LSDV 
and to delete SOD in LSDV 
Initially two transfer vectors were designed that included reporter genes and selection markers.  
The first transfer vector included an improved SOD gene that had been redesigned to improve 
stability.  The second transfer vector deleted SOD.  Later on in the project, recombinant LSDVs 
without the marker or selection genes were constructed to ensure that the differences observed 
between viruses with and without the SOD gene were due to the changes in SOD and not the 
marker genes. 
3.3.2.1 Construction of transfer vector to delete the SOD gene in LSDV 
(pHM1) 
The transfer vector pHM1 was designed to delete the SOD homologue gene from the Neethling 
strain of LSDV. This plasmid was constructed by overlapping PCR fragments (Figures 3.8 and 
3.9). Initially 3 individual PCR fragments were generated from pZG1, pZG2 and pZG4 (section 
3.2.3.1) to produce the left flank, right flank and gpt-GFP respectively. Figure 3.8B shows PCR 
fragments of 466bp (lane 1) for the left flank, 405bp (lane 2) for the right flank and 1505bp 
(lane 3) for the marker and selection genes. These products were purified and subjected to 
overlapping PCR as depicted in Figures 3.2 and 3.8. PCR products of approximately 2.2kbp 
were obtained (Lanes 4, 5 and 6), as expected. BamHI digestion linearised the plasmid to 
produce a fragment of 5224bp (Figure 3.9). DNA sequencing confirmed the transfer vector to 
be correct (see Appendix for sequence). 
3.3.2.2 Construction of transfer vector to insert an improved SOD gene 
into LSDV (pHM2v3)  
It was hypothesized that the SOD gene in Herbivac was unstable due to the AT repeats and so 
this gene was redesigned to improve the stability of the gene. SODis (improved stability) was 
designed in such a way that the AT repeats were replaced by other nucleotides coding for the 
same amino acids (see Figure 3.10).  
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Figure 3.8. Construction of transfer vector pHM1. A – Schematic showing the binding sites of primers designed and 
used in the assembly of the three fragments. Primer 130 forward was designed to bind in LSDV 130. Primer 130 reverse 
was designed to bind inside LSDV 130 with additional oligonucleotides complementary to the GPT-GFP cassette.  This 
cassette carries a selection marker (GPT) and an expression marker (GFP). Another primer was designed, GPT forward, which 
binds in the selection cassette but also includes some oligonucleotides complementary to LSDV130. Primer GPT reverse binds 
in the GPT GFP cassette with oligonucleotides complementary to LSDV 132. LSDV 132 forward binds in the LSDV 132 
region and contains additional nucleotides complementary to the GPT-GFP cassette.  132 reverse binds in the 132 region. B – 
1% Agarose gel electrophoresis of PCR fragments:  amplification of the left flank (1) using primers 130 FOR and 130 REV, 
right flank (2) using primers 132 FOR and 132 REV and pRO-2 DNA /cassette (3) using primers GPT FOR and GFP REV 
(130 FOR and 132 REV). The PCR products from lanes 1,2 and 3 were fused in an overlapping PCR using primers 130 FOR 
and 132 REV (Table 3.1) to generate a fusion product of approximately 2.2.kbp (Lanes 4,5,6).  
 
Figure 3.9. pHM1. A – Plasmid map of transfer vector pHM 1, used to delete the SOD gene in nLSDV. LSDV 130 and 
132 are open reading frames that flank the LSDV SOD homologue, ORF 131. GPT, xanthine-guanine 
phosphoribosyltransferase, GFP, green fluorescent protein. B – 1% agarose gel electrophoresis of pHM 1 subjected to 
BamHI restriction enzyme digestion. 
The transfer vector pHM2v3 was designed to reintroduce the full-length SOD homologue gene 
into the SOD knock-out virus to generate the SOD knock-in virus nLSDVSODis-M. SODis 
was synthesised and ligated into pUC57-Simple by GenScript (New Jersey, USA). The plasmid 
map is shown in Figure 3.11. 
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Figure 3.10. DNA sequence synthesised and ligated into a pUC57-Simple vector by GenScript (New Jersey, USA) to 
generate transfer vector pHM2v3. The purple section is the section of homology to GPT, light green sequence contains the 
SOD promoter region, the green region shows the SOD gene, the region in blue font is the mH5 promoter and the region in 
red represents the mCherry gene. The right flanking sequence is highlighted in orange and represents LSDV 132. 
107 | P a g e  
 
 
Figure 3.11. Plasmid map of transfer vector to insert an improved SOD gene into LSDV- pHM2v3. Modified SOD 
homologue gene based on LSDV 131. The transfer vector pHM2v3 contains part of GPT and nLSDV 132 as flanking 
sequences. SODis and mCherry are placed within the flanks. 
Restriction digestion was performed on pHM2v3 (Figure 3.12). There are single XbaI and SalI 
sites in pHM2v3. BamHI sites are located on each side of the SOD gene (see figure 3.11). 
 
Figure 3.12. Confirmation of pHM 2v3 by restriction enzyme digestion. Plasmid pHM2v3 was untreated (lane 2) or treated 
with XbaI (lane 3), SalI (lane 4) and BamHI (lane 5). Lane 1 is a marker (Thermofisher O’GeneRuler, SM0312). Samples 
were subjected to 1% agarose gel electrophoresis.  
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3.3.3 Isolation of recombinant viruses 
3.3.3.1 Isolation of nLSDVdSOD-M (SOD knock-out). 
The SOD homologue ORF was completely removed from nLSDV by homologous 
recombination of nLSDV with transfer vector pHM1. Figure 3.13 shows expression of 
eGFP in infected cells showing that the pSS promoter was recognised by LSDV. 
Recombinant nLSDVdSOD-M was isolated after 7 passages, of which 6 were done in the 
presence of mycophenolic acid (MPA).  
 
Figure 3.13.  Transient expression of GFP following infection with nLSDV and transfection with pHM1. Primary lamb 
testes cells were infected with nLSDV at an MOI of 0.04 and transfected with 3 ug of pHM 1 (G and H). Cells were 
photographed after 48 hours using UV light and a green filter (A, C, E, G) and phase contrast (B, D, F, H). Controls included 
uninfected and untransfected lamb testes cells (A and B), uninfected transfected cells (C and D) and infected cells not 
transfected with plasmid (E and F). Imaging was done using a fluorescence microscope (Zeiss, Germany) using the 10X 
objective and the scale bar depicts 200µm. 
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PCR was used to confirm the recombinant was indeed the desired knockout virus. The 
sequences of the primers used in the screening of recombinant viruses can be found in section 
3.2.4.2. Primers that bind in the left and right flank (HM 130 FW and HM 132 respectively) 
and those that bind in the SOD region (131 FW and 131 REV) were used (Figure 3.14). The 
primer set 130 FW and 132 REV generated a fragment of 1745 in the recombinant and 808 in 
the parent virus. The primer set 131 (FW and REV) generated a fragment of 300bp in the parent 
virus and no fragment in the recombinant, showing that the SOD gene is not present in this 
virus. Results confirm that the SOD gene was successfully knocked out.  
Table 3.2. Primers used to detect presence of recombinant nLSDVdSOD-M. The respective fragment sizes are also listed. 
Primer sequences are found in section 3.2.4.2. The positions of the primer binding sites are given in Fig 3.14. 
 Forward Primer Reverse Primer Size of fragment 
nLSDVdSOD-M 
nLSDV 
HM 130 FW HM 132 REV 1745 
HM 131 FW HM 131 REV 0 
HM 130 FW HM 132 REV 808 




Figure 3.14. A - Diagram to show primer binding sites and fragments they generate. The primer sets are colour coded 
and Table 3.2 shows the names of the primers used. B - 1% agarose gel electrophoresis of PCR products. Lanes 1 and 2 – 
products generated from primer set HM 130 FW&132 REV on recombinant virus and parent virus respectively. Lanes 3 and 
4 - PCR products from primer set HM 131 FW and 131 REV on recombinant virus and parent virus respectively.  
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Since this recombinant contained a green fluorescent protein as an expression marker, green 
fluorescence was used to establish the presence of the recombinant. The recombinant 
nLSDVdSOD-M was grown to a titre of 108.5 TCID50 per ml (see section 3.2.5 for method) in 
MDBK cells. This stock was confirmed to be a pure culture of recombinant nLSDVdSOD-M 
by PCR and sequencing. No product of 300bp could be detected using primers which amplify 
the SOD gene. In addition, sequencing across the region of insertion of GPT and eGFP using 
primers Left Flank FW, Right Flank REV, and GPT FOR confirmed SOD was replaced by the 
marker eGFP and selection marker (GPT) genes. Figure 3.15 shows the appearance of 
nLSDVdSOD-M at passage 7. Figure 3.19 shows PCR confirmation of this virus stock. 
 
Figure 3.15. Appearance of MDBK cells infected with nLSDVdSOD-M recombinant virus after 7 passages (6 were done 
in the presence of MPA). A - phase contrast image, B - fluorescent image and C - a merged image. Imaging was done using 
a fluorescence microscope (Zeiss, Germany) using the 10X objective. 
3.3.2.2 Isolation of nLSDVSODis-M 
Once nLSDVdSOD-M was successfully made, this recombinant virus was used as parent virus 
in the generation of a SOD knock-in virus.  Since nLSDVdSOD-M contains GPT and GFP, 
within the flanking regions 130 and 132, the second recombinant containing the stabilised form 
of SOD was inserted using part of the GPT gene and the right flank (132) as sites of homologous 
recombination. Included in this insert was mCherry which is a red fluorescing protein gene. 
After infecting lamb testes cells with nLSDVdSOD-M and transfecting with pHM2v3, red 
fluorescing cells were observed less than 24 hours post transfection (see Figure 3.16). The red 
fluorescing virus was purified by 2 rounds of picking. At passage 4, a single fluorescing focus 
was identified in a 96 well plate and expanded for further analysis.  
111 | P a g e  
 
 
Figure 3.16. Transient expression of mCherry. Primary lamb testes cells were infected with nLSDVdSOD-M (which 
expresses GFP – green) at an MOI of 0.01 (C and D) and transfected with 3 ug of pHM 2v3 (B and D). Plasmid pHM2v3 
contains mCherry which causes infected cells to fluoresce red. Figures show merged images. Appearance of uninfected cells 
(A), cells with plasmid only (B), infected cells with parent virus (C) and infected, transfected cells (D). Imaging was done 
using a fluorescence microscope (Zeiss, Germany) using the 10X objective. 
After isolating the recombinant nLSDVSODis-M the virus was grown up to high titres in 
MDBK cells. Viral titration using TCID50 was done and the viral titre was determined as 108 
TCID50/ml. MDBK cells infected with nLSDVSODis-M were shown to express mCherry and 
not eGFP using fluorescence microscopy. This indicated that there was no parent virus present 
in the nLSDVSODis-M stock (Figure 3.17). 
 
Figure 3.17. Fluorescence microscopy of cells infected with nSDVSODis-M. Appearance of cells infected with recombinant 
nLSDVSODis-M after 3 passages of cell lysate from Phase contrast (A), green fluorescence (B), red fluorescence (C) and a 
merged image (D). Infected MDBK cells were photographed 72 hours post infection. Imaging was done using a fluorescence 
microscope (Zeiss, Germany) using the 10X objective. 
PCR confirmed that the desired insert was present in the LSDV genome and that no parent 
virus was present in the stock of recombinant nLSDVSODis-M (Figure 3.18). Primers that 
bound in the left flank and SOD region (130 FW and 131 REV), right flank and SOD region 
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(131 FW and 131 REV) were used to check if the desired recombinant was obtained. Primer 
set 130 FW and 131 REV generated a fragment of 1365bp (lane 4) from the recombinant and 
a fragment of 730bp from nLSDV (lane 2). The primer set 131 FW and 131 REV generated 
fragments of 300bp from both the recombinant nLSDVSODis-M and nLSDV (lanes 3 and 5) 
indicating the presence of the SOD gene in both these viruses.  
Table 3.3 Primers used to detect presence of recombinant nLSDVSODis-M. Primer set A binds in the left flank and the 
SOD gene and primer set B binds in the SOD gene only. Primer set A produced PCR products of 730bp and 1365bp in lanes 
2 and 4 in Figure 3.18. Primer set B produces PCR products of 300bp in lanes 3 and 5 (Figure 3.18). The respective fragment 
sizes are also listed. Primer sequences are found in section 3.2.4.2. 
 Forward Primer Reverse Primer Primer 
set 




HM 130 FW HM 131 REV A 730 2 
HM 131 FW HM 131 REV B 300 3 
HM 130 FW HM 131 REV A 1365 4 
HM 131 FW HM 131 REV B 300 5 
 
Figure 3.18. Confirmation of nLSDVSODis-M by PCR analysis. 1% gel electrophoresis image of amplified products from 
nLSDV (lanes 2 and 3) and nLSDVSODis-M (lanes 4 and 5) using primer sets A (lanes 2 and 4) and B (lanes 3 and 5). These 
primer sets generate fragments of 730bp from nLSDV (lane 2), 300bp from nLSDV (lane 3), 1365bp from nLSDVSODis-M 
(lane 4) and 300bp from nLSDVSODis-M (lane 5).  
The two recombinant viruses nLSDVdSOD-M and nLSDVSODis-M were successfully made. 
The presence of SOD was confirmed by PCR with a forward primer outside the left flank 
(LSDV 129 FOR) and another inside the right flank (LSDV 132 REV). The regions where 
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these primers bound and the fragments they generated is shown in Figure 3.19. The gel image 
in Figure 3.19B shows that the recombinants were successfully obtained. 
 
Figure 3.19. A – Diagram to show primer binding sites and fragments generated from recombinants nLSDVSODis-M 
and nLSDVdSOD-M. Primer 129 forward binds in the LSDV 129 region and Primer 132 reverse in the LSDV132 region. 
They generate PCR fragments of 1600bp in nLSDV, 2500bp in nLSDVdSOD-M and 3000bp in nLSDVSODis-M.  B – 1% 
Agarose gel electrophoresis of PCR products from nLSDV (lane 1), nLSDVdSOD-M (lane 2) and nLSDVSODis-M (lane 3).   
3.3.2.3 Construction of nLSDVdSOD-UCT and nLSDVSODis-UCT 
In the final part of the project, two more recombinant LSDVs were constructed, one with the 
SOD homologue deleted and one with the Neethling SOD homologue replaced by SODis, but 
no reporter genes were present in these recombinants.  This was to confirm that the differences 
observed were due to the SOD homologues and not the two different reporter genes or GPT.  
Transfer vectors pHM1dSOD and pHM1-SOD_pos were made to generate nLSDVdSOD-UCT 
and nLSDVSODis-UCT respectively (Figure 3.20). Sanger sequencing confirmed these 
plasmids. 
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Figure 3.20. A – plasmid map of transfer vectors pHM1dSOD and B - pHM1-SOD_pos used to construct nLSDVdSOD-
UCT and nLSDVSODis-UCT respectively. Plasmids contain an ampicillin resistance gene (bla) and an origin for replication 
(pMB1).  
The two recombinant viruses without markers, nLSDVdSOD-UCT and nLSDVSODis-UCT 
were successfully made as described in section 3.2.4.3. PCR was performed using a forward 
primer that binds outside the left flank (LSDV 129 FOR) and another inside the right flank 
(LSDV 132 REV) to confirm the recombinants. The regions where these primers bound and 
the fragments they generated is shown in Figure 3.21. Figure 3.21 B shows that the 
recombinants were successfully obtained. nLSDVSODis-UCT produced a PCR fragment of 
the expected size of 1600bp (lane 1), as did nLSDV (lane 3). The expected fragment of 1100bp 
was generated from nLSDVdSOD-UCT (lane 4) and a 2500bp fragment was generated from 
nLSDVdSOD-M (lane 2). 
 
Figure 3.21. A – Diagram to show primer binding sites and fragments generated from recombinants nLSDVdSOD-
UCT and nLSDVSODis-UCT. Primer 129 forward binds in the LSDV 129 region and Primer 132 reverse in the LSDV132 
region..  B – 1% Agarose gel electrophoresis of PCR products. DNA was amplified from nLSDVSODis-UCT (lane 1), 
nLSDVdSOD-M (lane 2), nLSDV (lane 3) and nLSDVdSOD-UCT using primers 129 forward and 132 reverse. 
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3.3.4 Growth of parent LSDV vaccines and recombinants in cell culture.  
The recombinant viruses without markers, nLSDVdSOD-UCT and nLSDVSODis-UCT were 
compared with respect to growth in MDBK cells (Figures 3.22 and 3.23). Cytopathic effect, 
indicated by cell foci and gaps in the monolayer, was seen earlier in MDBK cells infected with 
nLSDVSODis-UCT compared to nLSDVdSOD-UCT (Figure 3.22). This could have 
influenced virus yield as at day 5, most nLSDVSODis-UCT infected cells were dead as shown 
by the morphology of cells and presence of gaps. Hence day 5 was removed from the growth 
curve shown in Figure 3.22. Virus yield from nLSDVdSOD-UCT infected cells appeared to be 
lower than that of nLSDVSODis and nLSDV infected cells at 1-day post infection. Days 2-4 
post infection, there was an increased growth of nLSDV with significant difference between 
virus yield from nLSDV infected cells compared to nLSDVdSOD-UCT infected cells (p<0.01) 
and not nLSDVSODis-UCT (p>0.05) (Figure 3.23).  
 
 
Figure 3.22. MDBK cells uninfected or infected with nLSDVdSOD-UCT, nLSDVSODis-UCT or nLSDV at an MOI of 0.015. 
A. Monochrome light inverted microscopic images were taken at time points as indicated.  
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Figure 3.23. Growth curves of nLSDV (red), nLSDVSODis-UCT (green) and nLSDVdSOD-UCT (blue) in MDBK cells. 
Cells were infected at an MOI of 0.015 in triplicate and lysates were prepared 2 hours post infection and at subsequent 1-day 
intervals. Titrations were performed using the TCID50 method and titres were converted to ffu/ml. A one-way ANOVA was 
done on each time point, n=3. Post-hoc T-test was performed to identify which titres at which time points were significantly 
different from another. The symbol ** represents a significance level of p<0.01. The symbol ++ represents a difference 
between nLSDVdSOD-UCT and nLSDVSODis-UCT at p<0.01. Data points denote mean and error bars SEM. 
3.3.5 Growth of vaccines and recombinants on CAMs 
Virus was isolated and titrated from chorioallantoic membranes (CAMs) of 7-day-old fertilised 
eggs which were infected with nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT. The 
growth curves of the three viruses, nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT are 
shown in Figure 3.24.  
Looking at the virus yield per day, there was lower viral yield from CAMs infected with 
nLSDVdSOD-UCT compared to nLSDV and nLSDVSODis-UCT at days 4 and 5 (Figure 3.25).  
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Figure 3.24. Macroscopic appearance of infected chick CAMs on day 5 post infection. 7-day-old embryonated hens’ eggs 
were inoculated with PBS (A), nLSDV (B), nLSDVdSOD-UCT (C), nLSDVSODis-UCT (D). Membranes were collected 
daily for 5 days in triplicate. Representative images are shown. 
 
Figure 3.25. Growth curves of nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT on CAMs of fertilized hens’ eggs. 7-
day-old fertilized hens’ eggs were infected with virus at 103 TCID50 per egg and incubated at 34 °C. Eggs were harvested 
daily from Day 0 to Day 5, triplicate membranes were pooled and crude virus extracts were titrated. One-way ANOVA was 
done at each time point and Tukey post-hoc was performed to identify which titres at which time points were significantly 
different from another. The symbols represent a significance level of p<0.001. The symbol * represents difference between 
nLSDV and nLSDVdSOD-UCT, the symbol # difference between nLSDV and nLSDVSODis-UCT and the symbol + 
represents the difference between nLSDVdSOD-UCT and nLSDVSODis-UCT. Data points denote mean and error bars SEM. 
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3.3.6 Histopathology of CAMs infected with viruses 
CAMs of fertilised hens’ eggs infected with nLSDV, nLSDVdSOD-M, nLSDVSODis and 
Herbivac (described section 3.2.6) were examined histologically at day 6, when the mean titre 
of all the viruses were approximately 106.0 TCID50/ml. Figure 3.26 shows H&E staining of the 
sections. Comparing nLSDV and Herbivac (Figure 3.26) there was notable proliferation of 
fibroblasts as well as increased immune cell infiltration in the mesoderm of Herbivac-infected 
CAMs. When comparing nLSDVdSOD-M and nLSDVSODis-M (Figure 3.26) there was 
pronounced ectodermal thickening in CAMs infected with nLSDVSODis-M. There was a loss 
of fibroblasts in nLSDVdSOD-M infected cells whereas proliferation of fibroblasts in the 
mesoderm of nLSDVSODis infected CAMs was observed. There was a lot of vacuolation in 
the mesoderm of nLSDV infected CAMs and nLSDVdSOD-M infected CAMs. There was also 
ballooning degeneration (cell death) in the epithelial layers of nLSDVdSOD-M and 
nLSDVSODis-M infected CAMs. The level of ballooning degeneration was comparable in 
CAMs infected with nLSDVdSOD-M and nLSDVSODis-M. It could not be concluded which 
infection had the most ballooning degeneration because nLSDVSODis-M had a lot of 
proliferation in the epithelial layers which could have replaced the dying cells with newer ones.  
Recombinant vaccines nLSDVdSOD-UCT and nLSDVSODis-UCT were also characterised 
based on their differences in histology on CAMs (Figure 3.27). For this experiment 5 sections 
were prepared from a single membrane collected on days 1, 3 and 5 post infection. The grade 
of inflammation, epithelial hyperplasia and presence of inclusions progressively increased 
from day 1 to day 5. Major differences were noted at day 5 post infection (Table 3.3).  
Inflammation in the mesoderm and chorionic epithelial hyperplasia achieved the highest score 
by day 5 and in general; the nLSDV and nLSDVSODis-UCT achieved higher scores (more 
intense inflammation) for each time point - than nLSDVdSOD-UCT (Table 3.3 and Figure 
3.27). Hyperplasia and viral inclusions were absent in the control section (PBS). There was 
increased ballooning degeneration associated with nLSDVdSOD-UCT and nLSDV infection 
which was absent in nLSDVSODis-UCT infected CAMs. Intracytoplasmic viral inclusions 
were observed more often in the sections of nLSDVSODis-UCT, compared to nLSDV and 
nLSDVdSOD-UCT. Vacuolar change (ballooning) often accompanied the inclusions in 
sections of nLSDV and nLSDVSODis-UCT. 




Figure 3.26. H&E staining of fixed membranes 6 days post inoculation with PBS (A & F), nLSDV (B & G), Herbivac (C & H), nLSDVdSOD-M (D & I) and nLSDVSODis-M (E & J). 
Membranes were fixed in buffered formalin at day 6 where their mean titre was 106 TCID50/ml. Arrows indicate vacuolation (yellow arrow), angiogenesis/vascularisation (orange arrow), immune 
cell infiltration (blue arrow), ballooning degeneration/cell death (green arrow) and fibroplasia (black arrow).  Purple arrow shows ectodermal thickening and the red arrow shows a pock on the 
membrane. Upper panel shows low magnification (100X) and the bottom panel higher magnification (400X).  
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Figure 3.27. H&E staining of fixed membranes 5 days post inoculation with PBS (A & E), nLSDV (B & F), nLSDVdSOD-UCT (C & G), nLSDVSODis-UCT (D & H). Membranes 
were fixed in buffered formalin at day 5. Arrows indicate immune cell infiltration (red arrow) and ballooning degeneration/cell death (blue arrow). Upper panel shows low magnification 
(100X) and the bottom panel higher magnification (400X). 
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Table 3.3. Histology. Chorioallantoic membranes (CAMs) were inoculated with PBS, nLSDV, nLSDVdSOD-UCT and nLSDVSODis-UCT. Day 5 formalin fixed, and 
paraffin embedded sections were stained by haematoxylin and eosin using routine methods. Scoring was done based on presence of intracytoplasmic inclusions, epithelial 
hyperplasia and inflammatory changes. 








Chorionic Allantoic Mesoderm 
nLSDV  
A + 4 2 5 ballooning and inclusions 
B + 4 1 4   
C + 4 1 5   
D + 5 1 5   
E + 4 1 5   
nLSDVdSOD-UCT 
A + 2 1 3 - 
B + 3 2 3 ballooning degeneration 
C + 3 2 2 ballooning degeneration 
D + 3 1 3 - 
E + 3 2 3 - 
nLSDVSODis-UCT 
A + 4 1 5 - 
B + 4 1 4 - 
C + 2 0 3 - 
D + 3 0 4 - 
E + 4 1 5 high numbers of inclusions (chorion) 
PBS 
A - 0 0 0 - 
B NP NP NP NP - 
C NP NP NP NP - 
D NP NP NP NP - 
E NP NP NP NP - 
0 - Not detectable; 1 - Minimal (Barely detectable in a minority of fields); 2 – Mild (Barely detectable, but present in most fields); 3 - Moderate (Clearly visible in at least 
50% of fields); 4 - Marked (Clearly visible in more than 50% of fields); 5 - Severe (Outspoken changes in the majority of fields); NP (Not performed) 
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The inflammatory scores from each section in Table 3.3 were averaged and the results are 
presented in Figure 3.28. Bars represent the inflammatory score and standard error of the mean 
(SD). There is a significant decrease in the inflammatory score of nLSDVdSOD-UCT 
compared to nLSDV (p <0.001) and nLSDVSODis-UCT (p < 0.01).  There was no significant 
difference in the number of immune cells infiltrating the mesoderm of nLSDV and 
nLSDVSODis-UCT infected CAMs (Figure 3.28).  This suggested a role for the truncated SOD 
in immune infiltration which, when deleted, is lost.  
 
Figure 3.28. Immune infiltration in H&E stained sections. CAMs infected for 5 days were washed, fixed with 4% buffered 
formalin, embedded, sectioned and stained with haematoxylin and eosin. Five consecutive sections were evaluated under the 
light microscope and scored for inflammation (oedema, haemorrhage and infiltration with white blood cells). One-way 
ANOVA and Tukey post hoc testing was used to test for significance. The symbol *, **, *** represents a significance level 
of p<0.05, p<0.01 and p<0.001 respectively. Bars denote mean and standard deviation. 
3.3.7 Effect of the LSDV superoxide homologues on activity of cellular SOD activity 
SOD activity in MDBK cells infected with nLSDV, Herbivac, nLSDVdSOD-M and 
nLSDVSODis-M was measured at 3 different time points post infection using a SOD 
determination kit (Sigma, USA). No significant difference in SOD activity could be detected 
between the different viruses at any of the time points post infection (2 hrs, 6 hrs and 24 hours) 
(Figure 3.29). 
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Figure 3.29. Total SOD activity. MDBK cells were infected for 2, 6 and 24 hours and lysed using a lysis buffer and 
mechanical disruption. SOD activity was normalised to amount of protein loaded. Bars represent mean percentage SOD 
activity. Experiment was done at 2, 6 and 24 hours post infection (hpi). No significant differences at p<0.05 were observed 
between viral infections at any time (One-way ANOVA). Bars denote mean and error bars SEM. 
3.3.8 Induction or inhibition of apoptosis / necrosis by viruses 
An experiment to determine the ability of the different LSDVs to induce cell death and to 
inhibit camptothecin induced cell death was done. At two hours post infection with LSDVs at 
an MOI of 10, there was significantly increased apoptosis in MDBK cells infected with 
nLSDVSODis-M (p < 0.001) compared to nLSDV, Herbivac or nLSDVdSOD-M (Figure 
3.30A). Six hours post infection, there was increased apoptotic cell death induced by Herbivac 
and nLSDVSODis-M relative to cells, but no significant increase in apoptosis induced by 
nLSDV and nLSDVdSOD-M (Figure 3.30B).  
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Figure 3.30. Apoptotic cell death detection. MDBK cells were either uninfected or infected with nLSDV, Herbivac, 
nLSDVdSOD-M and nLSDVSODis-M at an MOI of 10. Bars represent absorbance which is proportional to the amount of 
oligonucleosomes released in the cytoplasm of apoptotic cells. A - After 2 hours of infection, media was removed, and the 
cells lysed. The Roche cell death detection ELISAPLUS kit was the used to measure the number of nucleosomes released from 
the cells. The three symbols *** represents a significance level of p<0.001. Symbols *, ~, $, #, represent significance level of 
nLSDVSODis-M compared with cells, nLSDV, Herbivac and nLSDVdSOD-M respectively. B - After 6 hours of infection, 
media was removed, and the cells lysed. The Roche cell death detection ELISAPLUS kit was the used to measure the number 
of nucleosomes released from infected cells only. The symbol *, **, *** represents a significance level of p<0.05, p<0.01 and 
p<0.001 respectively. Bars denote mean and error bars SEM. 
The effect of virus on apoptosis in MDBK cells was most noticeable at 24 hours post infection 
(Figure 3.31). Viruses nLSDVSODis-M and Herbivac had comparable induction of cell death 
by virus only. Viruses nLSDV and nLSDVdSOD-M had comparable induction of cell death, 
however, the level of induction of apoptosis was lower than the level of induction observed for 
nLSDVSODis-M and Herbivac.  
In addition to measuring the induction of apoptosis by viruses at 24 hours post infection the 
inhibition of camptothecin induced apoptosis was measured. As can be seen in Figure 3.31 (B-
D), all viruses effectively inhibited apoptosis showing that LSDV encodes anti-apoptotic gene 
products. When the absorbance values for infected cells without camptothecin were taken as 
baseline values of cell death and the camptothecin induced cell death values were used to 
denote induction or inhibition of apoptosis, all viruses inhibited camptothecin induced 
apoptosis (Figure 3.31C). Of note, there was greater inhibition of camptothecin induced 
apoptosis following infection with Herbivac and nLSDVSODis-M compared to nLSDV and 
nLSDVdSOD-M (Figure 3.31D) in MDBK cells.   
Cell death by necrosis was investigated 24 hours post infection. All viruses tested induced 
necrosis relative to uninfected cells.  However, there was increased necrotic cell death after 
infection with nLSDVSODis-M and Herbivac compared to nLSDV and nLSDVdSOD-M 
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(Figure 3.32). Upon inducing cell death with camptothecin (1µg/ml), the ability of viruses to 
inhibit necrotic cell death was investigated. When necrosis was induced using camptothecin 
there was inhibition of necrosis by all 4 viruses shown by an enrichment factor of 1 compared 
to uninfected cells with an enrichment score of 4 (Figure 3.32C).  
 
Figure 3.31. Apoptotic cell death detection. A – Induction of apoptotic cell death. MDBK Cells were either uninfected or 
infected with nLSDV, Herbivac, nLSDVdSOD-M or nLSDVSODis-M at an MOI of 1. After 24 hours of infection, media was 
removed, and the cells lysed. The Roche cell death detection ELISAPLUS kit was the used to measure the number of 
nucleosomes released. Bars represent absorbance which is proportional to the amount of oligonucleosomes released in the 
cytoplasm of apoptotic cells. The symbol *, **, *** represents a significance level of p<0.05, p<0.01 and p<0.001 respectively. 
B - Inhibition of apoptotic cell death. MDBK Cells were either uninfected or infected with nLSDV, Herbivac, nLSDVdSOD-
M or nLSDVSODis-M and apoptosis induced using 1µg/ml camptothecin. C - Apoptosis enrichment factor of MDBK cells. 
The absorbance of dying cells (CAM induced cell death) was divided by the absorbance of infected cells or cells only (control) 
without camptothecin to establish the number of mono/oligonucleosomes released after CAM treatment. An enrichment factor 
of >1 means there was camptothecin induced cell death whereas a value of 1 means there was no camptothecin induced cell 
death. A value of < 1 shows there was inhibition of camptothecin induced cell death. D - Inhibition of camptothecin induced 
apoptosis. The enrichment factor of infected cells was normalised to the enrichment factor of uninfected cells to obtain the 
fold decrease in apoptosis. Graphs represent the mean + S.E.M of 3 biological experiments. To compute the fold decrease in 
absorbance, the enrichment factor after CAM induction of apoptosis for cells was divided by the enrichment factor of virus 
infected cells A high fold decrease in apoptosis shows the extent to which the virus inhibits camptothecin induced apoptosis. 
The symbol *, **, *** represents a significance level of p<0.05, p<0.01 and p<0.001 respectively. Bars denote mean and error 
bars SEM. 
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Figure 3.32. Necrotic cell death detection. A – Induction of necrosis by viruses. MDBK cells were either uninfected or 
infected with nLSDV, Herbivac, nLSDVdSOD-M or nLSDVSODis-M. They were tested for cell death 24 hours post infection. 
Media in which cells were growing was used to investigate the amount of oligonucleosomes released by necrotic cells. 
Uninfected cells were used as a negative control. Bars represent absorbance which is proportional to the amount of 
oligonucleosomes released in the cytoplasm of apoptotic cells. The symbol *, **, *** represents a significance level of p<0.05, 
p<0.01 and p<0.001 respectively. Symbols *, ~, $, #, represent significance level of necrosis of cells compared with nLSDV, 
Herbivac and nLSDVdSOD-M and nLSDVSODis-M respectively. B - Inhibition of necrotic cell death. MDBK cells were 
either uninfected or infected with nLSDV, Herbivac, nLSDVdSOD-M or nLSDVSODis-M and necrosis induced using 1µg 
/ml camptothecin. Note camptothecin in equal amounts was added to all viruses and cells. Measurement was done 24 h.p.i and 
post CAM addition. C - Necrosis enrichment factor in MDBK cells. The absorbance of dying cells (CAM induced cell death) 
was divided by the absorbance of infected cells or cells only (control) without camptothecin to establish the number of 
mono/oligonucleosomes released after CAM treatment. An enrichment factor of >1 means there was camptothecin induced 
cell death whereas a value of 1 means there was no camptothecin induced cell death. A value of < 1 shows there was inhibition 
of camptothecin induced cell death. The symbol *, **, *** represents a significance level of p<0.05, p<0.01 and p<0.001 
respectively. Bars denote mean and error bars SEM. 
The first experiments were done in a permissive cell line where LSDV was able to replicate.  
The ability or inability of the four viruses to induce or inhibit apoptosis in a non-permissive 
cell line, HeLa S3, was also tested with nLSDV, Herbivac, nLSDVdSOD-M and 
nLSDVSODis-M at an MOI of 10 with and without camptothecin (100µg/ml). Using the cell 
death detection ELISA to determine induction or inhibition of apoptosis or necrosis, there was 
no significant difference in the number of oligonucleosomes released after 24 hours. However, 
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upon addition of camptothecin, a trend towards inhibition of camptothecin induced apoptosis 
by nLSDV, Herbivac and nLSDVSODis-M was shown. Virus nLSDVdSOD-M is the only one 
that did not show a trend in apoptosis inhibition. (Figure 3.33B). 
 
Figure 3.33. Apoptosis enrichment factor of HeLa S3 cells 24 h.p.i. A – Induction of apoptosis. The absorbance of dying 
cells (CAM induced cell death) was divided by the absorbance of infected cells or cells only (control) without camptothecin 
to establish the number of mono/oligonucleosomes released after CAM treatment. An enrichment factor of >1 means there 
was camptothecin induced cell death whereas a value of 1 means there was no camptothecin induced cell death. A value of < 
1 shows there was inhibition of camptothecin induced cell death. Camptothecin was used at a concentration of 100µg /ml. B - 
Inhibition of camptothecin induced apoptosis. HeLa S3 cells were infected with nLSDV, Herbivac, nLSDVdSOD-M and 
nLSDVSODis-M at an M.O.I of 10. Apoptosis was induced by adding camptothecin to infected cells. The fold decrease in 
apoptosis was measured against uninfected cells. Graphs represent the mean + S.E.M of 3 biological experiments. To compute 
the fold decrease in absorbance, the enrichment factor after CAM induction of apoptosis for cells was divided by the 
enrichment factor of virus infected cells A high fold decrease in apoptosis shows the extent to which the virus to inhibits 
camptothecin induced apoptosis. Significance was set at p<0.05. Bars denote mean and error bars SEM. 
3.4 Discussion 
To fully characterise the full-length LSDV SOD and to investigate whether it has functional 
domains similar to the leporipoxvirus SOD homologues, a protein domain alignment was done. 
The amino acid sequence and structural domains of SOD in a virulent field strain LSDV (Nl 
2490) were compared with the LSDV vaccine strains (nLSDV and Herbivac), vaccinia virus, 
myxoma virus, Amsacta Moorei with bovine and human SOD.  
An important step in SOD activation (Figure 1.16) is the dimerization of the copper chaperone 
for SOD with monomeric SOD (Culotta et al., 1997). Leporipoxvirus SOD homologues have 
been reported to bind the copper chaperones and thereby act as inhibitors of the proper 
metalation of Cu Zn SOD (Cao et al., 2002, Teoh et al., 2005, Teoh et al., 2003). The level of 
inhibition is at the stage of SOD-CCS dimerization observed in the activation of cellular SOD 
128 | P a g e  
 
(reviewed in Chapter 1) (Teoh et al., 2003, Teoh et al., 2005). Regions of homology between 
the second domain of CCS and Cu Zn SOD and some homologues including LSDV SOD were 
shown (Teoh et al., 2003). It is interesting to note that the truncated SOD from nLSDV did not 
have all the motifs needed to dimerise with CCS. However, Herbivac and the virulent field 
strain of SOD contained all the residues important in heterodimerisation. These residues have 
also been reported to be present in leporipoxviruses although they have been shown to also 
include a cysteine at position 56 homologous to a cysteine at position 57 in CCS which further 
stabilises the heterodimer (Cao et al., 2002). Myxoma virus contains a small deletion that places 
cysteine in the 56th position (Cys 56). This cysteine is thought to play a role in dimerization 
between MYX SOD and CCS because it occupies a similar position as Cys 57 in yeast. (Cao 
et al., 2002, Teoh et al., 2003). This amino acid plays a role in binding copper and stabilises 
the formation of the CCS-SOD heterodimer (Culotta et al., 2006). However, this residue was 
absent from all the LSDV SOD homologues.  
There are conserved domains important for SOD enzyme function and these include a catalytic 
arginine at amino acid position 142 and copper binding residues (Figure 3.7). The absence of 
this conserved domain in the active site may be the reason LSDV SOD homologues are 
catalytically inactive as a SOD enzyme. LSDV Nl 2490 and Herbivac contained 5 out of 6 
domains required for the active site.  SOD from nLSDV however did not show most of the 
required domains which include residues at position 119 and 142 in bovine SOD (Figure 3.7).  
The β sheets are responsible for maintaining the structure of cellular SOD. These β-sheets can 
aggregate through hydrogen bonding via the interaction of their edges with other β-sheets they 
encounter (Richardson and Richardson, 2002). The β sheet strand numbers 5 and 6 in nLSDV, 
Herbivac and LSDV Nl 2490 are known as ‘edge strands’ and are able to form hydrogen bonds 
with other edge strands synonymous to the finding in amyloid fibrils. In native SOD 1 (Cu Zn 
SOD) these edge strands are protected as they bind metals (Valentine and Hart, 2003). However, 
nLSDV becomes particularly more interesting as it ends at the 6th β sheet and lacks other 
residues which coordinate metal binding. This, in turn, exposes the β sheet edges which can 
bind other proteins including cellular SOD 1. Aggregates formed are not generally problematic 
in mammalian cells as they are sequestered into an aggresome for proteolytic degradation. The 
exception is when the aggregates are soluble like Cu Zn SOD aggregates which become harder 
to clear (Valentine and Hart, 2003, Banci et al., 2007). Aggregation of mutant Cu Zn SOD with 
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low or no affinity to the metals are toxic to cells (Kabashi et al., 2007). These aggregates may 
lead to cell death possibly through apoptosis (Oh et al., 2008).  
SOD homologues from LSDV Nl 2490 have been shown to cluster phylogenetically with other 
SOD homologues that have been reported to act as decoy proteins (Teoh et al., 2003). A SOD 
homologue from vaccinia virus was shown to be in a different cluster compared to the 
homologues from LSDV and the leporipoxviruses (Teoh et al., 2003) which clustered together. 
It is important to note that vaccinia virus SOD (A45R) has been shown to be inactive as an 
enzyme and a decoy (Almazan et al., 2001). It was therefore more likely for LSDV to 
functionally resemble proteins in the same cluster and therefore could potentially retain some 
decoy activity like the other homologues closely related to it, such as the SOD from 
leporipoxviruses. This finding was instrumental in doing functional assays to investigate 
whether full length SOD from Herbivac functioned as a SOD decoy as has been reported for 
the leporipoxviruses. 
Findings from the investigation of the growth of different LSDV viruses in cell culture showed 
that the presence or absence of the SOD influenced virus yields.  The yields of nLSDVdSOD-
UCT were lower than those of nLSDV and nLSDVSODis-UCT. This is in contrast to 
experiments with SOD homologue deletion mutants in recombinant SFV and MYX which were 
shown in two independent experiments to grow ten times better in a one-step growth curve in 
tissue culture (Teoh et al., 2005, Cao et al., 2002). Therefore, it can be concluded that the 
presence of a LSDV SOD homologue (truncated or full-length) contributes to the better growth 
yields in cells and CAMs.  This is important when considering growth of virus for use as 
vaccine. 
Growth curves of LSDV in chick CAMs had a similar growth profile to that shown by van 
Rooyen et al. (1969). In that experiment virus titres peaked at day 6 and started declining at 
day 7. Also in agreement with our study, virus yield did not exceed 106 TCID50/0.2 ml (results 
not shown). It does appear that there is a limit to the amount of virus one can extract from 
infected CAMs. Therefore performing growth curves within the first 5 days of experiment can 
be more informative than after 6 days as viral titres drop.  
The presence or absence of SOD in LSDV resulted in different histological changes in CAMS.  
There were increased numbers of fibroblasts in nLSDV, Herbivac, and nLSDVSODis-M and 
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not nLSDVdSOD-M infected CAMs when compared to uninfected CAMS. Interestingly, there 
was ectodermal proliferation in nLSDVSODis-M infected CAMs. Also, CAMs infected with 
nLSDVSODis-M had the most pronounced epithelial hyperplasia and ectodermal thickening. 
Inhibition of SOD leads to an increase in the superoxide radical and this has been reported to 
promote cell proliferation (Behrend et al., 2003). In one study, Teoh and colleagues infected 
rabbits with SFV, measured the sizes of lesions and performed histological examination of 
lesion biopsies. They reported that the presence of a decoy SOD was associated with an 
increase in the size of lesions and microscopically with fibromatous cell proliferation  (Teoh et 
al., 2005). Our results support this as nLSDVSODis-M was shown to induce more fibroplasia 
compared to nLSDVdSOD-M. Our results also showed a role of the truncated gene product 
from nLSDV as nLSDV infected CAM sections also contained more fibroblasts compared to 
nLSDVdSOD-M.  
Infiltration of leukocytes was observed in the mesoderm of all infected CAMs with highest 
amounts shown after infection with Herbivac in the first histology experiment. Scoring in a 
blinded fashion by an independent specialist veterinary pathologist in a second experiment 
revealed that there was increased immune infiltration after infection with nLSDV and 
nLSDVSODis-UCT at day 5. nLSDVdSOD-UCT had the least amount of immune infiltration 
(Table 3.3 and Figure 3.27). Leukocyte infiltration after infecting CAMs with poxviruses has 
been reported before and it has been postulated to act as an indicator for an acute inflammatory 
response (Offerman et al., 2013, Prozesky and Barnard, 1982). The SOD knockout virus 
therefore appeared to have the least inflammatory response whereas the SOD knock-in (both 
truncated and full-length SOD) viruses had the highest inflammatory response. This could 
account for the improved immunogenicity that was observed in cattle (unpublished 
observations, Deltamune). Lesions from rabbits infected with wild type SFV expressing a SOD 
homologue showed extensive leukocyte infiltration (Teoh et al., 2005). Because our viruses 
only differ at the SOD locus, we conclude that the SOD homologue contributes to the 
differences observed. The presence of marker genes did not appear to influence major 
differences in histopathology. 
Despite nLSDV (containing the truncated SOD) having the same inflammatory score as the 
SOD knock-in virus, our chick CAM experiment showed some differences in pathology. In 
fact, nLSDV resembled the SOD knock-out in those pathologies. In both CAM histology 
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experiments with and without marker genes there was more pronounced ballooning 
degeneration in CAMs infected with nLSDV and nLSDVdSOD-M/UCT than with 
nLSDVSODis-M /UCT. (Table 3.3). Fewer cells were observed in the epithelium of CAMs 
infected with the knock-out than with the SOD knock-in viruses. CAMs infected with 
nLSDVSODis-M may have compensated for the degenerating cells through cellular 
proliferation and epithelial hyperplasia. There was pronounced epithelial hyperplasia as well 
as fibroplasia following infection with nLSDVSODis-M. The presence of a functional decoy 
SOD has been implicated in survival and proliferation of cells (Teoh et al., 2005). Ballooning 
degeneration is however not a new finding in LSDV infections. Van Rooyen and colleagues 
also showed necrosis in CAM sections infected with LSDV (van Rooyen et al., 1969). It is thus 
evident that infection with LSDV is associated with cell death. However, what makes the SOD 
knock-in recombinants particularly interesting here, is that their presence was associated with 
some form of protection from cell death or the dying cells are efficiently replaced.  
SOD can have antiviral properties and so many viruses have evolved mechanisms to modulate 
the host SOD activity (Cao et al., 2002).  SOD homologues from leporipoxviruses have been 
shown to compete for copper thereby inhibiting the activity of SOD. Teoh et al. (2003) showed 
that the SOD homologues from leporipoxviruses bind the copper chaperone for copper, 
indirectly inhibiting cellular SOD activity. Since full-length LSDV SOD resembled and 
clustered with SOD from leporipoxviruses, we investigated whether this SOD was active as an 
enzyme or whether SOD from LSDV inhibited the activity of cellular SOD. In this experiment, 
we failed to show any involvement of the truncated or full-length SOD homologue from LSDV 
in the perturbation of the activity of cellular Cu Zn SOD. The vaccinia virus SOD homologue 
(product of the A45R) gene is a late gene product which is packaged in the viral core (Almazan 
et al., 2001) and can exert its effect early in infection. Similarly, LSDV encodes a SOD 
homologue that is believed to be a late protein because of its promoter sequence (Tulman et al., 
2001). However, we were not able to show any significant differences in SOD activity at any 
time point. This may have been due to the cellular feedback mechanisms which maintain a 
steady concentration of SOD within the cell making it impossible to determine whether the 
SOD homolog is acting as a decoy or an active enzyme. 
The superoxide anion has been shown to be anti-apoptotic and proliferative (Pervaiz and Clement, 
2002b, Behrend et al., 2003). We did not observe any enrichment of the superoxide anion in our 
in vitro SOD assays in LSDV infected cells, but, interestingly, the proliferative nature of viruses 
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containing the full-length SOD was observed on the histology of infected CAMs (refer to section 
3.3.6). There was fibroplasia in the mesoderm of CAMs infected with Herbivac and 
nLSDVSODis-M compared to nLSDVdSOD-M infected CAMs.  There was also epithelial 
hyperplasia in CAMs infected with nLSDVSODis-M and Herbivac and not nLSDV or 
nLSDVdSOD-M. Using viruses without markers, increased epithelial hyperplasia associated 
with nLSDV and nLSDVSODis-UCT was observed though it was not significantly different 
compared to nLSDVdSOD-UCT. 
We showed increased induction of cell death following viral infection with LSDV containing 
the full-length SOD homologue compared to nLSDV and the SOD knock-out at 24 hours post 
infection (Figure 3.31). This trend was different at 2 and 6 hours post infection where 
nLSDVSODis-M infected cells only, had increased induction of apoptosis (Figure 3.30). The 
differences in induction of cell death between nLSDVSODis-M and Herbivac at these times 
may be as a result of Herbivac being a mixture of the full-length SOD and truncated SOD 
observed in nLSDV.  
In an experiment to determine the role of the full-length SOD homologue in the inhibition of 
camptothecin induced cell death, we observed that there was an increased inhibition of 
camptothecin induced cell death following infection with viruses containing a full-length SOD 
homologue (Herbivac and nLSDVSODis-M) compared to nLSDV and the SOD knock-out 
(Figure 3.31D). This observation implies that there were different pathways of apoptosis being 
affected by virus infection and camptothecin. Virus infection could have induced apoptosis 
via the extrinsic pathway. Camptothecin is known to induce death via the  intrinsic pathway 
(Zeng et al., 2012). Death via the extrinsic pathway is mediated by cell membrane surface 
bound death receptors which include tumor necrosis factor receptor 1 (TNF-R1), FAS, TNF-
related apoptosis-inducing ligand (TRAIL) (Veyer et al., 2017, Zhou et al., 2017). The intrinsic 
pathway of apoptosis is triggered by different intracellular stimuli that includes DNA damage, 
cytokine deprivation, oxidative stress, calcium overload and endoplasmic reticulum stress (Zhou 
et al., 2017). Once the above stated stimuli are evoked, they all converge to cause mitochondrial 
outer membrane permeabilization (MOMP). MOMP is highly regulated by proteins belonging 
to the BCL-2 family. Upon induction of the intrinsic pathway of apoptosis, the BCL-2 homology 
domains can interact with BCL-2 associated protein X (BAX) or BCL-2 agonist or killer (BAK) 
(Zhou et al., 2017). Camptothecin causes DNA damage (Horwitz et al., 1972) and consequently 
evokes the intrinsic form of apoptosis. The involvement of the extrinsic apoptotic death pathway 
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in nLSDVSODis infection is further substantiated by the fact that immediately after infection 
(2 and 6 h.p.i) we started to observe a general induction of apoptosis. It can be inferred that virus 
binding to death ligands on the cell surface may contribute to the induction of the extrinsic cell 
death pathway.  
There was a general trend of inhibition of camptothecin induced cell death by all 4 viruses 
showing that LSDV contains anti-apoptotic genes or gene products. The observation that the SOD 
knock-out virus also inhibited camptothecin induced apoptosis indicated that this was not 
completely dependent on SOD. LSDV has been shown to encode apoptosis regulatory genes 
such as LSDV003, LSDV017 and LSDV154. LSDV also includes ankyrin repeat genes (Tulman 
et al., 2001, Kara et al., 2003) which from studies using vaccinia virus in vitro (Ryerson et al., 
2017) have been shown to be antiapoptotic. Thus, there would be a general anti-apoptotic 
environment from gene products other than SOD. Interestingly, the truncated form of SOD 
present in nLSDV did not appear to play a role in inhibition of camptothecin induced cell death 
as there was no significant difference in the inhibition of camptothecin induced apoptosis 
between nLSDV infected cells compared to nLSDVdSOD-M infected cells (Figure 3.31D). In 
addition a SOD decoy from myxoma was shown to mount partial protection against apoptosis 
and able to mount full defense, possibly in concert with other antiapoptotic gene products like 
M11L (Teoh et al., 2005). 
Camptothecin has been shown to affect both mammalian and poxviral DNA topoisomerases 
making it a candidate antiviral agent for poxviruses (Horwitz et al., 1972, Da Fonseca and Moss, 
2003). Camptothecin could have bound viral topoisomerases thereby inhibiting them. Regardless 
of this however, our assertions that viruses containing full-length SOD inhibit CPT induced cell 
death remain true as equal amounts of camptothecin were added to both the knock-out and knock-
in viruses but had varying effects. The SOD knock-out was a control showing LSDV without 
SOD inhibited camptothecin induced cell death and viruses expressing full-length SOD showed 
even greater inhibition.  
In this study, we did not manage to detect SOD decoy activity that was reported of 
leporipoxviruses, yet we got the same antiapoptotic effects when SOD was present. The likely 
explanation of this is that SOD from Herbivac could be exerting its effects differently to 
leporipoxviruses’ SOD. Molloscum Contagiosum encodes a MC163 whose amino acid residues 
(46-108) have been shown to possess properties of a Cu Zn SOD (Coutu et al., 2017). MC163 
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was shown to bind apoptotic factor BAX in the mitochondria thereby inhibiting apoptosis 
(Coutu et al., 2017). It can be inferred therefore that since the full-length SOD homologue from 
Herbivac did not appear to interfere with cellular Cu Zn SOD, binding and inactivation of 
apoptotic factors may be the mechanism by which full length SOD homologues from LSDV 
exert their antiapoptotic effect. Although Cu Zn SOD is a cytosolic protein, it and its mutant 
SODs have also been shown to localize to the mitochondria further substantiating the claim that 
the full length SOD homologue from LSDV could localize to the mitochondrion where it binds 
apoptotic factors  (Sturtz et al., 2001, Magrané et al., 2009). 
It can be inferred therefore that the inhibition of apoptosis by Herbivac and possibly 
nLSDVSODis-M leads to the host increasing antiviral mechanisms to clear the infection. This is 
however absent in nLSDV and potentially nLSDVdSOD-M infected cells. The implications of 
this are that Herbivac and nLSDVSODis-M may induce a more potent immune response than 
nLSDV or nLSDVdSOD-M. This finding is substantiated by the finding from our microarray 
experiment in Chapter 2 that LSDV infection was characterized by an upregulation of antiviral 
genes that are associated with pathogen recognition receptors, interferon related genes and 
immune system related genes. Thirteen genes were unique to Herbivac infection alone (Chapter 
2 section 2.3.4.1). Amongst those that were commonly upregulated by both viruses (section 
2.3.4.1) though they were not compared statistically against each other, most genes that were 
upregulated which are associated with an antiviral response had a greater fold change in 
upregulation after Herbivac infection compared to nLSDV.   
In the presence of camptothecin, the full-length SOD homologue expressed by both Herbivac and 
nLSDVSODis-M could have contributed to better protection of the infected cells from cell death. 
Inhibition of cell death however is a means by which viruses evade the host’s antiviral 
mechanisms. This aids the virus to complete its replication cycle and produce infectious viral 
particle (Nichols et al., 2017). Since apoptosis of infected cells is an innate function that is 
used to remove the infected cell (Everett and McFadden, 1999), its inhibition may result in 
the infected cells resorting to other means of cell death that include necrosis or necroptosis 
Walsh (2014). Induction of necroptosis is beneficial in effecting a strong immune response to 
viral infection (Orzalli and Kagan, 2017). Vaccinia virus was shown to inhibit caspase 8 
leading to infected cells inducing necroptosis (Li and Beg, 2000). This inhibition in vaccinia 
virus was averted by necroptosis (Cho et al., 2009, Veyer et al., 2017). A vaccine/vector that 
inhibits apoptosis causing the infected cell to engage in necroptosis could be desirable as 
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necroptosis is an immunogenic form of cell death (Sarhan et al., 2018). It is interesting to note 
that in a whole system in mice, GO processes relating to cell death were elevated after 
Herbivac infection and not nLSDV infection (Chapter 2).  More interestingly, there was an 
upregulation of Gzma which is involved in the induction of caspase independent cell death. 
Taken together, this suggests that infection by Herbivac elicits a more potent immune response 
possibly due to the type of cell death induced.  
We speculate that the viral induction of apoptosis and necrosis that was shown by viruses 
expressing full-length SOD in vitro could account for an increase in transcripts related to cell 
death that were detected in mice infected with Herbivac. Cellular processes and pathways 
involved in cell death were activated after Herbivac infection. Also, though paradoxical, the 
ability of viruses containing full-length SOD to inhibit apoptosis could account for the increased 
expression of cell death transcripts in vivo. Granzyme A and poly (ADP-ribose) polymerase 9 
(Parp 9) upregulation was observed after Herbivac infection only. Gzma participates in caspase 
independent cell death (Martinvalet et al., 2005). Necroptosis has been reported to be caspase 
independent making our findings striking. Inhibition of apoptosis may result in the induction of 
a more immunogenic form of cell death. This observation suggests that when apoptosis is 
inhibited, the host cell/organism activates expression of other cell death machinery. Essentially, 
the elevated cell death processes and pathways following infection with Herbivac observed from 
analyzing our microarray data confirms this. More work will need to be done in the way of using 
different assays/methods to test for different forms of cell death such as necroptosis. 
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Chapter 4 Conclusion and future work 
Chapter 1 of this thesis reviewed literature on the use of LSDV as a vaccine and vaccine vector. 
A more immunogenic vaccine strain of LSDV, Herbivac was supplied to our group and whole 
genome sequencing done. Whole genome sequencing revealed that there was a single potential 
functional difference between Herbivac and the widely used Neethling vaccine strain (nLSDV). 
The mutation in Herbivac restored the SOD ORF which was truncated due to a single base pair 
deletion in nLSDV. There was an additional 2 bp deletion which restored the ORF back into 
frame in Herbivac.  
The first objective of this thesis was to establish whether there was a difference between 
nLSDV and Herbivac in the innate response in mice 24 hours post infection. Initial studies in 
a mouse model (chapter 2) showed that when mice were infected by either Herbivac or nLSDV, 
there was differential expression of 98 genes compared to the uninfected mice. These were 
largely related to the response to a viral infection.  A few notable differences were observed. 
nLSDV differed in the unique expression of 6 genes and Herbivac differed in the unique 
expression of 36 genes, which included granzyme A and Poly (ADP-ribose) polymerase (Parp 
9) (Figure 2.5). A lot more Gene ontology (GO) processes were enriched after Herbivac 
infection (16) than nLSDV (8) infection (Figure 2.6). The difference observed as alluded to in 
Chapter 2, could either be as a result of the SOD gene/gene product or experimental variation 
within the nLSDV group. Gzma was particularly interesting in that it is linked to the caspase 
independent form of cell death. Also, Parp 9 contributes to necrosis. There has been a new form 
of immunogenic, programmed necrotic cell death (necroptosis) descibed, which is activated 
when caspase activity is inhibited (Han et al., 2011). The finding that these transcripts were 
upregulated following Herbivac infection corroborates the finding in Chapter 3, that Herbivac 
induced viral apoptosis in infected cells (extrinsic apoptosis). Further studies should be 
performed to study the response at more time points earlier after infection. The use of a 
permissive animal/host model may also be more informative. 
Even though the transcripts differentially expressed were largely similar, there was a trend 
towards Herbivac having more immune related transcripts being upregulated compared to 
nLSDV. This finding in a non-permissive host is interesting as it warrants further studies which 
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can substantiate the use and advantage of having Herbivac as a vaccine vector. Since, the only 
functional difference between Herbivac and nLSDV was the presence of a full-length SOD 
homolog, clonal viruses expressing the full-length SOD, nLSDVSODis-UCT and 
nLSDVSODis-M may therefore be superior vaccines and vaccine vectors. Testing the vaccine 
vectors in rabbits and conducting immunogenicity experiments can be informative as to 
whether viruses expressing full length SOD are more immunogenic than the viruses expressing 
the truncated SOD homolog or where the SOD homologue was deleted.   
In the final experimental chapter, recombinant viruses expressing a full-length SOD 
homologue (nLSDVSODis) and with SOD knocked out (nLSDVdSOD), were made. When the 
SOD homologue was deleted from LSDV it could be shown that this virus grew to lower titres 
in both cell culture and on CAMs. This novel finding presents a possible and exciting 
manufacturing advantage when growing nLSDVSODis-UCT for use as a vaccine and vaccine 
vector. Histological analyses also revealed that there was less immune cell infiltration 
associated with nLSDVdSOD-UCT infection compared to nLSDV and nLSDVSODis-UCT 
showing a possible role of the SOD homolog.  
SOD activity assays could not show whether the truncated SOD and full-length SOD 
homologue exerted their effects in a way that may involve metabolism of the superoxide anion. 
Initially, it was hypothesised from results of the amino acid alignment that both the truncated 
and full-length SOD homologues were not functional SOD enzymes. This is because they 
lacked the catalytic arginine at position 147 and resembled leporipoxvirus SOD homologs 
(Figure 3.7). This finding was later substantiated by SOD activity assays which did not show 
any increased SOD activity in cells infected with viruses containing the full-length SOD. 
Unlike leporipoxviruses’ SOD, SOD activity assays did not show a perturbation or inhibition 
of cellular SOD activity (Figure 3.29). Feedback mechanisms could have contributed to a 
steady state of the superoxide anion levels. However, the inhibition of camptothecin induced 
cell death could have been therefore brought about by other mechanisms. Molluscum 
Contagiosum encodes a SOD homologue which binds apoptotic factors in the mitochondria 
(Coutu et al., 2017, Nichols et al., 2017). Previous studies that have been done to understand 
the role of the SOD homologue in leporipoxviruses involved generating antibodies to SOD 
which were then used to purify the protein. This assisted in enzymatic assays and 
immunoprecipitation assays which showed the involvement of SOD homologues in binding 
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the copper chaperone for SOD and eventual inhibition of cellular SOD activity (Cao et al., 
2002, Teoh et al., 2005, Teoh et al., 2003). Also, having antibodies against SOD will help 
understand where SOD localises in light of the recent finding by Coutu et al., 2017, that a SOD 
homolog from Molluscum Contagiosum binds apoptotic factors in the mitochondria.  
In Chapter 3, it was also shown that the presence of a full-length SOD homologue in SOD 
knock-in recombinants contributed to resistance to camptothecin induced cell death (possibly 
via the intrinsic arm of apoptosis).  This is an interesting finding in that inhibition of the 
intrinsic form of apoptosis can result in the propagation of virus and consequential induction 
of other forms of cell death which may be immunogenic. Apoptosis is not an immunogenic 
form of death and its inhibition may be associated with induction of other salvage methods of 
cell death that can contribute to better immunogenicity. Whether this cell death is pyroptosis 
or the highly desirable necroptosis due to it being an immunogenic form of cell death remains 
to be tested.  
Also, linking the growth curve data with the ability of nLSDVSODis-UCT to inhibit 
camptothecin induced cell death to a greater extent than the SOD knock-out virus may explain 
why SOD knock-in viruses grew to higher titres. We hypothesise that the increased titre 
observed for the SOD knock-in viruses was as a result of the virus inhibiting cell death of the 
infected cells, which could have given the virus more time to replicate and make infectious 
virions before the cell died. The presence of a SOD homologue in leporipoxviruses has also 
been associated with thermal stability and conferring resistance of the virus to protease activity 
(Zachertowska et al., 2004). This can also be investigated as a plausible explanation why 
reversion to the full-length SOD observed in Herbivac was favoured. This could have impacted 
immunogenicity as more stable virus particles could contribute to better immunogenicity.  
This thesis has shown a clear difference in phenotype in in vitro and in vivo studies, helping to 
understand how the full-length SOD from Herbivac could be contributing to improved 
immunogenicity. An animal experiment in the natural host of LSDV i.e. cattle, may also help 
in understanding the role of the full-length SOD in immunogenicity. Using results from this 
thesis, we hypothesise that that infection of cattle with the SOD knock-in virus will result in 
greater pathology due to nLSDVSODis inhibiting the intrinsic arm of cell death. This is 
because of persistence of the virus due to the infected cells not dying. However, this assertion 
remains to be tested as nLSDVSODis-UCT was associated induction of the extrinsic arm of 
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apoptosis. This could mean that if there is more virus induced apoptosis following 
nLSDVSODis-UCT infection, then the infection would be cleared early leading to lesser 
pathology.  
Our CAM histology results, however, would suggest that infection of cattle with the SOD 
knock-out (nLSDVdSOD-UCT) would result in reduced immune infiltration compared to 
nLSDVSODis-UCT. The effect of the reduced immune infiltration may be increased pathology 
as the viral infection is not effectively controlled. Infection of cattle with the SOD knock-in 
virus will possibly be associated with increased immune infiltration as observed in CAM 
histology where infection with nLSDVSODis-UCT was associated with greater immune cell 
infiltration compared to infection with nLSDVdSOD-UCT (Figure 3.28). In the same way, we 
would speculate that pathology may be reduced following nLSDVSODis-UCT infection. 
Overall, the recombinant nLSDVSODis-UCT may have greater immune infiltration and 
therefore better immunogenicity in cows compared to nLSDVdSOD-UCT.  
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Appendix 1 – R code used to analyse the mouse transcriptome 
#set working directory 
setwd("c:/R/henry") 



























#read in .cel files 
RawData <- read.celfiles(list.celfiles("C:/R/henry", full.names = T),verbose=TRUE) 
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#load phenotype data 
pd<-read.AnnotatedDataFrame("phenodata.txt",header=TRUE,row.names=1) 
pd.2<-read.table("phenodata.txt",header=T,row.names=1) 
x <- varMetadata(pd) 
x <- data.frame(x, channel = "_ALL_") 
varMetadata(pd) <- x 
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 # Get the transcript cluster IDs from the expressionset 
ID <- featureNames(OligoEset) 
 
 # Look up the Gene Symbol, name, and Ensembl Gene ID for each of those IDs 
Symbol <- getSYMBOL(ID, "mogene20sttranscriptcluster.db") 
Name <- as.character(lookUp(ID, "mogene20sttranscriptcluster.db", "GENENAME")) 
Ensembl <- as.character(lookUp(ID, "mogene20sttranscriptcluster.db", "ENSEMBL")) 
Entrez <- as.character(lookUp(ID, "mogene20sttranscriptcluster.db", "ENTREZID")) 
#GO<-as.character(lookUp(ID, "mogene20sttranscriptcluster.db", "GO")) 
  
# Make a temporary data frame with all those identifiers 
tmp <- data.frame(ID=ID, Symbol=Symbol, Name=Name, 
Ensembl=Ensembl,Entrez=Entrez, stringsAsFactors=F) 
 
# set the featureData for your expressionset using the data frame you created above. 












#variance filter - (the interquartile range of log2-intensities should be at least 0.5) 
f2<-function(x)(IQR(x) > 0.5) 
 
ff<-filterfun(f1,f2) 
selected <- genefilter(OligoEset, ff) 










#limma for linear model of data 
 
# Export all affy expression values to a tab delimited text file 
write.exprs(esetSub, file="OligoEset.txt") 
 
#differential expression analysis 






# Create appropriate contrast matrix for pairwise comparisons 
contrast.matrix <- makeContrasts(PBS-iLSDV, PBS-nLSDV, PBS-MVA, levels=design) 
 
# Fit a linear model for each gene based on the given series of arrays 
fit <- lmFit(esetSub, design) 
 
# Compute estimated coefficients and standard errors for a given set of 
contrasts 
fit2 <- contrasts.fit(fit, contrast.matrix) 
 
# Compute moderated t-statistics and log-odds of differential expression by empirical Bayes 
shrinkage of the standard errors towards a common value 
fit2 <- eBayes(fit2) 
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# Generate list of top 10 DEGs for first comparison 




for (i in 1:3){ 
  genes<-topTable(fit2, coef=i, adjust="fdr", sort.by="B",p.value=0.05,number=600)$ID 





gr <- decideTests(fit2 , adjust.method="none") 








#heatmap.2 using gplots  
heatmap.2(results, col=redgreen(75), scale="none", key=TRUE, symkey=FALSE, 
density.info="none", trace="none", cexRow=0.5) 
 
#generate gene lists (dif. expr. genes) for each comparison (1-6) 




nLSDV<-topTable(fit2, coef=2, adjust="fdr", sort.by="B",resort.by="logFC", 
p.value=0.05,number=Inf) 


























# annotate with entrez info 
all_genes1 <- iLSDV$Entrez 






ggo1 <-groupGO(iLSDV1, organism="mouse", ont = "BP", level=3, readable = TRUE) 




#GO enrichment analysis - HYPERGEOMETRIC MODEL (left out universe="")  




#GO enrichment analysis - KEGG pathway enrichment analysis 
kk1<-enrichKEGG(gene=iLSDV1,organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
head(summary(kk1)) 
 




#visualization of results 
barplot(ggo1, drop=TRUE, showCategory=12) 
barplot(ego1, drop=TRUE, showCategory=10) 
barplot(kk1, drop=TRUE, showCategory=10) 










# annotate with entrez info 
all_genes2 <- nLSDV$Entrez 
all_genes2 <- all_genes2[!is.na(all_genes2)] 
all_genes2<-all_genes2[!duplicated(all_genes2)] 






ggo2 <-groupGO(nLSDV, organism="mouse", ont = "BP", level=3, readable = TRUE) 
head(summary(ggo1)) 
 
#GO enrichment analysis - HYPERGEOMETRIC MODEL (left out universe="")  




#GO enrichment analysis - KEGG pathway enrichment analysis 
kk2<-enrichKEGG(gene=nLSDV,organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
head(summary(kk1)) 
 
#Reactome pathway enrichment analysis - results in error 
rp2<-enrichPathway(gene=nLSDV,organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
 
#visualization of results 
barplot(ggo2, drop=TRUE, showCategory=12) 
barplot(ego2, drop=TRUE, showCategory=10) 
barplot(kk2, drop=TRUE, showCategory=10) 
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# annotate with entrez info 
all_genes3 <- MVA$Entrez 






ggo3 <-groupGO(MVA, organism="mouse", ont = "BP", level=3, readable = TRUE) 
head(summary(ggo3)) 
 
#GO enrichment analysis - HYPERGEOMETRIC MODEL (left out universe="")  




#GO enrichment analysis - KEGG pathway enrichment analysis 
kk3<-enrichKEGG(gene=MVA,organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
head(summary(kk3)) 
 
#Reactome pathway enrichment analysis - results in error 
rp3<-enrichPathway(gene=MVA,organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
 
#visualization of results 
barplot(ggo3, drop=TRUE, showCategory=12) 
barplot(ego3, drop=TRUE, showCategory=10) 
barplot(kk3, drop=TRUE, showCategory=10) 




#Biological Theme Comparison 
allcomparison<-cbind(iLSDV,nLSDV,MVA) 









ck<-compareCluster(geneCluster=allc, fun="enrichKEGG", organism="mouse", 
pvalueCutoff=0.05, readable=TRUE) 
head(summary(ck)) 
cGO<-compareCluster(geneCluster=allc, fun="enrichGO",ont="BP", organism="mouse", 
pvalueCutoff=0.05, readable=TRUE) 
cGOMF<-compareCluster(geneCluster=allc, fun="enrichGO",ont="MF", 
organism="mouse", pvalueCutoff=0.05, readable=TRUE) 
cGOCC<-compareCluster(geneCluster=allc, fun="enrichGO",ont="CC", organism="mouse", 
pvalueCutoff=0.05, readable=TRUE) 
 
plot(ck, type = "dot", showCategory=NULL, by = "count", title = "KEGG enrichment", 
font.size = 12) 
plot(ck, type = "bar", showCategory=NULL, by = "count", title = "KEGG enrichment", 
font.size = 12) 
plot(ck, type = "bar", showCategory=NULL, by = "percentage", title = "KEGG enrichment", 
font.size = 12) 
 
plot(cGO, type = "dot", showCategory=30, by = "count", title = "GO enrichment", font.size = 
12) 
plot(cGO, type = "bar", showCategory=30, by = "count", title = "GO enrichment", font.size = 
12) 
 
plot(cGOMF, type = "dot", showCategory=20, by = "count", title = "GO enrichment", 
font.size = 12) 
plot(cGOCC, type = "dot", showCategory=20, by = "count", title = "GO enrichment", 
font.size = 12) 



























a<-merge(iLSDV1,mva1, by="ID", all = TRUE) 




all<-read.csv("c:/R/henry/heatmap/c.csv", header=T, row.names=1) 
all[is.na(all)] <- 0 
all<-as.matrix(all) 




#heatmap.2(all1, cexCol=1, col=redgreen(75),colsep=c(1:4),Colv=NA, scale="none", 
key=TRUE, symkey=TRUE, density.info="none", trace="none", cexRow=0.7, 
sepwidth=c(0.01), sepcolor="white", lhei = c(0.02,1),lwid = c(1,1),margins=c(5,5) ) 
heatmap.2(all, col=redgreen(75),scale="row", key=TRUE, symkey=FALSE,symbreaks=F, 






#Generation of Gene Lists 
############################################ 
 
#set working directory 
setwd("c:/R/henry/lists") 
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a<-merge(iLSDV1,mva1, by="Symbol", all = TRUE) 



















c<-merge(iLSDV1d,mva1d, by="Symbol", all = TRUE) 
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Appendix 2 – pJET map 
 
Figure A.34. Plasmid vector map of pJET 1.2 / blunt vector. The vector contains an 
ampicillin resistance gene, origin of replication and an insertion sited for a blunt end product. 
The vector contains a lethal gene which if the vector circularises on its own, causes death of 
bacteria carrying the circularised plasmid. Figure taken from the CloneJet Manual 
(Thermofisher, USA).   
 
Appendix 3 – Reagent formulations 
3.1  McIlvains Buffer pH 7.4 
Solution A: 1.8mM citric acid (2.1g citric acid in 100ml dH2O) 
Solution B: 0.36mM Na2HPO4.12H2O (7.2g Na2HPO4.12H2O in 100ml dH2O) 
Add 18.17ml Solution A and 1.83ml Solution B and make up to 1L with dH2O. 
3.2  10x Phosphate Buffered solution (PBS) 
80g NaCl 
2.0g KCl 




Dilute in 800ml dH2O. Adjust pH to 7.4 and make up to a volume of 1L with 
dH2O. 
1x solution made up with 25ml 10X PBS added to 250ml dH2O 
3.3  PBS + Penicillan/Streptomycin and Fungin (PSF) 




3.4  Physiological saline 
0.85% w/v NaCl 
0.85g NaCl 
Made up to a final volume of 100 ml dH2O 
3.5  TE Buffer pH 9.0 
10mM Tris-HCL 
1mM EDTA 
Made up in 400ml dH2O, adjust pH to 9 and make up to 500ml with dH2O. 
3.6  Complete DMEM (10% FCS in DMEM) 
 445 ml DMEM 
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 50 ml fetal calf serum (FCS) 
 5 ml Penicillin and Streptomycin 
 500 µl 
  
 
